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CHAPTER I 
 
INTRODUCTION 
 
I.1. Mitochondrial biology  
Mitochondria are semi-autonomous, double membrane-bound sub-cellular organelles 
present in nearly all eukaryotic cells. Cells typically contain numerous mitochondria. The 
space between the two membranes that bound each mitochondrion is referred to as the 
mitochondrial intermembrane space and that which is contained within the inner 
membrane is referred to as the mitochondrial matrix space. Mitochondria are very 
dynamic structures.  They grow, divide, fuse, and are degraded. Mitochondria cannot be 
created de novo by the cell, but must be formed by the growth and division of existing 
mitochondria, a process called mitochondrial biogenesis. 
 
Mitochondria are the predominant source of cellular energy. As the sites of oxidative 
phosphorylation, mitochondria generate most of the cellular ATP, the energy currency of 
the cell. Each mitochondrion possesses a number of copies of a small circular genome 
(16.6 kbp in humans). The compact mitochondrial DNA (mtDNA) molecule only 
includes protein encoding genes for 13 essential subunits of the respiratory chain (and 
genes for translation of those 13 genes). The other 72 subunits of the respiratory chain, as 
well as the much larger number of proteins that function in mitochondrial biogenesis and 
maintenance and in mtDNA replication and maintenance, are encoded in the nuclear 
genome (nDNA). The nDNA-encoded proteins with mitochondrial localization are 
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translated by the ribosomes in the cytoplasm and then transported as unfolded peptide 
chains into the mitochondria through special protein channels called TOM-TIM 
complexes [1].  
 
Besides ATP production, mitochondria are important players in many key cellular 
functions. These include metabolism of amino acids and fatty acids, the citric acid cycle, 
and apoptosis to name a few. Mitochondria are essential for life – and this is probably 
due to their role in the assembly of iron-sulfur clusters [2], rather than their more famous 
identity as the powerhouses of the cell. Because of their substantial contribution to the 
proper functioning of cells, mitochondrial dysfunction has been implicated in an array of 
important human pathologies, including, but not limited to, cancer, neurodegenerative 
disorders, and a family of genetic diseases called mitochondrial DNA depletion 
syndromes (MDS) [3]. Mitochondrial DNA depletion syndromes are characterized by a 
reduction in the cellular amount of mitochondrial DNA and result from mutations in at 
least nine known nuclear genes (Table 1). Eight of these nine genes code for proteins 
with functions either in the apparatus that replicates mtDNA or in the production of the 
deoxyribonucleoside triphosphates required for mtDNA replication.  
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Table 1: Mitochondrial DNA depletion syndromes. 
 
 
 
Gene OMIM ID OMIM name 
TK2 609560 MTDPS2 (Myopathic type) 
DGUOK 251880 MTDPS3 (Hepatocerebral type) 
MPV17 256810 MTDPS6 (Hepatocerebral type) 
C10ORF2 271245 MTDPS7 (Hepatocerebral type) 
POLG 203700, 613662 MTDPS4A (Alpers type), MTDPS4B (MNGIE type) 
SUCLG1 245400 
MTDPS9  
(Encephalomyopathic type with methylmalonic aciduria) 
SUCLA2 612073 MTDPS5 (Encephalomyopathic with methylmalonic aciduria) 
TYMP 603041 MTDPS1 (MNGIE type) 
RRM2B 612075 
MTDPS8A (Encephalomyopathic type with renal tubulopathy),  
MTDPS8B (MNGIE type) 
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I.2. Nucleotide metabolism 
Nucleotide metabolism can be broadly defined as the set of anabolic and catabolic 
conversions of nucleotides.  
 
Let us briefly review some terminology associated with nucleotide metabolism. A 
nucleoside consists of a sugar molecule attached to a base. The common bases are 
adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U).  
 
Nucleosides can be divided into two classes, ribonucleosides and deoxyribonucleosides. 
The difference is in the sugar molecule, which is ribose in the former and deoxyribose in 
the latter. Thus, the common deoxyribonucleosides (dN) are deoxyadenosine, 
deoxycytidine, deoxyguanosine, deoxythymidine (also referred to as thymidine), and 
deoxyuridine; while the common ribonucleosides (rN) are adenosine, cytidine, guanosine, 
and uridine. 
 
A nucleoside can undergo as many as three enzyme-catalyzed phosphorylations. 
Nucleotide is the term for a phosphorylated nucleoside. Thus for each deoxyribo- as well 
as ribo- nucleoside, three corresponding nucleotides are possible. For 
deoxyribonucleosides, these are deoxyribonucleoside monophosphate (dNMP), 
deoxyribonucleoside diphosphate (dNDP), and deoxyribonucleoside triphosphate 
(dNTP).  
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dNTPs and rNTPs are essential for the replication, maintenance, and repair of DNA and 
RNA, respectively. dNTPs are generated via two routes, the de novo pathway and the 
salvage pathway. In the de novo pathway, after small molecules are converted to 
ribonucleoside diphosphates, a cytoplasmic enzyme called ribonucleotide reductase 
(RRM) converts the ribonucleoside diphosphates to the corresponding 
deoxyribonucleoside diphosphates [4]. These resulting deoxyribonucleoside diphosphates 
can then be phosphorylated to generate the dNTPs. Additionally, dNTPs can also be 
synthesized through three successive phosphorylations of deoxyribonucleosides. This 
pathway of dNTP generation is referred to as the salvage pathway.  
 
In the cell, DNA resides in two places, the nucleus and the mitochondria, and therefore 
dNTPs are required in both compartments. In the cytoplasm, the majority of dNTPs are 
generated via the de novo pathway. The existence of the de novo route in the 
mitochondria has not been established, and therefore, dNTP production in the 
mitochondria is thought to occur solely through the salvage route. The primary focus of 
the remainder of this dissertation is on mitochondrial dNTP pools. All of the genes 
discussed in this dissertation are encoded in the nuclear genome. 
 
I.3. Generating mitochondrial dNTP pools 
Mitochondrial salvage: Deoxyribonucleotide metabolism for generating dNTPs within 
mitochondria occurs through the salvage pathway (Figure 1), though other sources may 
also exist. This metabolism within the mitochondrion is separate from the corresponding 
metabolism that provides dNTPs for nuclear DNA replication. There exists one report of 
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a mitochondrial ribonucleotide reductase, thus suggesting the presence of a mitochondrial 
de novo pathway, but that finding remains uncorroborated [5]. In the mitochondrial 
salvage pathway, the canonical A, C, G, and T deoxyribonucleosides, after entering the 
mitochondrion through equilibrative nucleoside transporters (ENTs), are converted to the 
corresponding deoxyribonucleoside triphosphates through three successive 
phosphorylations. This is a complex process with some reactions occurring in parallel for 
the four deoxyribonucleosides, and some reactions using the same enzyme (for example, 
the first phosphorylation of dT and dC are both catalyzed by thymidine kinase 2) in 
addition to the presence (not shown in Figure 1A) of feedback mechanisms (for example, 
dTTP and dCTP inhibition on thymidine kinase 2 [6]).  
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Figure 1: Mitochondrial deoxyribonucleoside salvage metabolism. (A) Biochemical 
pathway representation of the mitochondrial deoxyribonucleoside salvage metabolism. 
Deoxyribonucleosides undergo a series of reversible phosphorylations to become 
deoxyribonucleoside triphosphates (substrates for mtDNA replication). Enzymes that are 
yet to be identified are represented by question marks. (B) Subcellular localizations of 
some enzymes important for the production of intra-mitochondrial dNTPs. Arrows 
denote the flow of substrates between the enzymes.  The question marks denote substrate 
flows that appear to be required by the enzyme localization data, but which seem 
unreasonable. Reproduced from Gandhi and Samuels (2011) [7]. 
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The known elements of the mitochondrial salvage pathway are as follows. 
Deoxyguanosine kinase (DGUOK) and thymidine kinase 2 (TK2) are the purine and 
pyrimidine deoxyribonucleoside kinases, respectively. Apart from these 
deoxyribonucleoside kinases, other elements of this pathway are relatively less studied. 
Mitochondria possess a pyrimidine 5’,3’-deoxyribonucleotidase (NT5M) which can 
dephosphorylate dTMP. The existence of additional deoxyribonucleotidases as well as 
the extent of NT5M’s contribution towards opposing dAMP, dCMP, and dGMP 
production is not established. For monophosphate kinase activity, candidates include 
adenylate kinase (AK) isoforms, cytidine monophosphate kinase 2 (CMPK2), and 
thymidine monophosphate kinase 2 (TMPK2) acting on dAMP, dCMP, and dTMP 
respectively. It is unclear which AK isoform has the most contribution towards producing 
mitochondrial dADP. Regarding CMPK2, its kinetics with dUMP as a substrate were far 
more favorable than the kinetics with dCMP which is its second-most preferred substrate 
[8]. Additionally, CMPK2 might be dispensable in dCTP synthesis given that its 
expression is restricted and was not detected in tissues with high energetic demand such 
as heart and muscle [8]. Following putative identification, attempts at characterizing the 
enzyme activity of TMPK2 have been unsuccessful both in vitro and in cell extracts [9]. 
No candidates exist for dGMP phosphorylation activity in the mitochondria. Assuming 
that mitochondria possess a complete salvage pathway, the lack of knowledge of the 
monophosphate kinases is a fundamental gap in our understanding. NME4 is a candidate 
for the mitochondrial nucleoside diphosphate kinase activity. Again, knowledge about 
mitochondrial nucleoside diphosphate kinase activity is scarce, and multiple NME 
isoforms have been reported.  
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The physical structure of the mitochondrion provides another complication that is rarely 
considered in this context.  The mitochondrion has an intermembrane space (between the 
inner and outer membranes) and a matrix compartment within the inner membrane 
(Figure 1B). Several contact sites exist between the inner and outer membranes. mtDNA 
is tethered to the inside of the inner membrane, within the matrix, so it would be expected 
that the enzymes of the salvage pathway also would be located within the matrix. In the 
simplest picture of the mitochondrial salvage pathway, deoxyribonucleosides are 
transported through the inner membrane by the equilibrative nucleoside transporter and 
then phosphorylated to dNTPs within the matrix. However, evidence exists to suggest 
that the AK2 adenylate kinase as well as NME4 nucleoside diphosphate kinase might 
actually be localized to the mitochondrial intermembrane space [10, 11], not in the 
matrix. It is possible that other isoforms of these enzymes might localize to the 
mitochondrial matrix [10, 11]. If so, which versions are more crucial to intra-
mitochondrial dNTP pools? If it is not the matrix versions, it is hard to understand how 
the salvage pathway would function without an unnecessarily complicated transport of 
deoxyribonucleotides back and forth across the inner membrane (arrows marked with 
question marks in Figure 1B).  
 
In a recent report, in addition to its presence in mitochondria, a cytosolic form of TK2 
was detected in multiple rat tissues [12]. This is in addition to the well-studied thymidine 
kinase 1 (TK1) which is the distinct cytoplasmic counterpart of mitochondrial TK2. In 
summary, it is possible that despite intensive study we currently might know only a 
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fraction of the components that participate in the pathways of mitochondrial dNTP pool 
generation.   
  
Deoxyribonucleotide flow between the cytoplasm and mitochondria: Older evidence 
supported the view that mitochondrial nucleotides may be isolated from the 
corresponding cytoplasmic pools [13], but several more recent studies exist to support the 
transport of deoxyribonucleotides between the cytoplasm and mitochondria [14-18] and 
show that nucleotide import from the cytosol very likely contributes to mitochondrial 
dNTP pools in both cycling and quiescent cells [17, 18] (Figure 2). dCTP transport 
activity in proteoliposomes containing the mitochondrial protein fraction of human acute 
lymphocytic leukemia cells has been observed [14]. Because the orientation of the 
insertion of proteins in lipid vesicles is not controlled, we cannot conclude whether the 
dCTP transport was unidirectional or bidirectional [14]. Other ribonucleoside and 
deoxyribonucleoside triphosphates were able to inhibit the dCTP transport, thus raising 
the possibility of a more general, non-specific transport function for this protein. A 
mitochondrial transporter (pyrimidine nucleotide carrier, PNC1) with a preference for 
UTP has also been described [16]. Again, PNC1 was also able to transport a variety of 
other molecules, including other ribonucleoside and deoxyribonucleoside triphosphates. 
Transport of dTMP into and out of isolated mitochondria also has been reported [15]. In 
that experiment, a fraction of dTMP was converted to thymidine, dTDP, and dTTP both 
in the medium and in the mitochondria. Thus, interpretation of the exact nature of that 
transport is complicated. Using isotope experiments, Bianchi and colleagues have 
established the importance of cytoplasmic enzymes in the maintenance of mitochondrial 
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dTTP and dGTP pools [17, 18]. By following the flux of radioactivity, they identified 
two-way transport of thymidine and deoxyguanosine nucleotides between the cytoplasm 
and mitochondria, and determined that while the cytoplasmic de novo pathway is the 
predominant source of mitochondrial dTTP in proliferating cells, even non-proliferating 
cells depend on ribonucleotide reduction in the cytoplasm. Details of the transport, such 
as the identities of the transporter and the transport substrate, and the kinetics of transport 
remain unresolved. It is also unknown if the behavior of deoxyadenosine and 
deoxycytidine nucleotides is similar to what has been observed regarding thymidine and 
deoxyguanosine nucleotides. Thus, even though solid evidence has accumulated to 
support the transport of deoxyribonucleotides between the cytoplasm and mitochondria, 
in the end we know little about the molecular mechanisms of this transport process.  
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Figure 2: The origin of intra-mitochondrial dNTPs. dN = deoxyribonucleoside, dNMP, 
dNDP and dNTP = mono, di, or tri phosphorylated deoxyribonucleoside respectively.  
The solid arrow denotes the identified deoxyribonucleoside transport mechanism.  Dotted 
arrows represent possible but unidentified deoxyribonucleotide transport mechanisms. 
The conversions between nucleosides and dNMPs are irreversible and carried out in the 
forward and reverse direction by separate enzymes. Reproduced from Gandhi and 
Samuels (2011) [19]. 
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I.4. The importance of mitochondrial dNTP pools 
Mitochondrial DNA depletion syndromes: Mitochondrial DNA depletion syndromes 
are a set of genetic diseases commonly defined as a reduction in the amount of cellular 
mitochondrial DNA without other defects such as deletions or point mutations [20]. 
However, underlying this definition is a clinically and genetically complex set of diseases 
(Table 1). Genetic and allelic heterogeneity; variable penetrance, severity of symptoms, 
and ages of onset; and gene-dependent tissue-specificity of phenotype are all 
characteristics of mtDNA depletion syndromes. Another complication in the 
characterization of mtDNA depletion syndromes is that depletion of mtDNA is not 
always exclusive of other genomic defects. For example, in mitochondrial 
neurogastrointestinal encephalomyopathy (MNGIE), deletions may accompany the 
depletion of mtDNA [21]. Mutations in the mitochondrial DNA polymerase (POLG) may 
lead to any of a diverse set of disorders, including progressive external opthalmoplegia 
(PEO). Also in PEO, mutations, deletions, and depletion of mitochondrial DNA may not 
necessarily be mutually exclusive [21], and the inheritance may be sporadic, dominant, or 
recessive [22]. Thus, while the inheritance of mtDNA depletion syndromes is usually 
deemed to be autosomal recessive [23], features of the mtDNA depletion syndrome 
phenotype also follow other inheritance patterns. The diseases that make up the mtDNA 
depletion syndrome family are shown in Table 1, along with their OMIM IDs. MDS is 
nearly always severely debilitating and often lethal in infancy or early childhood for 
homozygous patients [23]. The prevalence of these diseases is not yet well determined. 
However, quantification of mtDNA in the liver or muscle tissue of 100 children with 
unexplained respiratory chain deficiency showed mtDNA depletion to be less than 35% 
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of the control values in 50% of these cases, indicating that depletion of mtDNA is a 
common cause of respiratory chain deficiency in childhood [24]. Mutations in nine 
nuclear-encoded genes are known to cause mtDNA depletion syndrome. Eight of the nine 
genes code for enzymes that contribute to generating mitochondrial deoxyribonucleoside 
triphosphates or that participate in mtDNA replication. The function of the ninth gene, 
MPV17, which encodes a mitochondrial inner membrane protein, remains to be 
determined.  
 
The discoveries of a mutated p53-inducible small ribonucleotide reductase subunit 
(RRM2B) [25] and a mutated thymidine phosphorylase (TYMP) [26] as causes of 
mtDNA depletion syndrome highlight the importance of cytoplasmic nucleotide 
metabolism in maintaining mtDNA. Both RRM2B and TYMP are cytoplasmic enzymes 
of nucleotide metabolism (Figure 1B). RRM2B is a subunit of cytoplasmic ribonucleotide 
reductase, the key enzyme of the de novo pathway which reduces ribonucleoside 
diphosphates to deoxyribonucleoside diphosphates. TYMP converts deoxythymidine to 
thymine, and thus a lack of TYMP activity can result in excess deoxythymidine. This 
association between DNA depletion in the mitochondria and defects in cytoplasmic 
nucleotide metabolism implies that cytoplasmic nucleotides influence and contribute 
significantly to intra-mitochondrial pools of deoxyribonucleotides. We can therefore 
speculate that defects in other enzymes of cytoplasmic nucleotide metabolism, in addition 
to RRM2B and TYMP, could also lead to mtDNA depletion.   
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On a side note, the intermembrane localization of NME4 is interesting considering the 
importance of RRM2B-catalyzed ribonucleotide reduction in the cytoplasm for 
maintaining mitochondrial DNA. In the presence of active production of 
deoxyribonucleoside diphosphates in the cytoplasm, terminal phosphorylation of those 
dNDPs by NME4 and the subsequent entry of the resulting dNTPs into the mitochondrial 
matrix would appear to be a logical benefit of NME4’s localization to the intermembrane 
space. 
 
Mitochondrial dNTP pools in patient cells: Experiments with patient cells have 
demonstrated the effects of pathogenic mutations on mitochondrial dNTP pools. In 
fibroblasts from a patient with deoxyguanosine kinase deficiency where quiescence was 
induced through serum starvation, reduced mitochondrial dGTP led to an imbalance 
between the four dNTPs compared to controls [27]. In fibroblasts from patients with TK2 
deficiency, mitochondrial dTTP, dCTP, and dATP pools were all decreased while dGTP 
was slightly increased in one patient and slightly decreased in another patient [28]. The 
fact that externally supplied deoxyribonucleosides and deoxyribonucleoside 
monophosphates are able to rescue mtDNA depletion provides further evidence that 
limited substrate availability can cause mtDNA depletion [27, 29, 30]. Experiments from 
cellular and animal models have also reported disruptions in mitochondrial dNTP pool 
homeostasis [31-33]. TK2 H126N (c.378–379CG>AA) knockin mice had unbalanced 
mitochondrial dNTP pools due to reduced dTTP in brain and reduced dCTP in liver [31]. 
Culturing HeLa cells in the presence of high levels of thymidine (50 µM) to mimic the 
conditions leading to MNGIE (caused by mutations in TYMP), led to an expansion of 
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mitochondrial dTTP and dGTP pools and a reduction of the mitochondrial dCTP pool 
[33]. In another cellular model of MNGIE, incubation of quiescent fibroblasts in the 
presence of high levels of deoxythymidine or deoxyuridine led to an expansion of 
mitochondrial dTTP, but mitochondrial dCTP was unaffected [32]. 
 
In conclusion, the availability and balance of the intra-mitochondrial dNTP pools are 
major determinants of the rate and fidelity of mtDNA replication and thus of the integrity 
of the mitochondrial genome [34]. Besides mtDNA depletion syndromes, mitochondrial 
dNTP pools are important in other human pathologies. Mitochondrial toxicity induced by 
HIV/AIDS therapy can manifest as severe clinical phenotypes and increased mortality 
[35, 36]. This toxicity is likely the result of interference with mtDNA replication and 
intra-mitochondrial nucleotide metabolism brought about by nucleoside analogs [37-40]. 
To advance our understanding of these numerous human disorders, to elucidate the role 
of mtDNA mutations in aging and cancer [3, 41-46], and to devise suitable therapies, it is 
critical that we understand the formation and regulation of intra-mitochondrial dNTP 
concentrations. Because mitochondrial dNTP levels are disrupted in mtDNA depletion 
syndromes, a thorough understanding of the maintenance of mitochondrial dNTPs is a 
necessary step towards insights on the mechanisms and the potentials therapies of 
mtDNA depletion syndromes. 
 
Considering that mitochondrial dNTP pools are crucial for normal functioning of 
cells, what are the features of wild-type mitochondrial dNTP pools? We know that 
flow of deoxyribonucleotides between the cytoplasm and mitochondria is possible. 
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What is the influence of this flow on the relationship between wild-type 
mitochondrial dNTP pools and cytoplasmic dNTP pools?    
 
I.5. Regulation of dNTP pools and DNA replication 
The fidelity of nDNA replication and cell-cycle progression are influenced by the 
concentrations of the DNA precursors, the substrate dNTPs [47]. S-phase specific 
activities of the cytoplasmic de novo ribonucleotide reductase and the salvage thymidine 
kinase 1 enzymes lead to a many-fold difference in dNTP levels between S-phase and 
non-S phase cells [48, 49]. This mechanism prevents an out-of-phase excess or imbalance 
of DNA precursors, thus also preventing unscheduled or erroneous DNA replication. 
Ribonucleotide reductase reduces ribonucleotides to the corresponding 
deoxyribonucleotides and has an important role in cell proliferation. Increased 
ribonucleotide reductase activity has a role in cancerous transformation as well as 
metastasis [50]. It is also known that oncogenically transformed mammalian cells contain 
much higher dNTP pools than normal cells [34]. Recently, it was shown that nucleotide 
deficiency results in DNA damage in early stages of oncogenesis as cells are forced to 
proliferate despite low nucleotide pools [51]. A mitochondrial transporter (PNC1) with 
the ability to transport a variety of substrates including ribonucleoside and 
deoxyribonucleoside triphosphates but a preference for UTP has been reported [16, 52]. It 
is interesting that the PNC1 gene had higher expression in transformed cells and primary 
prostate cancers and that enhanced expression of PNC1 was reported to have a role in 
transformation and in the invasive potential of tumor cells. 
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In summary, it is well-acknowledged that the process of carcinogenic 
transformation is often connected to impaired nucleotide homeostasis. Combined 
with the fact that a cross-talk between cytoplasmic and mitochondrial 
deoxyribonucleotides is possible, what are the features of mitochondrial dNTP pools 
in transformed cells? How do their features relate to those of the cytoplasmic dNTP 
pools in such cells?      
 
Mitochondrial DNA replication [53], and the mitochondrial nucleoside salvage pathway 
that generates the precursor deoxyribonucleoside triphosphates for mitochondrial DNA 
replication, generally have been believed to function independently of nuclear DNA 
replication and cytoplasmic nucleotide metabolism. The mitochondrial DNA molecule 
has a half-life of 10-30 days [54]. To maintain the mtDNA content of the cell, mtDNA 
must replicate even in postmitotic cells [53]. Synthesis of mtDNA and mitochondrial 
biogenesis, therefore, must be able to proceed independently of nuclear DNA synthesis 
and cellular division [53]. However, mtDNA and nDNA synthesis cannot be completely 
decoupled since mtDNA replication must be increased at some point in cell division to 
provide sufficient mtDNA for the two daughter cells. Clearly there must be a flexible 
system of control linking these two parallel metabolic pathways that allows them to work 
together sometimes and independently at other times. The observation associating 
mutated RRM2B (a p53-inducible ribonucleotide reductase subunit) with mtDNA 
depletion and at least one observation of mtDNA replication restricted to S-phase in 
deoxyguanosine kinase deficient cells further make it clear that mtDNA replication and 
maintenance are not always completely independent of the cytoplasmic state [25, 30]. 
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How does the expression of genes coding for mitochondrial enzymes of 
deoxyribonucleotide metabolism relate to the expression of genes of the 
corresponding cytoplasmic enzymes? Can we reconcile these gene expression 
patterns with the patterns in the dNTP pools that result from the activities of the 
enzymes encoded by the genes? 
 
I.6. The difficulty of studying mitochondrial dNTP pools 
Due to the small physical scale of mitochondria and relatively rapid dynamics of the 
pathways, it is very difficult to study the dynamics of mitochondrial dNTPs through 
traditional wet-lab methods. Owing to the complexity of the pathways that generate 
mitochondrial dNTP pools for the maintenance of mitochondrial DNA, there exist many 
open questions in the field, as we have seen. I outline some more below. 
 
Although we know deoxyribonucleotide transport between the cytoplasm and 
mitochondria occurs, what is the identity of the transported substrate? Is it the 
mono-, di-, or the tri-phosphate? What is the implication of a lack of transport? 
Which pathway components represent major bottlenecks in the generation of 
mitochondrial dNTP pools?  
 
I.7. Research summary and significance 
The unifying objective of this dissertation was to increase our understanding of the 
features of mitochondrial dNTP pools. 
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The extent of the association between cytoplasmic and mitochondrial dNTP pools was 
not clear prior to my research. Chapter II shows that mitochondrial and cytoplasmic 
dNTP concentrations are correlated in normal cells but not in transformed cells. In the 
research presented in Chapter II, although the raw data was not produced in our 
laboratory, I generated a usable resource out of it. I converted, analyzed, and summarized 
all relevant published data to a more comprehensive form, thus substantially adding to the 
usefulness of the data. It can be misleading to compare previously published results as 
they were originally reported because of the units that are used to report such data. My 
work of converting all relevant data to biochemically meaningful micromolar 
concentrations allows for comparisons of published dNTP pool measurements between 
published experiments; sub-cellular compartments; and normal and transformed cell 
lines. An additional significant contribution of the analysis presented in Chapter II is the 
suggestion of specific experiments furthering the field. The highly significant association 
between cytoplasmic and mitochondrial dNTP concentrations that I discovered would 
indicate the existence of regulatory mechanisms that synchronize the respective dNTP 
pools. Finally, for publication of these results, I incorporated my analysis into the context 
of an overall review of the field and pointed out both the state of our understanding as 
well as key areas where knowledge is lacking. 
 
What mechanism might give rise to the strong and highly statistically significant 
correlation between cytoplasmic and mitochondrial dNTP pools in normal cells but not in 
transformed cells? I offer one mechanism through the research presented in Chapter III. I 
hypothesized that coordinated gene expression could be one mechanism to explain the 
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correlation between cytoplasmic and mitochondrial dNTP pools. At the time I 
commenced my research, the enzymes that generate dNTP pools in the mitochondria 
were not considered to be carefully regulated. In fact, it was not uncommon for them to 
be perceived as housekeeping enzymes. I also tested this perception in my research 
presented in Chapter III. I obtained tissue-expression data for a selected set of genes from 
the NCBI Unigene database and conducted an in silico gene expression analysis. My 
results showed that in normal tissues, the expression of genes encoding proteins of 
mitochondrial salvage varies in coordination with the expression of the corresponding 
genes of cytoplasmic salvage. However, in transformed tissues, consistent with the 
disruption in the correlation in dNTP concentrations I found in Chapter II, the 
coordination in the gene expression is also disrupted. Unlike in normal tissues, the 
expression of mitochondrial genes is negatively associated with the expression of 
cytoplasmic genes. To my knowledge, such a systematic investigation into the expression 
network of genes important for cytoplasmic and mitochondrial dNTP pools has not been 
carried out apart from my research.  
 
By discovering the results in Chapters II and III that have implications for transformed 
tissues and by highlighting mitochondrial deoxyguanosine kinase expression as 
potentially a significant factor for transformed tissues, my research highlighted the 
possibility of important connections between mitochondrial dNTP pools and cancer. 
 
Chapter IV presents a comprehensive analysis of enzyme kinetics of the mitochondrial 
deoxyribonucleoside salvage pathway enzymes. The complexity of the homeostasis of 
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mitochondrial dNTP pools makes it extremely difficult to understand the processes in 
their entirety using traditional laboratory techniques. For developing novel approaches 
for therapy, it is important to first improve our understanding of the mitochondrial 
salvage pathway. I attacked this using a logical, objective, and systematic approach, and 
my work is the only computational model incorporating all available relevant knowledge 
regarding this complex biological process. While it was accepted that 
deoxyribonucleotide import from the cytoplasm to the mitochondria is possible, my 
results showed that it is in fact essential for mtDNA maintenance in most circumstances. 
I also discovered that import would need to occur at the diphosphate or triphosphate 
levels; import at the monophosphate level does not satisfy the rate at which dNTP 
substrates are required for mtDNA replication in cycling cells.  
 
The content in this dissertation was reproduced with revisions from published papers on 
which I am first author [7, 19]. A paper describing the work presented in Chapter III is in 
preparation. 
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CHAPTER II 
 
A REVIEW COMPARING DEOXYRIBONUCLEOSIDE TRIPHOSPHATE 
CONCENTRATIONS IN THE MITOCHONDRIAL AND CYTOPLASMIC 
COMPARTMENTS OF NORMAL AND TRANSFORMED CELLS 
 
 
 
II.1. Introduction 
Although mitochondrial dNTP generation is an important pathway, much about the origin 
of mitochondrial dNTPs remains unclear. Since the etiology of mtDNA depletion 
syndromes can be traced to altered mitochondrial dNTP pools, it is critical to understand 
how the mitochondrial dNTP pools relate to the corresponding cytoplasmic pools. The 
evidence reviewed in Chapter I repeatedly points toward a significant amount of 
interaction between the mitochondrial and cytoplasmic dNTP pools. What data exists 
concerning the relationship between the dNTP concentrations in these two subcellular 
compartments, and is the existing data consistent with the increasing evidence of 
communication between the cytoplasm and mitochondria with respect to 
deoxyribonucleotides? In this chapter we focus on these questions. We reviewed the 
available data on simultaneous measurements of cytoplasmic and mitochondrial dNTP 
pools in wild-type cells [27, 32, 33, 55-59]. 
 
The content of this chapter has been reproduced with revisions from a published paper on 
which I was first author [19]. 
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II.2. Overview 
The deoxyribonucleoside triphosphate pools that support the replication of mitochondrial 
DNA are physically separated from the rest of the cell by the double membrane of the 
mitochondria. Perturbed homeostasis of mitochondrial dNTP pools is associated with a 
set of severe diseases collectively termed mitochondrial DNA depletion syndromes. It is 
important to determine the degree of interaction of the mitochondrial dNTP pools with 
the corresponding dNTP pools in the cytoplasm. We reviewed the literature on previously 
reported simultaneous measurements of mitochondrial and cytoplasmic 
deoxyribonucleoside triphosphate pools to investigate and quantify the extent of the 
influence of the cytoplasmic nucleotide metabolism on mitochondrial dNTP pools. We 
converted the reported measurements to concentrations creating a catalog of paired 
mitochondrial and cytoplasmic dNTP concentration measurements. We found that over 
experiments from multiple laboratories, dNTP concentrations in the mitochondria are 
highly correlated with dNTP concentrations in the cytoplasm in normal cells in culture 
(Pearson R = 0.79, p = 3 x 10-7) but not in transformed cells. For dTTP and dATP, there 
was a strong linear relationship between the cytoplasmic and mitochondrial 
concentrations in normal cells. From this linear model we hypothesize that the salvage 
pathway within the mitochondrion is only capable of forming a concentration of 
approximately 2 µM of dTTP and dATP, and that higher concentrations require transport 
of deoxyribonucleotides from the cytoplasm. 
 
 
 
25 
 
II.3. Methods 
Conversion to correct concentration units: With the goal of investigating whether 
concentrations calculated from previously measured dNTP pools are consistent with the 
biochemical evidence of deoxyribonucleotide flow between the cytoplasm and 
mitochondria, we converted the reported data to molar concentrations. This conversion 
requires the estimation of several parameters. Enzyme activities, kinetics, and the rate 
and fidelity of mtDNA replication are all influenced by the local dNTP concentrations. 
These concentrations are maintained by metabolic pathways that function in two 
subcellular compartments with very different volumes. Although concentrations are 
indeed the true biochemical driving factors, dNTP data is instead generally reported as 
amounts per million cells in culture. Per cell amounts can be misleading, since the 
conversion from these experimentally convenient units to the actual units of 
concentration in subcellular compartments can vary radically between different cell 
types. Paradoxically, the justification for using units such as the amount per million cells 
is to make comparisons possible; but, all the while, the cell lines and culture conditions in 
different experiments are different in the critical parameters needed to convert these units 
to actual concentration units. For reporting dNTP pools, the most commonly used units in 
the literature are picomoles per million cells for both subcellular compartments, or 
picomoles per milligram mitochondrial protein. In the following section we give 
estimates to convert these units to true concentration units. 
 
To obtain concentrations from data reported as amount dNTP (picomoles) per cell, we 
must use estimates of cell and subcellular compartment volumes (for details see Table 2). 
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Bestwick et al. [55] reported dNTP amounts in subcellular fractions of asynchronously 
growing HeLa cells. For cellular and mitochondrial volumes of HeLa cells, we referred to 
a publication from Posakony et al. [60] who followed cellular and mitochondrial volume 
at different times along the cell cycle of HeLa cells. We combined nuclear and 
cytoplasmic amounts reported by Bestwick et al. [55], and converted these to molar 
concentrations using averaged cellular volume subtracted for mitochondrial volume. We 
calculated mitochondrial concentrations by using the average mitochondrial volume from 
different cell cycle phases. 
 
Song et al. [33] reported mitochondrial dNTP pools in HeLa cells as the amount dNTP 
(in picomoles) per milligram mitochondrial protein. To calculate the corresponding 
concentrations, we used a factor of 0.82 microliters water space per milligram rat heart 
mitochondrial protein [61]. For converting whole-cell amounts from picomoles per 
million cells, we first used the calculated mitochondrial concentrations and the 
mitochondrial volume measure for HeLa cells in G1 phase [60] to estimate the picomole 
amounts of dNTPs in mitochondria per million HeLa cells. After subtracting 
mitochondrial amounts and volume from corresponding whole-cell values for HeLa cells 
in G1 phase [60], we arrived at an approximation of cytoplasmic concentrations of Song 
et al.’s data for confluent HeLa cultures.  
 
Rampazzo et al. [59] measured dNTP amounts in exponentially growing human 
osteosarcoma line (HOS) cells and mouse fibroblasts (3T3) cell lines. Since we did not 
find a publication that provides the required conversion factors for the HOS cells, as an 
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estimate we used the measurements from HeLa cells. We averaged cellular and 
mitochondrial volumes measured in different cell cycle phases of HeLa cells [60] and 
obtained cytoplasmic and mitochondrial dNTP concentrations. For the cytoplasmic 
volume, we subtracted the total mitochondrial volume from the cellular volume to 
account for the fact that Rampazzo et al. combined nuclear and cytosolic dNTP pools. 
We did not find the mitochondrial volume measure for 3T3 cells. As an estimate, we 
averaged the mitochondrial volumes reported for HeLa and Chinese hamster cells [60, 
62] and obtained the cytoplasmic volume after correcting whole-cell volume [63] for the 
total mitochondrial volume. We then converted dNTP amounts for 3T3 cells to 
concentrations using these volume measures. 
 
Ferraro et al. [57] and Pontarin et al. [32] reported dNTP amounts measured in human 
lung and skin fibroblasts. We used the human skin fibroblast volume reported by 
Imaizumi et al. [64]; and after correcting this whole-cell measure by subtracting 
mitochondrial volume, we transformed the reported cytoplasmic picomole amounts to 
cytoplasmic concentrations. We obtained the averaged mitochondrial volume from HeLa 
cells [60]. We used the cytoplasmic volume of fibroblast cells obtained by subtracting 
mitochondrial volume from fibroblast cell volume to account for the fact that Ferraro et 
al. [57] and Pontarin et al. [32] combined nuclear and cytosolic dNTP pools. The 
parameters used for these conversions were also used to convert the data from Saada [27] 
and Frangini et al. [58]. 
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Finally, to convert dNTP amounts reported by Desler et al. [56] for HeLa cells, we used 
parameters from HeLa cells [60] for average cellular and mitochondrial volumes. We 
subtracted mitochondrial amounts and volume from corresponding whole-cell measures 
and obtained cytoplasmic and mitochondrial concentrations. 
 
The conversion parameter values are listed in Table 2. There exist reports of 
mitochondrial dNTP pool measurements that are not discussed here [15, 28, 65-67]. In 
these experiments, because the corresponding cytoplasmic dNTP pools were not also 
reported, the mitochondrial dNTP measurements were not useful for the purposes of 
answering the questions posed in this chapter.  It should be clear from the preceding 
paragraphs that the conversion of the traditionally used units to the actual units of 
concentration is not trivial.  Ideally, each experiment should take care to measure and 
report the additional information needed for this conversion to true concentration units.  
The missing parameter values, which we estimated as described above, may have 
introduced noise into the following analysis potentially obscuring any relationship 
between the cytoplasmic and mitochondrial pools. 
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Table 2: Parameter values used to calculate subcellular dNTP concentrations. Not all 
parameters were available for all cell lines. 
 
 
 
Reference Parameter Estimate 
 
[60] Cellular volume per HeLa cell 1766 ± 55 fL 
[60] Cytoplasmic volume per HeLa cell 1611 ± 62 fL 
[60] Number of mitochondria per HeLa cell 545 ± 31 
[60] Volume of a mitochondrion in  HeLa cells 0.285 ± 0.005 fL 
[60] Mitochondrial volume per HeLa cell 155 ± 29 fL 
[60] Cellular volume per HeLa cell (G1 phase only) 1353 ± 54 fL 
[60] Cytoplasmic volume per HeLa cell (G1 phase only) 1235 ± 55 fL 
[60] Number of mitochondria per HeLa cell (G1 phase only) 417 ± 39 
[60] Volume of a mitochondrion in HeLa cells (G1 phase only) 0.283 ± 0.006 fL 
[60] Mitochondrial volume per HeLa cell (G1 phase only) 118 ± 11 fL 
[61] Mitochondrial volume per milligram protein 0.82 µL 
[60, 62, 63] Cytoplasmic volume per 3T3 cell 2622 ± 67 fL 
[60, 62] Mitochondrial volume per 3T3 cell 96 ± 15 fL 
[60, 64] Cytoplasmic volume per fibroblast cell 3252 ± 29 fL 
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II.4. Results and Discussion 
Variation in cytoplasmic and mitochondrial dNTP concentrations: Paired 
measurements of dNTP levels in mitochondria and cytoplasm, converted to concentration 
units as described above, are given in Tables 3-5 and shown in Figures 3 and 4. The 
variation in dNTP concentrations in both compartments is striking. Even for cells within 
each particular category, the range of dNTP concentrations in both compartments spans 
an order of magnitude. This argues for measuring dNTP levels in a wide variety of cell 
lines, especially those cell types that are affected in mitochondrial DNA depletion 
syndromes. Also, given these characteristics of the distribution of dNTP concentrations, 
the usefulness of calculating a mean value across cell types is diminished. Nevertheless, 
the mean dNTP concentrations that we calculated in both cellular compartments are 
higher in cycling cells than in quiescent cells (fold difference of ~10 in the cytoplasm and 
~4 in the mitochondria). It is interesting that mitochondrial dNTP pools vary 
proportionally with the cytoplasmic pools and cycling state of cells. This observation is 
consistent with deoxyribonucleotide flow between the cytoplasm and mitochondria and is 
indicative of mitochondrial dNTP pools being regulated in a similar manner as the 
cytoplasmic pools. Mean cytoplasmic dNTP micromolar concentrations in postmitotic, 
mitotic, and transformed cells were approximately 1, 12, and 21 respectively; and mean 
mitochondrial micromolar concentrations were about 2, 8, and 10 respectively. These 
calculated mean concentrations hint that perhaps the equilibrium between the cytoplasm 
and mitochondria with respect to dNTP concentrations could be qualitatively and 
quantitatively different for the three cell categories, since the calculated mean 
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mitochondrial concentration is lower than the mean cytoplasmic concentration in normal 
mitotic and transformed cells, and higher in postmitotic cells.  
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Table 3: dNTP concentrations in the cytoplasm and mitochondria of normal mitotic cells. 
 
 
 
Cell line (Reference) dNTP Cytoplasmic concentration 
(micromolar) 
Mitochondrial concentration 
(micromolar) 
Cycling skin fibroblasts [32] T 26 ±0.2 12±2.2 
Cycling skin fibroblasts [32] C 20±0.2 13±2.3 
Cycling lung fibroblasts [57] T 18±2.0 10±1.9 
Cycling lung fibroblasts [57] A 3.9±1.0 1.9±0.3 
Cycling lung fibroblasts [57] C 6±1 4±1 
Cycling lung fibroblasts [57] G 2.2±0.2 1.3±0.3 
Cycling skin fibroblasts [57] T 26±0.2 12±2.2 
Cycling skin fibroblasts [57] A 18±0.2 9.0±1.6 
Cycling skin fibroblasts [57] C 20±0.2 13±2.3 
Cycling skin fibroblasts [57] G 3.7±0.03 2.6±0.5 
Cycling skin fibroblasts [27] T 8.2±1.5 7.2±2.0 
Cycling skin fibroblasts [27] A 3.8±0.5 4.8±1.2 
Cycling skin fibroblasts [27] C 3.7±1.1 7.4±2.1 
Cycling skin fibroblasts [27] G 3.8±1.7 14±3.3 
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Table 4: dNTP concentrations in the cytoplasm and mitochondria of normal postmitotic 
cells. 
 
 
 
Cell line (Reference) dNTP Cytoplasmic concentration 
(micromolar) 
Mitochondrial concentration 
(micromolar) 
Quiescent skin fibroblasts [32] T 0.30±0.002 1.4±0.3 
Quiescent skin fibroblasts [32] C 0.980±0.008 2.1±0.4 
Quiescent lung fibroblasts [57] T 0.760±0.006 0.8±0.2 
Quiescent lung fibroblasts [57] A 3.5±0.3 1.9±0.3 
Quiescent lung fibroblasts [57] C 2.46±0.61 1.28±0.23 
Quiescent lung fibroblasts [57] G 1.1±0.3 0.25±0.05 
Quiescent skin fibroblasts [57] T 0.92±0.01 0.96±0.17 
Quiescent skin fibroblasts [57] A 1.07±0.01 3.5±0.6 
Quiescent skin fibroblasts [57] C 2.15±0.01 1.4±0.3 
Quiescent skin fibroblasts [57] G 1.23±0.01 0.8±0.1 
Quiescent skin fibroblasts [27] T 0.6±0.3 4.2±1.1 
Quiescent skin fibroblasts [27] A 1.7±0.3 3.1±1.7 
Quiescent skin fibroblasts [27] C 0.3±0.2 2.6±0.8 
Quiescent skin fibroblasts [27] G 0.8±0.3 8.5±1.9 
Quiescent skin fibroblasts [58] T 0.5±0.1 0.7±0.2 
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Table 5: dNTP concentrations in the cytoplasm and mitochondria of transformed cells. 
 
 
 
Cell line 
(Reference) 
dNTP Cytoplasmic concentration 
(micromolar) 
Mitochondrial concentration 
(micromolar) 
HOS [59] T 27±5.5 4.4±0.8 
HOS [59] A 6.8±0.3 2.9±0.5 
HOS [59] C 12±0.4 4.8±0.9 
HOS [59] G 3.6±0.1 1.7±0.3 
3T3 [59] T 7.2±0.2 5.4±0.8 
3T3 [59] A 4.2±0.1 4.7±0.7 
3T3 [59] C 7.6±0.2 5.8±0.9 
3T3 [59] G 2.09±0.05 4.0±0.6 
HeLa [33] T 26±5.3 35±6.1 
HeLa [33] A 23±2.3 15±0.3 
HeLa [33] C 11±0.6 7.9±1.2 
HeLa [33] G 3.3±0.9 29±1.2 
HeLa [56] T 57±9.6 5.5±2.7 
HeLa [56] A 28±6.2 6.4±2.2 
HeLa [56] C 17±2.8 14±2.8 
HeLa [56] G 20±2.0 7.1±3.3 
HeLa [55] T 79±3.0 17±3.1 
HeLa [55] A 74±2.8 11±2.0 
HeLa [55] C 14±0.5 15±2.8 
HeLa [55] G 6.1±0.2 6.4±1.2 
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Figure 3: Cytoplasmic and mitochondrial concentrations compiled from the literature of 
dTTP and dATP from (A) mitotic cells data, (B) postmitotic cell data, (C) mitotic and 
postmitotic data combined, and (D) transformed cells. The error bars were calculated by 
statistically propagating the uncertainties in the original measurements. Lines are linear 
fits to the data, shown when statistically significant. 
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Figure 4: Cytoplasmic and mitochondrial concentrations compiled from the literature of 
dCTP and dGTP from (A) mitotic cells data, (B) postmitotic cell data, (C) mitotic and 
postmitotic data combined, and (D) transformed cells. The error bars were calculated by 
statistically propagating the uncertainties in the original measurements. Lines are linear 
fits to the data, shown when statistically significant. 
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A suggested problem with dNTP assays: It is possible that some of the reported dNTP 
measurements are overestimates. In a recent paper, Ferraro et al. [68] concluded that 
reported dNTP measurements can be contaminated by ribonucleotide triphosphates. This 
contamination is a consequence of the low discrimination power of the Klenow DNA 
polymerase fragment that is widely used to measure dNTP amounts by means of a 
polymerase assay. It was suggested that these assay complications might have resulted in 
overestimates of dNTPs, including the very high values reported for mitochondrial dGTP 
levels in rat tissues [67]. When Ferraro et al. extracted and measured dNTPs from cycling 
and confluent human fibroblasts, the original Klenow assay did not result in any 
overestimation of dTTP. The deoxyribonucleotides dATP, dGTP, and dCTP were all 
overestimated, and the severity of this complication seemed to most affect dGTP and, to a 
lesser extent, dCTP. From our interpretation of the Ferraro et al. analysis we judged that 
the dATP measurements analyzed here may not have significant contamination from 
ATP competition for incorporation. At an ATP/dATP ratio of 350 in cycling cells, the 
overestimation in Ferraro et al’s results for dATP was about 21% compared to their 
modified assay and about 26% compared to HPLC. At an ATP/dATP ratio of 1450 in 
confluent cells, the overestimation in dATP was slightly more than 100% compared to 
their modified assay. Ferraro et al. could not use HPLC for measuring dNTP pools in 
confluent cells. Since we did not have paired rNTP measurements for our dNTP data and 
since Ferraro et al.’s paper did not provide a spectrum of overestimation effects over a 
broad enough range of Klenow concentrations and ATP/dATP ratios, we cannot 
quantitatively determine the true effects of this complication on the dATP concentrations, 
although at a low ATP/dATP ratio, the observed overestimation was not substantial. 
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Ferraro et al. concluded that the Klenow enzyme is unsuitable for measuring dGTP and 
dCTP pools, but the assay can be used with modifications to measure dTTP and dATP 
pools. We took these concerns into account by reviewing the data on dTTP and dATP 
concentrations separately from the data on dGTP and dCTP concentrations. Accordingly, 
we have split our data discussion into two groups; the dTTP and dATP group and the 
dGTP and dCTP group. 
 
Analyzing simultaneous data on cytoplasmic and mitochondrial dNTP 
concentrations: dTTP and dATP observations: Figures 3 and 4 (and Tables 3-5) show 
the comparison of paired measurements of dNTP concentrations in the cytoplasm and in 
the mitochondrial compartments of the cell. Despite the relatively low number of 
available observations and the potential for additional noise due to the need for some 
parameter estimations, these data show highly significant correlations. In addition, the 
pattern of which correlations are highly significant and which are non-significant is 
interesting.  For the combined dTTP and dATP measurements in the mitotic cells (Figure 
3A) the mitochondrial and cytoplasmic concentrations had a very highly significant 
correlation (p-value = 0.0009) while the postmitotic cell measurements alone (Figure 3B) 
had no significant correlation.  However, when the postmitotic cell and mitotic cell 
measurements were analyzed together (Figure 3C) the correlation became extremely 
significant (p = 5 x 10-8). The concentrations were highly correlated (R2 = 0.9 in both 
cases, Figure 3A and Figure 3C).  Such a strong and highly significant correlation over 
the broad range of concentrations, in data from multiple independent experiments from 
different laboratories, is extremely compelling evidence for a tight connection between 
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the cytoplasmic and mitochondrial dTTP and dATP pools.  Correlations, of course, 
cannot prove which of these two pools is controlling the other.  However, considering the 
relatively small total cellular volume of the mitochondria compared to the cytoplasm, it is 
reasonable to assume that it is the larger cytoplasmic dNTP pool that is controlling the 
much smaller mitochondrial pool.   
 
We label the combined mitotic and postmitotic cells as ‘normal’ to contrast them with the 
final category which is transformed cells (Figure 3D) consisting of HeLa, HOS, and 3T3 
cells. The transformed cells show no significant correlation between the mitochondrial 
and cytoplasmic concentrations for dTTP and dATP.  This is in stark contrast to the 
normal cycling cells (Figure 3A) which had a very strong correlation.  The statistics are 
summarized in Table 6. 
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Table 6: Statistics for correlations between mitochondrial and cytoplasmic dNTP 
concentrations. NS = not significant. 
 
 
 
Cell Type dNTP Type Number of 
Observations 
Pearson R2 p-value Slope 
Mitotic dTTP and dATP 7 0.90 9 x 10-4 0.37 ± 0.05 
Postmitotic dTTP and dATP 8 0.01 0.77 NS 
Normal (Mitotic + 
postmitotic) 
dTTP and dATP 15 0.90 5 x 10-8 0.41 ± 0.04 
Normal (Mitotic + 
postmitotic) 
dTTP 9 0.92 3 x 10-5 0.42 ± 0.04 
Normal (Mitotic + 
postmitotic) 
dATP 6 0.77 0.01 0.36 ± 0.09 
Transformed dTTP and dATP 10 0.05 0.53 NS 
Mitotic dCTP and dGTP 7 0.42 0.11 NS 
Postmitotic dCTP and dGTP 7 0.14 0.39 NS 
Normal (Mitotic + 
postmitotic) 
dCTP and dGTP 14 0.49 0.005 0.53 ± 0.15 
Normal (Mitotic + 
postmitotic) 
dCTP 8 0.88 0.0005 0.56 ± 0.08 
Normal (Mitotic + 
postmitotic) 
dGTP 6 0.16 0.42 NS 
Transformed dCTP and dGTP 10 1 x 10-5 0.99 NS 
Normal (Mitotic + 
postmitotic) 
All dNTPs 29 0.62 3 x 10-7 0.43 ± 0.06 
Transformed All dNTPs 20 0.03 0.45 NS 
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In Figure 3 the two different deoxyribonucleotides dTTP and dATP are plotted with 
different symbols.  Although the amount of data for each deoxyribonucleotide separately 
is quite small, both dTTP and dATP appear to be following the same relationship 
between cytoplasmic and mitochondrial concentrations in mitotic cells and in the 
combined ‘normal cell’ category.  There are enough measurements in the normal cell 
category (Figure 3C) to allow an analysis of dTTP and dATP separately, and they are 
independently statistically significant (p = 3 x 10-5 for dTTP and p = 0.01 for dATP).  
More importantly, the slopes on the linear regressions for dTTP and dATP analyzed 
separately are consistent with each other (0.42 ± 0.04 and 0.36 ± 0.09 respectively) 
(Table 6). The simplest interpretation of this is that a common mechanism is acting on 
both dATP and dTTP. 
 
We fit a linear model of mitochondrial dTTP and dATP concentrations as a function of 
their cytoplasmic concentrations in normal cells obtaining the following equation: 
………………………………Eq. 1 
where dNTP is either dTTP or dATP and concentrations are measured in micromolar. 
The R2 of this model was 0.9 and the p-value of the F-statistic was 5 x 10-8. The model 
indicates that in normal cells, mitochondrial dTTP and dATP concentrations are slightly 
less than half the cytoplasmic dNTP concentration plus about 1.8 micromolar. If we 
assume that the mitochondrial salvage pathway is independent of the cytoplasm dNTP 
concentrations, then one simple interpretation of this model is that the slope represents 
the transport function between these two subcellular compartments and the intercept 
represents the production of the mitochondrial salvage pathway, independent of the 
[ ] ( )[ ] ( )0.41 0.04 1.8 0.4
mito cytodNTP dNTP Mµ= ± + ±
42 
 
cytoplasmic pathways.  Based on this linear model fit to the experimental data, we 
speculate that the mitochondrial salvage pathway alone is sufficient to support a 
concentration of roughly 2 micromolar of dATP and dTTP within the mitochondria. In 
postmitotic cells, the mitochondrial concentrations are in general higher than the 
cytoplasmic concentrations (Figure 3B). In these cells, because of low cytoplasmic 
concentrations, the intercept term of the model has increased influence on the 
mitochondrial concentrations compared to its influence in mitotic cells. 
 
dCTP and dGTP observations: For dGTP and dCTP the connection between the 
mitochondrial and cytoplasmic concentrations is far less clear (Figure 4).  No significant 
correlations exist for the mitotic and postmitotic cells analyzed separately (Figures 4A 
and 4B).  When these data are combined into the normal cell category (Figure 4C) the 
correlation is significant (p = 0.005). As was seen with dTTP and dATP, dGTP and dCTP 
were not significantly correlated in the transformed cell data.  When dCTP and dGTP 
were analyzed separately for the normal cell category the dCTP concentrations were 
significantly correlated (p = 0.0005) but the dGTP concentrations were not significant. 
The slope for the dCTP concentration correlation in normal cells was slightly larger (0.56 
± 0.08) than that obtained for dTTP and dATP (Table 6). The primary difference between 
the dNTP concentrations in the mitochondrial and cytoplasmic compartments occurs in 
dGTP, which is consistent with the concerns raised by Ferraro et al [68], and discussed 
above, about the validity of measured dGTP levels using current standard methods. 
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Interpreting the correlations in normal cells: The data show that in normal cells in 
culture, dTTP, dATP, and dCTP concentrations in the mitochondria are correlated with 
those in the cytoplasm with very highly significant p-values. While the mitochondrial 
dNTP concentrations within the quiescent cells when taken alone are not significantly 
correlated with the cytoplasmic dNTP concentrations, these values fit into the statistically 
significant linear correlation in the normal cycling cells. The lack of significant 
correlation within the quiescent cell data may be simply due to the small dynamic range 
of the concentrations within the quiescent cells, compared to the noise level in the 
measurements. dNTPs in mitochondria can in principle originate from two routes: import 
of cytoplasmic deoxynucleosides and subsequent phosphorylation within the 
mitochondria (the standard salvage pathway), and/or an import of phosphorylated 
deoxyribonucleotides from the cytoplasm (Figure 2). If the primary source of dNTPs 
within the mitochondrion was the salvage pathway then one would expect that the 
mitochondrial and cytoplasmic dNTP concentrations would be independent, since the 
salvage pathway could produce mitochondrial dNTPs completely independently of the 
cytoplasmic dNTPs. Our analysis of the available data shows this is not the case in 
normal cells and is in agreement with conclusions made by the researchers who produced 
the data. Our description of the original interpretation of the data is focused just on those 
conclusions that relate to our own, and we refer the readers to the original papers for the 
complete interpretations. Rampazzo et al. [59] in their study of transformed cells 
concluded that while dNTP levels were lower in the mitochondrial compartment than in 
the cytoplasmic compartment, the difference might be explained by different patterns of 
the concentrations in the three phosphorylation states, so that the summed 
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deoxyribonucleotide concentrations may be roughly equivalent in the two compartments.  
Since the deoxyribonucleotides other than dNTP were not measured in these experiments, 
their conclusion cannot be directly tested. In that paper Rampazzo et al. also reported that 
the mitochondrial dTTP level in the transformed cells varies with the cell cycle. In the 
later experiment by the same group Ferraro et al. [57] measured dNTP levels in non-
transformed cells and concluded that the proportions of mitochondrial to cytoplasmic 
dNTP levels in non-transformed cells was similar to that in their previous experiment on 
transformed cells [59].  In contrast to these interpretations, we have chosen to concentrate 
just on the reported dNTP levels, instead of attempting to extrapolate to the mono-
phosphate and di-phosphate levels.  Also in contrast to these papers, we have determined 
that there is a very significant difference between the results from the non-transformed 
and the transformed cells.   
 
The association between cytoplasmic and mitochondrial dNTP concentrations suggests a 
strong cytoplasmic control on the pathways that give rise to the mitochondrial dNTPs. 
The simplest form of this control would be the transport of deoxyribonucleotides from 
the cytoplasm to the mitochondrion with only a small amount of dNTP production from 
the mitochondrial salvage pathway. An alternative, but less parsimonious mechanism 
would involve a coordinated modulation of nucleotide metabolism in the two subcellular 
compartments. One caveat of our review is that the available data is based on cell cultures 
from a limited range of cell types, primarily lung and skin fibroblasts.  Quiescent 
fibroblasts may not be a good general model for all non-cycling cells, in particular for 
neurons and muscle fibers. This data indicates the need to carry out similar experiments 
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simultaneously measuring the cytoplasmic and mitochondrial dNTP concentrations in 
these postmitotic cell types that are directly relevant to the genetic diseases involving 
altered mitochondrial dNTP production. Measuring the compartmental volumes in the 
same experiment in addition to measuring dNTP levels would allow for a direct 
comparison of dNTP concentration measurements from different labs and between cell 
lines, avoiding the parameter assumptions that were necessary here.    
 
Since the mitochondrial dNTP levels are strongly affected by the cytoplasmic dNTP 
levels, alterations in many of the other genes of the cytoplasmic deoxyribonucleotide 
metabolism may also have phenotypes involving failure to properly maintain 
mitochondrial DNA.  The hypothetical transport mechanism that shuttles 
deoxyribonucleotides into the mitochondria would also be a candidate for mtDNA 
depletion syndromes, and its expression pattern would be a factor in determining the 
vulnerability of tissues to mutations in the transporter. These results, showing that the 
mitochondrial and cytoplasmic dNTP levels are tightly correlated, greatly expand the 
range of proteins that may lead to mitochondrial dNTP imbalances, and thus to problems 
with mtDNA replication.   
 
Interpreting the lack of correlations in transformed cells: The correlation between the 
mitochondrial and cytoplasmic dNTP concentrations, which is strong in normal cycling 
cells, is lost in this data from transformed cells.  A comparison of Figure 3D (transformed 
cells) to Figure 4A (normal mitotic cells) shows that the range of values for both the 
mitochondrial and cytoplasmic dTTP and dATP concentrations is increased by roughly a 
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factor of three in the transformed cells compared to the normal cycling cells. It is possible 
that the higher percentage of S-phase cells in a transformed cell culture compared to a 
culture of normal fibroblasts contributes to this increase in dTTP and dATP 
concentrations. The dNTP metabolism in both pools appears to be altered, though one 
could argue from the distribution of the data (Figure 3D) that the cytoplasmic values are 
more systematically increased than are the mitochondrial values. However, there is not 
enough data currently to make a confident comparison. Certainly, the tight correlation 
seen in the normal cycling cells is disrupted in the transformed cells by some unknown 
mechanism. One might reasonably ask whether this disruption of the correlation between 
the dNTP levels is a minor consequence of the transformation process or is a fundamental 
(perhaps even necessary) part of the transformation process. The Warburg hypothesis 
proposes that a shift of energy metabolism from oxidative phosphorylation to glycolysis 
is intimately involved in the transformation of normal cells to the cancerous state, and not 
just a side-effect [69]. The Warburg hypothesis has gone in and out of favor over the 
decades since it was first proposed, though recent experiments support it [70]. 
Diminished transcription or translation of mtDNA-coded components of oxidative 
phosphorylation would diminish the ATP production in the mitochondria. The correlation 
of cytoplasmic and mitochondrial dNTP concentrations in normal cells and its disruption 
in transformed cells indicates that the transformation process alters the cytoplasmic-
mitochondrial communication in dNTP levels. By our analysis, decoupling of dNTP 
concentrations can be attributed mostly to disproportionately higher dNTP concentrations 
in the cytoplasm, as the mitochondrial concentrations in such cells are generally not 
drastically elevated compared to normal cycling cells. One speculative mechanism that 
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could account for this disruption of the normally tight correlation in dNTP levels between 
the two compartments would be a limitation in the transport of deoxyribonucleotides 
from the cytoplasm into the mitochondrion.  This could come about simply through the 
saturation of the transport mechanism as the cytoplasmic dNTP concentrations rise in the 
transformed cells, or it could come about through the active suppression of the transport 
mechanism as part of the cell transformation process. Aside from the potential 
importance of the loss of this correlation in dNTP levels as a feature of transformed cells, 
there is a great practical importance to this observation.  This data supports the 
conclusion that transformed cells should not be used in studies of the mitochondrial 
deoxyribonucleotide metabolism, since something fundamental about that metabolism is 
altered in transformed cells. This would be inconvenient, since transformed cell lines are 
generally far easier to use in in vitro than are primary cell cultures.  However, the data in 
Figures 3 and 4 clearly indicate that something critical is disrupted in the mitochondrial 
dNTP metabolism pathway, at least in these three transformed cell types. An additional 
concern is the lack of data on the mitochondrial compartment size in 3T3 and HOS cells, 
as discussed above.  Conceivably, the parameter assumptions needed to convert the 
reported units to concentrations may introduce enough noise to mask a correlation 
between the two compartments in the transformed cells. Further work on this question is 
clearly needed.  In particular, an experiment measuring mitochondrial and cytoplasmic 
dNTP concentrations in both normal cells and their transformed versions would be very 
valuable.   
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Our interpretations in the context of the problem with dNTP assays: As described 
earlier, Ferraro et al. [68] recently concluded that the dNTP levels measured by the 
Klenow polymerase assay could be significantly contaminated by ribonucleotides. Their 
results indicated that dTTP measurements would have minimal contamination problems. 
The fact that the dATP correlation slope (Table 6) is consistent with the dTTP correlation 
slope, and that in general the pattern in the dATP data is indistinguishable from the 
pattern in the dTTP data (Figure 3) gives us confidence in the dATP measured values.  
The dCTP measured values also showed a significant correlation between the 
mitochondrial and cytoplasmic concentrations in normal cells, though with a slightly 
higher slope than the dTTP or dATP correlations (Table 6).  This slightly higher slope 
could reasonably be due to a ribonucleotide contamination in that assay, or it may reflect 
slightly different kinetics of the unknown mechanism causing this correlation.  Finally 
the dGTP values in the two compartments showed no correlation and this is consistent 
with Ferraro et al.’s results showing that the dGTP measurements could possibly be 
strongly contaminated by ribonucleotides, though of course we cannot rule out the 
possibility that the apparent correlation between cytoplasmic and mitochondrial dNTP 
concentrations simply does not occur for dGTP. 
 
Conclusion: We have carried out a meta-analysis of the available data on dNTP levels in 
the cytoplasmic and mitochondrial subcellular compartments. By compiling the data from 
multiple experiments into a single larger data set, we have been able to make quantitative 
interpretations and statistically significant tests of the data. Our review of the data 
showed that in normal cells the concentrations of dTTP and dATP in the mitochondrion 
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are very strongly correlated with that in the cytoplasm, but that this relationship does not 
occur in transformed cells. Thus, in terms of the subcellular distribution of dNTPs, 
transformed cells may not be suitable for studying normal in vivo regulation of intra-
mitochondrial dNTPs.   
 
The meta-analysis that we have carried out here, combining the results of multiple 
independent experiments, points the way toward a unified set of experiments carried out 
under consistent conditions and focused toward testing the hypothesis resulting from this 
meta-analysis. It would also be valuable to assess whether the extent of the cytoplasmic 
influence on the mitochondrial levels of dNTPs is different for the individual nucleotides, 
and if so, how divergent are the origins of the four canonical dNTPs? A suitable next step 
would be for a research group to simultaneously measure cytoplasmic and mitochondrial 
dNTPs in a broader set of cell lines including transformed cells, in a controlled, uniform 
environment. In order for measurement of dNTP levels to be truly useful, the extra effort 
of converting the experimentally convenient units of amount per million cells to the 
relevant units of concentration should be done.  In many cases in this analysis we had to 
estimate values for missing information. One side effect of estimating this missing 
information is the possible introduction of noise into the data. The strong correlations 
existed despite this unavoidable complication. Fundamental measurements, such as cell 
volume and total mitochondrial volume, need to be reported in these studies in order to 
make the data comparable across different studies.  While we understand the difficulty of 
the extra measurements needed to report dNTP levels in actual concentration units, we 
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would argue that the increased usability of the resulting data makes this effort 
worthwhile. 
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CHAPTER III 
 
CORRELATED TISSUE EXPRESSION OF GENES OF CYTOPLASMIC AND 
MITOCHONDRIAL NUCLEOTIDE METABOLISMS IN NORMAL TISSUES IS 
DISRUPTED IN TRANSFORMED TISSUES 
 
 
 
III.1. Introduction 
This analysis was motivated by the following questions. What is the relationship between 
the expression of corresponding genes of cytoplasmic and mitochondrial nucleotide 
metabolisms? Can gene expression patterns explain the observed correlation patterns in 
dNTP concentrations? We also know that the cytoplasmic and mitochondrial 
compartments are in metabolic communication and can exchange deoxyribonucleotides. 
Therefore, deoxyribonucleotide levels in the cytoplasm can impact mitochondrial 
deoxyribonucleotide levels, and vice versa. Since it is well established that 
transformation is associated with altered cytoplasmic dNTP pools, does the 
transformation process have an effect on the link between the cytoplasm and 
mitochondria?  
 
III.2. Overview 
We investigated the expression of a set of nuclear genes encoding proteins of the 
corresponding pathways of cytoplasmic and mitochondrial nucleotide metabolism in 
normal and cancerous tissues. We also included ribonucleotide reductase in our analysis. 
We were interested in determining the extent of coordination between these two 
corresponding metabolisms at the gene expression level in healthy tissues and whether 
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healthy and cancerous tissues differed in the coordination of gene expression of the two 
metabolisms. This analysis revealed a large number of highly significant positive 
correlations between the tissue expression profiles of the genes of the mitochondrial and 
cytoplasmic pathways in normal tissues indicating that in normal tissues the two 
metabolisms coordinately generate deoxyribonucleoside triphosphates. In transformed 
tissues, this correlation structure was disrupted. Multiple correlations involving the 
mitochondrial nucleoside kinase gene DGUOK were statistically significantly different 
between normal and transformed tissues suggesting that control of DGUOK expression 
relative to other cytoplasmic genes is important in transformed tissues. 
 
A paper describing the work presented in this chapter is in preparation. 
 
III.3. Methods 
Selection of genes: The list of relevant genes was defined based on Reactome’s 
‘Metabolism of nucleotides’ pathway [71]. Within ‘Metabolism of nucleotides’, the sub-
categories of interest to us were the reactions of the cytoplasmic and mitochondrial 
pathways of ‘Purine salvage’, ‘Purine catabolism’, ‘Pyrimidine salvage’, and ‘Pyrimidine 
catabolism’. These sub-categories are made of reactions of anabolism or catabolism of 
nucleotides, and contain the reactions of intra-mitochondrial salvage of 
deoxyribonucleosides, which were the focus of our analysis. Genes coding for enzymes 
involved in these reactions were chosen for our analysis. Genes coding for enzymes 
involved in anabolism or catabolism of nucleosides were not included (e.g., thymidine 
phosphorylase). Genes coding for interconversion of nucleotides were also not included 
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(eg: thymidylate synthase). Given its importance in maintaining both cytoplasmic and 
mitochondrial dNTPs, we included ribonucleotide reductase as a special exception 
although it does not conform to the above criteria. All genes are encoded by the nuclear 
genome. We refer to them as ‘cytoplasmic’ and ‘mitochondrial’ to refer to the 
localization of the proteins encoded by the genes. 
 
Obtaining expression values: The NCBI UniGene database provides EST frequencies of 
UniGene clusters, which are representative of the mRNA frequencies of the gene that 
corresponds to that cluster. The features of the UniGene database are described in [72]. 
All of the data is from human tissue samples. We obtained EST profiles for our selected 
genes from the UniGene database build #228 for the set of UniGene-classified 
‘Breakdown by Body Sites’ and ‘Breakdown by Health State’ tissues. The first category 
is comprised of tissues such as muscle, eye, liver, etc, and the second category is 
comprised of tumors, carcinomas, cancers, etc. We therefore denote these categories as 
‘normal tissues’ and ‘transformed tissues’, respectively. We did not include expression 
values for the tissues ‘ascites’ in the normal category and ‘normal’, and ‘non-neoplasia’ 
in the transformed category because of the ambiguity of the classification of those tissues, 
leaving 44 tissues in the normal category and 24 tissues in the transformed category. For 
four genes in our target set (TMPK2, AK6, NME2, and NT5C1A) we did not find 
expression values in UniGene, leaving 25 genes, of which five encoded mitochondrial 
enzymes. Our final dataset was comprised of expression values (transcripts per million) 
of 25 selected genes in 44 normal tissues and 24 transformed tissues. EST counts came 
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from non-subtracted and non-normalized libraries. The list of genes is given in Tables 7 
and 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
Table 7: Cytoplasmic protein genes used in this analysis. 
 
 
 
Gene Protein product 
RRM1 ribonucleotide reductase subunit M1 
RRM2 ribonucleotide reductase subunit M2 
RRM2B ribonucleotide reductase subunit M2B 
TK1 thymidine kinase 1 
DCK deoxycytidine kinase 
AK1 adenylate kinase 1 
AK5 adenylate kinase 5 
GUK1 guanylate kinase 1 
CMPK1 cytidine monophosphate kinase 1 
DTYMK deoxythymidylate kinase 
NME1 nucleoside diphosphate kinase 1 
NME3 nucleoside diphosphate kinase 3 
ADK adenosine kinase 
NT5E 5'-nucleotidase, ecto 
NT5C2 5'-nucleotidase, cytosolic II 
NT5C1B 5'-nucleotidase, cytosolic IB 
NT5C 5', 3'-nucleotidase, cytosolic 
NT5C3 5'-nucleotidase, cytosolic III 
UCK1 uridine-cytidine kinase 1 
UCK2 uridine-cytidine kinase 2 
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Table 8: Mitochondrial protein genes used in this analysis. 
 
 
 
Gene Protein product 
TK2 thymidine kinase 2 
DGUOK deoxyguanosine kinase 
NT5M 5',3'-nucleotidase, mitochondrial 
AK2 adenylate kinase 2 
NME4 nucleoside diphosphate kinase 4 
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Statistics: For statistical robustness, we used the non-parametric measure of Spearman 
rank correlation to measure the strength of pairwise relationships. Correlations that were 
statistically significantly different between normal and transformed tissues were obtained 
using Fisher’s z transformation.  
 
The full dataset and correlations are presented in Tables 9-11 in the Appendix.  
 
III.4. Results 
In a set of 25 genes, 300 gene-pairs are possible. For each of the 300 gene-pairs, we 
calculated the non-parametric Spearman rank correlation in both normal and transformed 
tissues. In Figure 1 we give an example of this correlation for the mitochondrial protein 
gene DGUOK and cytoplasmic protein gene GUK1. In normal tissues, the correlation of 
the expression levels is 0.46, with the highly significant p-value of 0.001 (Figure 5A).  
Note that since we are using a non-parametric correlation, any outliers such as can be 
seen in Figure 5A, have minimal effect on the correlation value. In transformed cells 
(Figure 5B), the correlation is -0.23 with an insignificant p-value of 0.26.  
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Figure 5: Correlation between DGUOK and GUK1 in (A) normal and (B) transformed 
tissues. The Spearman correlation Rho in normal tissues is 0.46 and is highly significant 
(p = 0.001), but is not significant in transformed tissues (Rho = -0.23, p = 0.26). 
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Correlations in transformed tissues are not independent of the correlations in 
normal tissues: We investigated the entire set of correlations to test for the presence of 
any systematic trends. The results are shown in Figure 6. Each point is a pair of genes, 
and their correlation in normal tissues and transformed tissues is represented by the X 
axis and Y axis respectively. The Spearman correlation between the correlations within 
the two tissue categories is 0.52 (p < 10-4). Thus, the correlations in transformed tissues 
are not independent from the correlations in normal tissues. This reproducibility of the 
general pattern in expression levels between the two data sets lends support for the 
validity of our analysis of these correlations. However, there is an important difference 
between the correlations in the transformed tissues compared to the normal tissues. For 
176 of the 300 pairs, the correlation in normal tissues was higher than the corresponding 
correlation in transformed tissues. Note that the line in Figure 6 is the line of equal 
values, not a fit to the data. The number of gene pairs below this line (176 of the pairs) 
was statistically significantly different from 150 (50% of 300) with a chi-square p-value 
of 0.002. In Figure 6, the gene pairs are color-coded based on whether their protein 
products are cytoplasmic and mitochondrial. However, visually there appears to be no 
difference in the patterns of the correlations for the three different categories of gene 
pairs. 
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Figure 6: Magnitudes of all 300 correlations in normal and transformed tissues. Each 
point is the magnitude of the Spearman correlation for a pair of genes. The line of equal 
values is shown. Red, both genes code for mitochondrial enzymes; green, both genes 
code for cytoplasmic enzymes; and blue, one gene codes for a cytoplasmic enzyme and 
the other gene codes for a mitochondrial enzyme. The correlations in transformed tissues 
are not independent of the correlations in normal tissues (Spearman correlation = 0.52, p 
< 10-4). The number of correlations below the equal value line, 176, is statistically 
significantly (chi-square test, p = 0.002) greater than 150 (50% of 300) indicating a trend 
of higher magnitudes of correlations in normal tissues. 
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Differences in normal and transformed tissue correlations are not due to different 
sample sizes: One possible confounding factor in this analysis is that the number of 
tissues in the transformed category was only 24, which is a smaller number than the 44 
tissues in the normal category. To control for this difference, we investigated the 
influence of the sample sizes on the number of significant correlations in this set of 
genes. We hypothesized that even when the sample size of the normal category was 
artificially made equal to that of the transformed category, the number of significant 
correlations in the truncated normal dataset would still exceed the number observed in the 
transformed category. The results are presented in Figure 7. These datasets for normal 
tissues were truncated by choosing 20 tissues randomly (out of 44) and removing the 
expression values for all genes for those 20 tissues. This cut the number of normal tissues 
to be equal to the number of transformed tissues, removing the potential for bias. This 
procedure was repeated to generate 100 random subsets of the normal dataset. The mean 
number of significant correlations in the truncated datasets was 43.5 with a standard error 
of 0.9. The number of significant correlations in none of the 100 truncated datasets was 
lower than the number observed in the full set of transformed tissues, indicating an 
empirical p-value of less than 0.01. We can conclude that the smaller number of 
significant correlations in transformed tissues compared to normal tissues is not simply 
due to the smaller sample size.    
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Figure 7: Smaller number of correlations in transformed tissues is not simply due to 
smaller sample size. We randomly chose 20 tissues and removed all gene expression 
values in order to truncate the number of tissues in the normal dataset to equal the 
number in the transformed dataset. This procedure was repeated 100 times, and for each 
truncated dataset the number of significant correlations was recorded. The mean of the 
resulting distribution was 43.5 with a standard error of 0.9 in the truncated normal 
datasets compared to the 26 correlations observed in the transformed tissue dataset 
containing the same number of tissues. 
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Transformed tissues have more negative correlations than normal tissues: Out of the 
300 gene-pair correlations, 83 were negative in normal tissues while 120 were negative in 
transformed tissues. Note that these numbers include both significant and non-significant 
correlations. As the non-significant correlations are by definition not statistically 
significantly different from 0, there should be no systematic trend in the sign of the 
correlations. However, that was not the case and the difference in the number of negative 
correlations was statistically significant (Fisher’s one-tailed p-value = 0.0009). 
Considering just the significant correlations, four out of the 26 correlations in 
transformed tissues were negative, while three out of the 66 correlations in normal tissues 
were negative. This difference was not statistically significant, likely due to small scale 
of the numbers of significant negative correlations.  
 
Cytoplasmic and mitochondrial genes are coordinately expressed in normal tissues 
and this coordination is disrupted in transformed tissues: Figure 8 shows the 
significant correlations between genes for cytoplasmic proteins and mitochondrial 
proteins in normal (A) and transformed (B) tissues. We emphasize that all of these genes 
are located in the nuclear genome, not the mitochondrial genome.  The distinction is 
between the subcellular localization of the gene products, not the localization of the genes 
themselves. For the purpose of focusing our analysis, we only plotted here the 
correlations between cytoplasmic protein and mitochondrial protein genes and 
disregarded those correlations where either both genes were for cytoplasmic proteins or 
both genes were for mitochondrial proteins. In Figure 8, red circles are mitochondrial 
protein genes and blue circles are cytoplasmic protein genes. Genes are further grouped 
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and aligned by enzyme class, indicating the role of the enzyme within the pathway. Solid 
lines represent positive correlations between gene expression levels and dashed lines 
represent negative correlations. The bold lines (greater width) are the correlations with 
the absolute value of the magnitude greater than 0.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
Figure 8: Statistically significant (p < 0.05) correlations between cytoplasmic and 
mitochondrial protein genes in normal and transformed tissues. A, normal tissues; B, 
transformed tissues; Blue, cytoplasmic protein genes; Red, mitochondrial protein genes; 
Solid lines, positive correlations; dashed lines, negative correlations. Lines with greater 
width represent absolute values of correlation magnitudes (Spearman Rho) of more than 
0.5. Cytoplasmic and mitochondrial genes are coordinately expressed in normal tissues 
and this coordination is disrupted in transformed tissues. The complete list of correlations 
is presented in Table 11 in the Appendix. 
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As seen in Figure 8A, normal tissues have a large number of significant correlations 
linking the tissue expression of cytoplasmic and mitochondrial protein genes. Moreover, 
all but one of the correlations is positive. Mitochondrial protein genes of the different 
enzyme classes are correlated to the cytoplasmic protein genes not only of the 
corresponding enzyme classes, but also to the cytoplasmic protein genes of other enzyme 
classes. Clearly, in normal tissues, the expression of cytoplasmic and mitochondrial 
proteins of this metabolism is coordinately up-and-down regulated. However, this 
coordination is disrupted in transformed tissues (Figure 8B). The number of correlations 
is much smaller in transformed tissues. As shown in Figure 7, this reduction is not simply 
due to the smaller sample size of the transformed category. The frequency of negative 
correlations is also higher in the transformed tissues. The correlations between the 
corresponding cytoplasmic and mitochondrial protein genes of the same enzyme classes, 
so numerous in normal tissues, are lost in the transformed tissues except within the 
nucleoside diphosphate kinase group, the final step in the salvage pathway to form 
nucleoside triphosphates needed to replicate DNA. This is interesting because of the 
evidence that puts the localization of mitochondrial NME4 protein to the mitochondrial 
intermembrane space [11]. The mitochondrial intermembrane space is considered to be in 
equilibrium with the cytoplasm for the small molecules that are the substrates of these 
enzymes, making the designation of this space as mitochondrial or cytoplasmic somewhat 
ambiguous. Mitochondrial AK2 also has been reported to localize to the intermembrane 
space [10]. As seen in Figure 7B, AK2 is positively correlated with cytoplasmic protein 
genes in the transformed tissues. Thus, genes coding for nucleotide metabolism enzymes 
located in the mitochondrial intermembrane space are expressed coordinately with the 
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genes encoding enzymes of cytoplasmic nucleotide metabolism in transformed tissues. 
On the other hand, DGUOK and TK2, which are nucleoside kinases localized to the 
mitochondrial matrix, are exclusively negatively correlated with cytoplasmic protein 
genes. Additionally, the positive correlations of NT5M, a mitochondrial nucleotidase that 
dephosphorylates nucleoside monophosphates to nucleosides, support the conclusion that 
the equilibrium of the metabolism in the mitochondrial matrix is shifted towards 
deoxyribonucleosides rather than phosphorylated deoxyribonucleotides. Together, the 
correlation structure in transformed tissues indicates that mitochondrial intermembrane 
space metabolism is coordinately regulated with the cytoplasmic metabolism while the 
matrix metabolism is negatively regulated.   
 
Genes of cytoplasmic nucleotide metabolism have higher expression in transformed 
tissues: From Figure 8B, we observed that the expression of mitochondrial protein genes 
is generally negatively correlated with the expression of the cytoplasmic protein genes. 
But in which subcellular compartment is expression significantly changed? To answer 
that question, we tested for statistically significant differences between gene expression 
in normal tissues compared to the expression in transformed tissues, using the non-
parametric Wilcoxon-Mann-Whitney test. The results are shown in Figure 9. Six of our 
25 genes had significantly different (p < 0.05) expression levels between normal and 
transformed tissues. Out of these six genes, five are for cytoplasmic proteins. The only 
mitochondrial protein gene in this group, NME4, codes for the nucleoside diphosphate 
kinase that has been reported to be localized to the mitochondrial intermembrane space 
[11]. As mentioned above, the mitochondrial intermembrane space is generally 
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considered to be in equilibrium with the cytoplasm for small molecules. As seen in 
Figure 9, genes encoding several critical and highly regulated members of cytoplasmic 
nucleotide metabolism such as RRM2, TK1, and NME1 have higher expression in 
transformed tissues. In fact, all of the genes whose expression was significantly different 
between the two tissue categories had higher expression in the transformed category. 
Thus, Figure 9 indicates, not surprisingly, that cytoplasmic nucleotide metabolism is 
upregulated in transformed tissues. None of the genes coding for mitochondrial matrix 
proteins are significantly different in their expression in normal and transformed tissues. 
Thus, unlike the cytoplasmic metabolism, the mitochondrial metabolism is not 
upregulated in transformed tissues. The negative correlations between the two 
metabolisms seen in Figure 8B additionally indicate that higher expression of the 
cytoplasmic protein genes is associated with lower expression of the mitochondrial 
protein genes in the transformed tissues. In Figure 9, we also observe that there is a 
noticeable overlap between the distributions of expression in normal and transformed 
tissues. However, in general transformed tissues contain fewer values of zero expression 
compared to normal tissues indicating that the switch from no expression in normal 
tissues to detectable expression in transformed tissues is an important driver of the 
statistically significant differences in expression. It should be mentioned that a 
statistically significant difference in expression does not necessarily equate to 
biologically significant difference. We also note the overlap between the distributions of 
expression values in normal and transformed tissues shown in Figure 9. Although we 
have used box-plots to capture the data, note that statistical significance was assessed 
using a non-parametric test.   
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Figure 9: Genes with statistically significantly different expression between normal and 
transformed tissues based on Wilcoxon-Mann-Whitney test. The expression of all genes 
is higher (p < 0.05) in transformed tissues and except NME4, all genes code for 
cytoplasmic enzymes. A. NME4, p-value = 0.03. B. RRM2, p-value = 0.03. C. TK1, p-
value = 0.0007. D. GUK1 = 0.01. E. UCK2, p-value = 0.01. F. NME1, p-value = 0.03. 
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DGUOK expression is important for transformed tissues: Which correlations 
distinguish normal tissues from transformed tissues? We answered this question by using 
the Fisher r to z transform to find the correlations that are statistically significantly 
different between normal and transformed tissues. The results are shown in Figure 10. 
Again, only the correlations connecting mitochondrial genes with cytoplasmic genes are 
evaluated. All three correlations with significant changes (p < 0.05) switched from being 
positive in normal tissues to being negative in transformed tissues. More importantly, all 
three correlations involved a single gene for a mitochondrial protein, DGUOK. This 
suggests that the control on the expression of DGUOK relative to the expression of other 
genes could be an important characteristic of transformed tissues. DGUOK is a 
mitochondrial matrix nucleoside kinase acting on deoxyguanosine and deoxyadenosine. 
Thus, due to its influence on dGTP and dATP synthesis, the expression of DGUOK is 
important for mtDNA maintenance.  
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Figure 10: Correlations that are statistically significantly different (p < 0.05) between 
normal and transformed tissues. Only correlations connecting cytoplasmic and 
mitochondrial protein genes are shown. All correlations changed from positive in normal 
tissues to negative in transformed tissues and all correlations involved mitochondrial 
DGUOK. 
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III.5. Discussion 
mRNA levels do not necessarily predict protein levels and protein levels are also 
controlled by translation rates and degradation rates. A more subtle point is that the 
strongest or the most significant correlations of any quantities may not necessarily be the 
most biologically significant.  Even considering these warnings, the pattern in the 
expression levels of this set of genes is consistent and is indicative of a strong 
relationship between the parallel mitochondrial and cytoplasmic metabolic pathways for 
dNTPs.  Furthermore, it is clear that this strong relationship is disrupted in transformed 
cells. 
 
Evidence from mammalian cell-culture models [53, 73] supports the paradigm that 
mitochondrial DNA molecules replicate randomly throughout the cell-cycle and continue 
replicating in postmitotic cells which do not replicate nDNA. To investigate the 
relationship between nucleoside salvage in the cytoplasm and mitochondria, we analyzed 
tissue expression profiles of genes involved in these two processes. The results give a 
consistent picture of a significant and positive linking between the parallel mitochondrial 
and cytoplasmic nucleoside salvage pathways that generate some of the substrate dNTPs 
for DNA replication. We observed that unlike the reported lack of coordination of 
mtDNA and nDNA replication, the expression profiles of genes encoding proteins that 
produce dNTPs were coordinated. Our observation suggests that dNTP production in the 
mitochondria increases correspondingly with increasing dNTP production in the 
cytoplasm and is consistent with the reports of deoxyribonucleotide transport between the 
cytoplasm and mitochondria. In further support, metabolic defects in cytoplasmic 
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nucleotide metabolism that manifest as reduced fidelity of replication of the 
mitochondrial genome are well-acknowledged [74]. Particularly, altered ribonucleotide 
reductase activity as a cause of DNA depletion in the mitochondria [25] is also well-
established. Ribonucleotide reductase, and more generally the 
cytoplasmic pathway of de novo nucleotide metabolism generate the majority of dNTPs 
in the cytoplasm and also contribute to mitochondrial dNTP pools.  
 
Figure 8A leads to the clear conclusion that the two parallel deoxyribonucleotide 
metabolisms collaborate to produce dNTPs in normal tissues. However, in transformed 
tissues (Figures 6 and 8B), we observed that correlations in the genes of cytoplasmic and 
mitochondrial nucleoside salvage were weakened, negative correlations were more 
frequent, and the total number of significant correlations was far smaller. Taken together, 
our results show that, at the gene expression level, the coordination between cytoplasmic 
and mitochondrial salvage genes is disrupted in transformed tissues. Dissecting the 
correlation patterns reveals two interesting insights. First, all correlations involving the 
mitochondrial nucleoside kinase genes TK2 and DGUOK in transformed tissues were 
negative. TK2 and DGUOK catalyze the first step of nucleoside salvage in the 
mitochondrial matrix. It follows that in transformed tissues, when dNTP production in the 
cytoplasm is high, dNTP production in the mitochondrial matrix through the salvage 
pathway would be suppressed. The positive correlations of the mitochondrial 
nucleotidase NT5M with cytoplasmic genes would also indicate that the mitochondrial 
metabolism is shifted towards deoxyribonucleosides. In this case, mitochondria would act 
as sources of deoxyribonucleosides via export to the cytoplasm through equilibrative 
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nucleoside transport. The second insight relates to the positive correlations shared by 
AK2 and NME4 with cytoplasmic genes. As noted earlier, AK2 and NME4 both localize 
to the intermembrane space, which is considered to be in equilibrium with the cytoplasm. 
This implies that the activities of AK2 and NME4 are more closely aligned to the 
enzymes of cytoplasmic nucleotide metabolism in transformed tissues. It seems that 
unlike the other mitochondrial enzymes, NME4 and AK2 are probably utilized to support 
deoxyribonucleotide metabolism in the cytoplasm in transformed tissues.    
 
An interesting transcriptional correspondence between the two metabolisms was 
observed in serum-starved resting HeLa cells [75] where the cellular response to an 
siRNA-induced decrease in the mitochondrial nucleoside kinase DGUOK mRNA was an 
increase in the expression of the cytoplasmic deoxycytidine kinase DCK. In our analysis, 
we discovered three correlations involving DGUOK that were statistically significantly 
different between normal and transformed tissues. Moreover, each of the three 
correlations switched from being positive in normal tissues to being negative in 
transformed tissues. DGUOK is important for the maintenance of mtDNA. Mutations in 
DGUOK are associated with mtDNA depletion [76]. Interestingly, it has been shown that 
lack of mitochondrial DNA (rho0) can lead to chromosomal instability in the nuclear 
genome [77]. We hypothesize that control of DGUOK expression is important in 
transformed cells and would recommend experimental validation of this hypothesis. One 
possible approach in this regard would be to alter the expression of DGUOK in 
transformed tissues or cells and investigate whether that affects the transformed state or 
transformation potential of transformed tissues or cells.  
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The Warburg Effect connects energy production, a key function of mitochondria, and 
cancer [69]. Most cancer cells generate cellular ATP through glycolysis even when 
oxygen is available [78, 79]. Mitochondria do not necessarily shut down in such cells. In 
fact, certain mitochondrial functions are essential for tumor cell proliferation [52]. We 
might speculate that by controlling the expression of a small set of nuclear genes 
encoding proteins of mitochondrial nucleotide metabolism, cancer cells would be able to 
control mtDNA replication and thus selectively control mitochondrial oxidative 
phosphorylation.   
 
Our analysis discovered a large number of statistically significant and biological 
plausible correlations showing that genes of cytoplasmic and mitochondrial nucleotide 
metabolism are coordinately expressed in normal tissues. In transformed tissues, this 
relationship is disrupted. It would be valuable for a research group to test either the 
strongest or the most significant correlations and correlations involving critical genes 
such as ribonucleotide reductase and deoxyguanosine kinase. It would be particularly 
illuminating to investigate the same correlations first in a set of normal tissues or cells 
and then upon induction of transformation of those tissues or cells.           
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CHAPTER IV 
 
ENZYME KINETICS OF THE MITOCHONDRIAL DEOXYRIBONUCLEOSIDE 
SALVAGE PATHWAY ARE NOT SUFFICIENT TO SUPPORT RAPID mtDNA 
REPLICATION 
 
 
 
IV.1. Introduction 
A considerable amount of data on the mitochondrial deoxyribonucleoside salvage 
pathway has accumulated over time. Most of this data was gathered from investigating 
discrete components of this pathway. There is a need for studying this collection of data 
in its entirety. This chapter presents a computational model for fulfilling this need. The 
mitochondrial salvage pathway is complex, and a systems analysis of this pathway as a 
whole is an important companion to the study of the individual enzyme kinetics. Our 
comprehensive computational model allowed us to investigate the dynamics and origins 
of mitochondrial dNTPs. Our modeling is based on experimentally measured kinetics and 
model results enable us to quantitatively track the concentrations as well as the balance of 
the various deoxynucleosides and deoxynucleotides over time within an individual 
mitochondrion.  
 
The content of this chapter has been reproduced with revisions from a published paper on 
which I was first author [7]. 
 
IV.2. Overview 
Using a computational model, we simulated mitochondrial deoxynucleotide metabolism 
and mitochondrial DNA replication. Our results indicate that the output from the 
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mitochondrial salvage enzymes alone is inadequate to support a mitochondrial DNA 
replication duration of as long as 10 hours. We find that an external source of 
deoxyribonucleoside diphosphates or triphosphates, in addition to those supplied by 
mitochondrial salvage, is essential for the replication of mitochondrial DNA to complete 
in the experimentally observed duration of approximately 1 to 2 hours [80]. For meeting 
a replication target of 2 hours, we found that almost two-thirds of the dNTP requirements 
had to be externally supplied as either deoxyribonucleoside di- or triphosphates, at about 
equal rates for all four dNTPs. Added monophosphates did not suffice. However, for a 
replication target of 10 hours, mitochondrial salvage was able to provide for most, but not 
all, of the total substrate requirements. Still, additional dGTPs and dATPs had to be 
supplied. Our analysis of the enzyme kinetics also revealed that the majority of enzymes 
of this pathway prefer substrates that are not precursors (canonical deoxyribonucleosides 
and deoxyribonucleotides) for mitochondrial DNA replication, such as phosphorylated 
ribonucleotides, instead of the corresponding deoxyribonucleotides. The kinetic constants 
for reactions between mitochondrial salvage enzymes and deoxyribonucleotide substrates 
are physiologically unreasonable for achieving efficient catalysis with the expected in 
situ concentrations of deoxyribonucleotides. 
 
IV.3. Methods 
As far as possible, we restricted our analysis to data from human enzymes. Exceptions 
are noted below. We assumed Michaelis-Menten kinetics for all enzymes except TK2 
which has negatively cooperative kinetics with Hill coefficient less than 1 with 
deoxythymidine [6]. 
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kcat / Km: Km values were obtained from the literature  [6, 8, 81-90] or the BRENDA 
database [91]. For most enzymes, we could only find a single report of kinetic 
parameters. For the nucleoside kinases DGUOK and TK2, we did find multiple reports of 
kinetic parameters. In these cases, we selected the reference providing the most 
comprehensive information. To compute kcat values, we first obtained reported Vmax 
values [6, 8, 81, 83-85, 87-90] and molecular weights [8, 82, 91, 92] of the various 
enzymes from the literature or the BRENDA database. If the enzyme was reported to be a 
multimer, we added the molecular weights of the subunits to calculate the molecular 
weight of the holoenzyme. The quantity kcat / Km (M-1 s-1) was calculated from the 
reported values of Vmax / Km (with units of µmol min-1 mg-1 µM-1) using the following 
conversion, 
…………………………………………………………Eq. 2 
where Wenzyme is the enzyme molecular weight. Reported values for Km, Vmax, and the 
calculated kcat / Km values are provided in Table 12 in the Appendix. 
 
Substrate concentrations: Values for the concentrations of the deoxyribonucleoside, 
deoxyribonucleotide, ribonucleoside, and ribonucleotide substrates were used to calculate 
‘(substrate) Concentration / (substrate) Km’ ratios. These values were used for a 
comparison of activities of the enzyme with different substrates and are not meant to be 
precise.  Instead, rough order-of-magnitude concentration values were used to compare 
values for this ratio, which often varies by several orders of magnitude within a single 
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enzyme for different substrates. Literature reports suggest that mitochondrial dNTP pools 
are higher in actively cycling cells compared to quiescent cells [27, 32, 57, 93]. We 
assumed a 10-fold lower concentration of deoxyribonucleotides in quiescent cells, and 
chose 10 µM and 1 µM as reasonable representative estimates of mitochondrial dNTP 
concentrations in cycling and quiescent cells respectively. The basis of these estimates 
are the concentrations calculated from published values in HeLa cells [33] and quiescent 
fibroblasts [58] respectively. We used a value of 0.82 ml/g mitochondrial protein [61] to 
calculate concentrations from the measured pool sizes in HeLa cells, and we used the 
value of 92.3 µm3 for mitochondrial volume per cell [60] to obtain the concentrations 
from the measured pool size in quiescent fibroblasts. For simplicity, we assumed 
ribonucleotides and deoxyribonucleotides to be equally concentrated in the three 
phosphorylation states (mono, di, or tri-phosphorylated). Again for simplicity we 
assumed all four nucleotides (dAXP, dCXP, dGXP, dTXP where X = phosphorylation 
state) to have equal concentrations. Nucleoside concentrations were assumed to be 
equilibrated between plasma, cytoplasm, and mitochondria and set at a constant 0.5 µM 
using a reported value for plasma concentration [94]. Lower nucleoside concentrations 
have also recently been reported [95, 96]. We have kept the higher value in our analysis 
since this is the most conservative choice.  Lower nucleoside concentration values would 
make the problems that we point out in this analysis even more severe. Ribonucleotide 
concentrations were assumed to be constant and set at 100 µM, that is, one order of 
magnitude higher in cycling cells and two orders of magnitude higher in quiescent cells 
compared to deoxyribonucleotide concentrations. This is a fairly conservative (i.e. low) 
choice for the ribonucleotide concentrations. For other special cases of substrates (such as 
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dUMP, dI, or IMP) concentrations data are not readily available so we again assumed low 
concentration values for these substrates. The complete list of assumed concentrations is 
provided in Table 13 in the Appendix. 
 
Inhibitions: In the case that we could not find Ki values of for enzyme inhibitors, we 
assumed competitive inhibition so that the Ki for the inhibitor was set to be equal to the 
Km for that chemical as a substrate. Inhibition kinetics data [6, 8, 81, 85, 88, 90, 97] are 
provided in Table 14 in the Appendix. 
 
Computational simulations: Our group has previously published a computational model 
of mitochondrial deoxyribonucleotide metabolism [93]. Parameter values for the model 
were based, whenever available, on published experimental values [6, 8, 9, 76, 81-86, 88-
93, 97-102]. As part of the present work, we updated the model to reflect the findings 
since the original model was defined. We refer the readers to the previous publication for 
a complete explanation of the basic framework of the model [93]. Briefly, enzymatic 
reactions were modeled with Michaelis-Menten equations (except TK2, which is 
modeled by the Hill equation) and rates of change of metabolites were modeled using 
ordinary differential equations. The updates to the model include adding (e.g. CMPK2) 
and removing (e.g. SLC25A19 or DNC) pathway components and updated kinetics (e.g. 
inhibition terms and kinetic constants). The model was written in Mathematica 7. The 
model files and model constants are available as supporting information S1-S3 in the 
Appendix. 
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Deoxynucleoside transport was modeled through the ENT protein as equilibrative 
between the cytoplasm and mitochondria. Thus, the net rate of deoxynucleoside transport 
was defined using the Michaelis-Menten equation as follows: 
…….………Eq. 3 
where j represents the four deoxynucleoside species (dA, dC, dG, dT) and i represents 
inhibitors. Vmax and Km were taken to be the same for both directions of transport.  
 
The various enzymatic reactions (i.e., phosphorylations and dephosphorylations) were 
modeled using the Michaelis-Menten equation. Thus, the reaction velocity was 
…………………..………………………………………Eq. 4 
where S stands for substrate and [C] stand for the concentration of any competitive 
inhibitors. For the reaction of dT with TK2, the above equation was modified by raising 
the Km and [S] terms to the power 0.5 to represent the Hill coefficient. 
 
The model of the mtDNA polymerization process was explained in the previous 
publication [93]. It models polymerization using fractions of the four deoxynucleotides in 
the mtDNA sequence, setting the prevalence of each base in the mtDNA light and heavy 
strands separately to match the prevalence in the rCRS reference sequence [103]. We 
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have modeled mtDNA replication as asynchronous [80] using the locations of the origins 
of replication of the light strand and the heavy strand.  
 
Differential equations for the concentrations of the various metabolites were defined by 
adding and subtracting the relevant reaction velocity equations. For example, for dNMPs 
(deoxyribonucleoside monophosphates), the following differential equation models the 
rate of change of a particular dNMP: 
………..…………………………Eq. 5 
where NK represents the nucleoside kinase reaction, NT represents the nucleotidase 
reaction, NMPK represents the forward and reverse monophosphate kinase reactions. The 
kinetic constants and inhibition parameter values are available in Tables 12-14 in the 
Appendix. 
 
We used this updated model to test the hypothesis that a source of deoxyribonucleotides 
in addition to intra-mitochondrial salvage is essential for completing mtDNA replication 
in cycling cells in the experimentally observed time of 1-2 hours [80]. To be 
conservative, we set the ‘target’ replication time to be 2 hours (requiring an average 
replication rate = 33136 (nucleotides) / 120 (minutes) = ~276 nucleotides / minute). We 
ran simulations with a replication time of 120 minutes (2 hours), with all dynamics 
including mtDNA replication starting immediately at the beginning of the simulation. We 
also tested a target replication time of 10 hours (requiring an average replication rate = 
33136 (nucleotides) / 600 (minutes) = ~55 nucleotides / minute), reasoning that in 
, ,
[ ]j
j j rev j fwd j
d dNMP NK NT NMPK NMPK
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quiescent cells the time constraints for completing mtDNA replication may be more 
relaxed.  
 
Transport of deoxynucleotides from the cytoplasm to the mitochondrial matrix was 
modeled in a simple manner, by setting a constant production term of either 
deoxynucleosides, dNMPs, dNDPs (deoxyribonucleoside diphosphates), or dNTPs.  
Transport was modeled as occurring at only one phosphorylation level at a time, in order 
to assess the effectiveness of transport at each level. The essence of our simulation 
experiments was to test whether mtDNA replication was completed in the target time 
under varying levels of added molecules, including no addition, of various (A, C, G, T) 
deoxynucleosides and deoxynucleotides. We note that in principle the additional source 
of deoxynucleotides in this model does not necessarily have to be import from the 
cytoplasm but could also be from other unknown intra-mitochondrial sources. However, 
considering the evidence that nucleotide transport does occur between the cytoplasm and 
mitochondria [17, 18], we assume that the additional source we have modeled 
corresponds to import from the cytoplasm. We tested multiple ‘transport profiles’. A 
transport profile is composed of simply the rate of the transported deoxynucleosides and 
deoxynucleotides. For each transport profile, we ran 100 simulations each beginning with 
a different, randomly selected (with uniform probability) set of initial mitochondrial 
concentrations of each deoxynucleoside and deoxynucleotide. As an initial test of the 
level of exogenous precursor transport needed, we set equal rates of import for all four 
(A, C, G, T) nucleosides (or nucleotides) at a particular phosphorylation level and then let 
the rate of import vary from 0 to 1200 molecules per minute, in increments of 100. Thus, 
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for example, for testing whether transport of deoxynucleosides alone suffices, we ran 13 
sets of 100 simulations. In each of those 13 sets, deoxynucleosides alone were imported 
at equal rates for each of the four nucleosides, in increments of 100 starting from 0 and 
up to 1200. Such simulation sets of 13 different import levels were conducted similarly 
for each phosphorylation level of the four deoxynucleoside species.  
 
The initial conditions of the simulations were set randomly with a uniform distribution 
over a set range. The allowed range (minimum and maximum) of initial deoxynucleoside 
concentrations was 0.05 µM to 5 µM and the range of initial deoxynucleotide 
concentrations was 0.1 µM to 10 µM. We set the concentrations of ribonucleosides, 
ribonucleotides, and non-canonical deoxynucleosides and deoxynucleotides to be 
proportional to the randomly selected dN and dNXP concentrations (see Table 13 in the 
Appendix for details) and held these concentrations (which only acted as inhibitors) 
constant throughout the time course of the simulation.  The simulations were repeated 
100 times with varying initial conditions. 
 
We extended the transport analysis further by obtaining the minimum number of 
molecules of each transported dNTP required for mtDNA replication to be completed in 
2 hours (representing cycling cells) or 10 hours (representing quiescent cells). For the 
simulations to determine the minimum transport profiles, we tested whether the 
replication rate exceeded 55 (‘quiescent cells’, fixed initial concentrations: dNs = 0.5 
micromolar and dNXPs = 1 micromolar) or 276 (‘cycling cells’, fixed initial 
concentrations: dNs = 0.5 micromolar and dNXPs = 10 micromolar) nucleotides per 
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minute. We started at equal import of all four dNTPs at a rate such that replication would 
be completed in slightly less than the target time (2 hours or 10 hours). Next, we 
decreased the import of one dNTP at a time to check whether the target replication rate 
was observed. We continued this relaxation process until we obtained the minimum 
transport for each individual deoxyribonucleotide species necessary to support the target 
replication rate.   
 
IV.4. Results 
The kcat / Km ratio: In Michaelis-Menten kinetics, kcat and Km are the basic parameters 
of an enzyme-substrate reaction pair. The parameter kcat is the number of substrate 
molecules catalyzed per enzyme molecule per unit time, and Km is the substrate 
concentration at which the reaction proceeds at half-maximal velocity. High kcat and low 
Km values imply a fast and efficient reaction, and thus, a high kcat / Km ratio indicate that 
this substrate is catalytically preferred by the enzyme.  We searched the literature [6, 8, 
81-90] and databases [91] and gathered the available data on the reaction kinetics of 
enzymes of mitochondrial nucleotide salvage. Figure 11A shows a plot of kcat / Km 
values. Each group of bars is for one enzyme, and within each group the bars are 
arranged from lowest to highest so that the best substrates lie to the right on each plot. 
For clarity, the substrates that are DNA precursors (presumed to be the ‘proper’ 
substrates of these enzymes) are in green, and non-DNA precursor substrates are in red. 
The kcat / Km values cover a very wide range and so are plotted on a logarithmic scale. 
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Figure 11: kcat / Km values of mitochondrial enzymes. (A) kcat / Km values of 
mitochondrial salvage enzymes. Each group of bars is for one enzyme, and within each 
such group the bars are arranged from lowest to highest so that the best substrates lie to 
the right on each plot. Substrates that are DNA precursors are in green, and non-DNA 
precursor substrates are in red. 2’-UMP and 3’-UMP refer to uridine 2’ monophosphate 
and uridine 3’ monophosphate. (B) kcat / Km values of the mitochondrial DNA 
polymerase POLG, justifying the use of kcat/ Km as a measure of substrate preference. 
Reproduced from Gandhi and Samuels (2011) [7]. 
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Figure 11A shows that each of these enzymes has significant reactions with non-DNA 
precursors. More importantly, except for TK2, none of the mitochondrial enzymes have 
DNA precursors as their preferred substrates, as seen from the fact that the substrates 
which lie to the right in each group of bars are non-DNA precursors. Prior work [104] has 
estimated the theoretical maximum of kcat / Km for an enzyme-substrate pair. This 
maximum is constrained by the diffusion limit, and was estimated to be ~108 per M per 
second [104]. Compared to the diffusion limit, the kcat / Km values for reactions of the 
mitochondrial salvage pathway with DNA precursors are orders of magnitude lower 
(range = 888 to 5.63 x 105 per M per second). In summary, in both absolute and relative 
terms these enzymes of the mitochondrial salvage pathway (with the possible exception 
of TK2) do not appear to be optimized for discriminating mtDNA precursor substrates 
from chemically related non-precursor substrates.   
 
To put the kcat / Km results in Figure 11A in perspective, Figure 11B is a plot of kcat / Km 
for the various substrates of the mitochondrial DNA polymerase gamma (POLG). In 
contrast to the enzymes of mitochondrial nucleotide metabolism, Figure 11B shows that, 
as expected, DNA precursors are preferably discriminated by POLG. This is true both 
absolutely and relatively. The kcat / Km values for the dNTP substrates approach the 
diffusion limit of ~108 per M per s, and the values for dNTP substrates are many orders 
of magnitude larger than the kcat / Km values of the ribonucleotide substrates. GTP and 
UTP kinetics data are not shown because the POLG kinetics with these potential 
substrates have not been measured. 
88 
 
The effects of substrate concentration: While the ratio kcat / Km captures the efficiency 
of a reaction between an enzyme and a substrate, it does not take into account the 
expected physiological concentration of the substrate, which may vary by several orders 
of magnitude between ribonucleotide and deoxyribonucleotide substrates. The ratio of 
‘(substrate) Concentration / (substrate) Km’ provides information that is complementary 
to that revealed in the previous section by the ratio kcat / Km. When the substrate 
concentration is much smaller compared to the Km, the enzyme is sensitive to substrate 
concentration and can thus operate at a range of velocities. However, the velocities in this 
range would be smaller than the maximum possible velocity. Depending on the relation 
between maximum possible velocity and the required rate of enzymatic output, substrate 
concentrations smaller than Km can be a detriment. This is the case for the mitochondrial 
salvage enzymes because mtDNA replication has to satisfy certain time constraints. We 
searched the literature [6, 8, 81-90] and databases [91] for Km values of the  
mitochondrial salvage enzymes for various substrates and their expected in situ 
concentrations. Figures 12A and 13A show plots of Concentration / Km values for all of 
the enzyme-substrate pairs for which we could find data. As before, each group of bars is 
for one enzyme, and within each such group the bars are arranged from lowest to highest 
value of the ratio. Preferred substrates would be expected to have higher concentrations 
relative to the reaction Km and thus would fall to the right in each enzyme. Substrates that 
are DNA precursors are plotted in green, and non-DNA precursor substrates are in red.  
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Figure 12: Concentration / Km values in ‘cycling cells’ for mitochondrial enzymes. 
Concentration / Km values at higher mitochondrial concentrations (‘cycling cells’) of the 
deoxyribonucleotide substrates (10 µM). (A) Values for mitochondrial salvage enzymes. 
All reactions involving DNA precursor substrates have Concentration / Km values less 
than 1, suggesting that none of these reactions would be expected to be running at even 
half-maximal velocity. (B) Values for POLG and SLC25A19, justifying the principle of 
using the ratio Concentration / Km as a measure of substrate preference. The 
Concentration / Km ratio for dNTP substrates for POLG is about an order of magnitude 
larger than the ratios for reactions with rNTPs. The Concentration / Km ratios of DNA 
precursor substrates of SLC25A19 are low. Reproduced from Gandhi and Samuels 
(2011) [7]. 
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Figure 12A shows Concentration / Km values at higher mitochondrial concentrations 
(‘cycling cells’) of the deoxyribonucleotide substrates (10 µM). The Concentration / Km 
values for DNA precursor substrates range from 0.001 to 0.19. Thus, none of the 
reactions involving DNA precursor metabolism in the mitochondria would be running at 
maximal reaction velocity. In fact, since all reactions involving DNA precursor substrates 
have Concentration / Km values less than 1, none of these reactions would be expected to 
be running at even half-maximal velocity. It is apparent that these enzymes of 
mitochondrial nucleotide metabolism have significant affinities for non-DNA precursors. 
In many cases, the enzymes have higher affinities for non-DNA precursors than for the 
DNA precursors. In the case of the nucleoside kinases TK2 and DGUOK, although they 
have higher affinities for DNA-precursors, there is a less than 10-fold difference from 
their preference of non-DNA precursors. For some reactions, the expected substrate 
concentrations are orders of magnitude lower than the reaction Km values (range: 0.001 to 
0.19). The same trends exist in the values of Concentration / Km assuming lower 
mitochondrial concentrations of substrates (Figure 13A). Moreover, comparing Figure 
13A (low deoxyribonucleotide concentrations) to Figure 12A (high deoxyribonucleotide 
concentrations), the disparity between DNA precursors and other substrates is more 
striking with an order of magnitude decrease in the Concentration / Km ratio of the DNA 
precursor substrates (range: 0.0007 to 0.19). This was expected as we assumed 
mitochondrial ribonucleotide concentrations to be constant and independent of high or 
low mitochondrial deoxyribonucleotide concentrations.  
91 
 
 
 
 
Figure 13: Concentration / Km values in ‘quiescent cells’ for mitochondrial enzymes. 
Concentration / Km values at lower mitochondrial concentrations (‘quiescent cells’) of the 
deoxyribonucleotide substrates (1 µM) for (A) mitochondrial salvage enzymes and (B) 
POLG and SLC25A19. Reproduced from Gandhi and Samuels (2011) [7]. 
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To place these enzyme kinetics values in context Figures 12B and 13B show positive and 
negative examples justifying the principle of using the ratio Concentration / Km as a 
measure of substrate preference. The Concentration / Km ratio for dNTP substrates for 
POLG is about an order of magnitude larger than the ratios for reactions with 
ribonucleoside triphosphates (rNTPs) (Figure 12B). It is noteworthy that POLG is the 
only enzyme of the mitochondrial ‘salvage’ (DNA replication) pathway whose DNA 
precursor substrates have expected concentrations that are larger than the enzyme Km 
values. For our negative example, we considered SLC25A19 (formerly named the 
deoxynucleotide carrier (DNC), now identified as the thiamine pyrophosphate carrier) 
[65] to be a suitable choice. In contrast to POLG, the Concentration / Km ratios of DNA 
precursor substrates of SLC25A19 are low both in the absolute and the relative sense. 
Dolce et al [82] published data on the Km and Ki values of substrates (we used Ki as a 
proxy for Km if Km was not reported) that were tested for transport by the SLC25A19 
protein, and it is seen in Figures 12B and 13B that DNA precursor substrates (green bars) 
are not the preferred substrates of this enzyme. Eventually, it was discovered that the 
function of SLC25A19 had been misinterpreted [65, 105]. When we compare the 
concentration / Km plots of the mitochondrial nucleotide metabolism (Figures 12A and 
13A) to those of POLG and SLC25A19 (Figures 12B and 13B) we observe that the 
Concentration / Km values of DNA precursors with the enzymes of mitochondrial 
nucleotide metabolism are at the same level as the Concentration / Km values of the DNA 
precursors with SLC25A19, even though these DNA precursors are not the physiological 
substrates of SLC25A19.  We note that SLC25A19 was not used a negative example in 
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Figure 11B because the enzyme kinetics values (kcat) were not available for the relevant 
deoxyribonucleotide or ribonucleotide substrates. 
 
As a side observation, we are intrigued by the fact that at lower dNTP concentrations the 
Concentration / Km values for rNTPs are essentially equal to those for dNTPs for 
polymerization by POLG (Figure 13B). This observation reveals that discrimination by 
POLG in this case is perhaps almost completely dependent on the corresponding reaction 
Vmax. As the Vmax (or kcat) of rNTPs with POLG are much lower than those for dNTPs, it 
is possible that in quiescent cells POLG faces more interference by ribonucleotides, thus 
obstructing the polymerization of deoxyribonucleotides into the DNA molecule being 
synthesized and at the same time promoting the incorporation of ribonucleoside 
triphosphates in the DNA strand. This is consistent with the reported incorporation of 
ribonucleotides in replicating mtDNA [106].   
 
Substrate flow through the salvage pathway: As an initial analysis of the function of 
the salvage pathway, we used the Michaelis-Menten equation to calculate reaction rates 
under assumed substrate concentrations. We ignored the effect of inhibitions. This 
implies that the reaction rates we calculated (number of substrate molecules catalyzed per 
enzyme molecule per minute) were the upper-bound of the rates at the estimated 
concentrations, because inhibitions would act to lower these rates. We call such reaction 
rates ‘effective velocities’. As we assumed deoxyribonucleoside concentrations to be 
constant at 0.5 µM and deoxyribonucleotide concentrations to be either 10 µM (high, 
‘cycling cells’) or 1 µM (low, ‘quiescent cells’), we obtained two sets of effective 
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velocities for the enzymes of mitochondrial nucleotide metabolism – one approximating 
the behavior in cycling cells, and one approximating the behavior in quiescent cells. 
 
Figure 14A is a plot of the effective velocities of nucleoside kinases versus NT5M. 
Remember from Figure 1A that NT5M is the nucleotidase that reverses the action of the 
nucleoside kinases, so the amount of material fed into the salvage pathway depends in 
part on the balance between these two groups of enzymes. The substrate dCMP is absent 
for Figure 14A because no reaction was observed between NT5M and dCMP [88]. Note 
that the nucleoside concentrations were assumed to be constant, so the high and low 
concentration rates are only given for NT5M. Because of inhibitions and competing 
reactions, the deoxyribonucleoside output from NT5M would be much lower than 
represented here, but it is still instructive to compare objectively the disparity between the 
forward and reverse reactions at the first phosphorylation level. It is clear that the 
theoretical maximum velocities (at the assumed concentrations) of NT5M reverse 
reactions are many-fold higher than the maximum velocities from nucleoside kinases. 
While the situation is poor for the dG and dT substrates, it is extremely poor for the dA 
substrate where the reverse reaction has well over an order of magnitude advantage over 
the forward reaction. Furthermore, NT5M may not be the only nucleotidase in the 
mitochondria, thus exacerbating this issue [88]. 
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Figure 14: Effective velocities of some of the reactions of mitochondrial nucleotide 
metabolism. (A) Effective velocities (number of substrate molecules catalyzed per minute 
per enzyme molecule) of nucleoside kinase reactions versus NT5M reactions. Theoretical 
maximum velocities of NT5M reverse reactions are many-fold higher than the maximum 
velocities from nucleoside kinases. (B) A comparison of the effective velocities for 
deoxynucleotide substrates for enzymes of the mitochondrial salvage pathway. The 
horizontal reference line shows the number of nucleotides (approximately 69) of each 
triphosphate needed per minute on average to complete mtDNA replication in two hours. 
Reproduced from Gandhi and Samuels (2011) [7]. 
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In addition to these qualitative comparisons of substrate preferences of mitochondrial 
nucleotide metabolism enzymes, we analyzed the reaction kinetics further to 
approximately quantify the flow of substrates through this enzymatic pathway. For 
simplicity, we ignored the inhibition terms in the Michaelis-Menten equations 
(inhibitions would further reduce reaction velocities). We could then investigate the 
effect of kcat, Km, and substrate concentrations on the upper-bound of velocity of the 
reactions at assumed substrate concentrations and compare the estimated velocities to the 
expected requirements for completing one round of mtDNA replication in a specified 
amount of time. It has been reported that one round of mtDNA replication in cell culture 
takes ~1-2 hours to complete [80]. To be conservative, we assumed that mtDNA 
replication takes 2 hours to complete. To replicate 16,568 bases pairs on two mtDNA 
strands in 2 hours, ~276 nucleotides are required per minute on average (with the log 
scale on Figure 14B it is unnecessary to precisely divide this quantity into the specific 
numbers of dATP, dCTP, dGTP, and dTTP molecules needed for the human mtDNA 
sequence). Figure 14B shows the effective velocities of some of the enzymes of 
mitochondrial nucleotide metabolism (DGUOK, TK2, CMPK2 and AK2). These are all 
the enzymes for which we found data that would enable us to calculate effective 
velocities. To facilitate comparison across these enzymes, some data for DGUOK and 
TK2 are repeated in Figure 14B from Figure 14A. As before, nucleoside kinase velocities 
in Figure 14B are the same for high or low concentration conditions because nucleoside 
concentrations are assumed to be constant. There exists a many-fold difference in the 
output of the four dNMPs, with dA nucleosides being fed into the salvage pathway by 
DGUOK at a rate many orders of magnitude lower than that required to support mtDNA 
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synthesis. Assuming a 2 hour replication duration and an approximately 276 / 4 
nucleotides per minute substrate requirement, the number of molecules of the DGUOK 
enzyme per mitochondrion required to catalyze the requisite output of dAMP is close to 
3000.  The poor kinetics of DGUOK with dA is not the only problem with the dA 
pathway.  Although there could be multiple AK isoforms in the mitochondria, some of 
them are reported to be lacking kinase activity and none of them appear to catalyze 
dAMP phosphorylation with comparable efficiency to that of AMP phosphorylation 
[107]. This is verified for AK2 as seen in Figures 11A, 12A, and 13A. 
 
A calculation of dCDP production by CMPK2 at low assumed dCMP concentrations 
shows that more than 1000 CMPK2 enzymes per mitochondrion would be required to 
produce the necessary dCMP output per minute (assuming an approximate requirement 
of 276 / 4 nucleotides per minute). This result is important considering that CMPK2 
expression was undetectable in many tissues [8], thus implying that CMPK2 function 
may not be essential for the production of mtDNA precursors as has been noted 
previously [8]. 
 
The data on the kinetic parameters of the human mitochondrial nucleoside diphosphate 
kinase (NME4 in Figure 1) is scarce (Km for dTDP of approximately 1 mM, which is 100 
to 1000 times the physiological concentration of dTDP) [86], which is why it is not 
included in Figure 14B. An NDPK isolated from the pigeon mitochondrial matrix 
preferred ribonucleoside diphosphates over deoxyribonucleoside diphosphates by several 
fold [99]. Surprisingly, it appears that both AK2 [10] and NME4 [11] are localized in the 
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mitochondrial intermembrane space, thus suggesting that if their reaction products 
participate in the mtDNA precursor synthesis, they would then have to be imported into 
the mitochondrial matrix. Although dAMP is not the preferred substrate for AK2 (Figures 
11A, 12A, and 13A), AK2 still has a very fast reaction with dAMP (Figure 14B). Good 
efficiency with dAMP and the localization of AK2 in the intermembrane space instead of 
in the mitochondrial matrix seem to contradict each other regarding the role of AK2 in 
mtDNA precursor synthesis.  
 
Computational simulations: To test our conclusions and to build upon them, we used an 
updated computational model to perform simulations of deoxyribonucleotide dynamics 
and mtDNA replication within the mitochondrion.  
 
Figure 15 shows our simulation results. The X-axis represents the number of molecules 
of each nucleotide supplied to the mitochondrion in the form of a ‘source’ term in the 
differential equations in addition to the output from salvage within the mitochondrion. 
Each value on the X-axis is the sum of molecules supplied of all four species. For 
example, the X-axis value of 400 means that 100 molecules per minute of each of the 
four (A, C, G, T) species were supplied. The Y-axis represents the average (over 120 
minutes of simulation time) mtDNA replication rate that we observed, calculated as 
number of nucleotides replicated divided by the time taken to replicate them. Initial 
values for the substrate concentration in the mitochondrion were randomly varied over a 
set range as described in the Methods section. Each Y value corresponds to the mean of 
100 replication rates from 100 simulations with differing initial substrate conditions. The 
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standard deviations were far smaller than the mean values (and are therefore not shown in 
Figure 15) indicating that the simulation was not sensitive to the initial substrate 
conditions. We compared the observed replication rates to those required to complete 
mtDNA replication in 2 hours (‘cycling cells’) or 10 hours (‘quiescent cells’). For the 
mtDNA length of 33,136 nucleotides (replicating both strands), these would be 33136 
(nucleotides) / 120 (minutes) and 33136 (nucleotides) / 600 (minutes) respectively or 
approximately 276 nucleotides per minute and 55 nucleotides per minute respectively. 
Since the mean observed replication rates with no additional nucleotides supplied (0 on 
the X-axis) fall below the 2 hour line, it is clear that the output from mitochondrial 
salvage cannot account for an mtDNA replication duration of 2 hours. In fact, even when 
a 10 hour replication target was set, mitochondrial salvage alone is an inadequate source 
of dNTPs, though only a slight amount of additional substrate supplied by transport is 
needed in this case. Next, we note that both deoxynucleoside as well as deoxynucleoside 
monophosphate import are insufficient to support a 2 hour replication target. Transport of 
either dNDPs or dNTPs is sufficient to achieve the target replication rate. The profiles of 
dNDP and dNTP transport are indistinguishable from one another on Figure 15 because 
of the extremely fast kinetics of NME4.  
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Figure 15: The effects of nucleotide import into the mitochondrion on the mtDNA 
replication rate. Each point is the mean mtDNA replication rate from 100 simulations 
with different randomly chosen initial concentrations of deoxynucleosides and 
deoxynucleotides. The X-axis represents the total amount of additional deoxynucleosides 
or deoxynucleotides supplied (sum total of equal amounts for each of the four species). 
Additional supply of dN, dNMP, dNDP or dNTP were simulated separately. The dNTP 
output from mitochondrial salvage alone is insufficient to support a replication rate of as 
long as 10 hours. Additional supply of dNs and dNMPs was insufficient to support a 
replication duration of 2 hours indicating that additional dNDPs or dNTPs are essential.  
The results were essentially identical for supply of either dNDPs or dNTPs. Reproduced 
from Gandhi and Samuels (2011) [7]. 
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Transport of approximately 48 molecules per minute for each of the four nucleotide 
species was required to complete mtDNA replication in 2 hours. The longer replication 
time of 10 hours required a transport of 15 dNTP molecules per minute for each of the 
four nucleotide species.  These rates were determined from the simulation by transporting 
all four nucleotide species at equal rates and with fixed initial concentrations (as 
described in Methods).We next addressed the question of the minimum transport of each 
dNTP species necessary to support the target replication. As described in the Methods 
section, the assumption of equal transport of the four dNTP species was relaxed to find 
the minimal amount of transport separately for each dNTP species required to meet the 
mtDNA replication rate goal. To achieve a replication rate of at least 276 nucleotides per 
minute (‘cycling cells’), 47, 31, 48, and 48 molecules per minute of dTTP, dCTP, dATP, 
and dGTP were required. Thus, for this condition of relatively fast replication, transport 
of all four nucleotide species at similar rates is necessary. The total dNTP transport rate 
sums to 174 nucleotides per minute, a large fraction of the 276 dNTPs per minute 
consumed by the mtDNA replication. For the slower mtDNA replication with a target of 
10 hours, Figure 15 shows that a relatively small amount of transport of dNTP molecules 
per minute suffices. To achieve the replication rate target of at least 55 nucleotides per 
minute (representing slow mtDNA replication in ‘quiescent cells’), individual dNTP 
transport rates of 0, 3, 8, and 15 molecules per minute of dTTP, dCTP, dATP, and dGTP 
were required. Due to the complexity of the system (a nonlinear one because of 
feedbacks and inhibitions), slightly different but often practically similar transport 
profiles were observed to result in similar replication rates. For example, for cycling cells 
the transport profile of 41, 34, 48, and 41 molecules per minute also achieved the 
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replication rate target. For quiescent cells, the profiles of 2, 2, 8, and 15 and 0, 2, 8, and 
15 molecules per minute (practically identical to the transport profile given above) also 
achieved the replication rate target.  
 
In summary, rapid replication of mtDNA requires a substantial additional source of all 
four dNTPs (or dNDPs) to supplement the limited kinetics of the mitochondrial salvage 
pathway. Under the conditions of quiescent cells, the primary requirement is for the 
transport of dATP and dGTP molecules, and the vast majority of the dNTPs consumed by 
the mtDNA replication can be provided by the salvage pathway. 
 
IV.5. Discussion 
Kinetic characteristics of the mitochondrial salvage enzymes and their contribution 
in producing dNTP substrates for mtDNA replication: Based on this analysis of the 
enzyme kinetics three properties of the mitochondrial nucleoside salvage pathway are 
thus apparent: 
i) The majority of the enzymes of this pathway are not restricted or specific for 
metabolism of mtDNA precursors. 
ii) The majority of the characterized enzymes prefer non-DNA precursor substrates. 
iii) For the majority of substrate-enzyme pairs, the kinetic constants are physiologically 
unreasonable for achieving efficient catalysis with the expected substrate concentrations 
in situ. 
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From the kinetics perspective mitochondrial nucleotide metabolism as defined by this set 
of enzymes (Figure 1A) cannot be expected to be the primary source of dNTP substrates 
for the rapid replication of mtDNA molecules. Since ribonucleotides exist at higher 
concentrations than deoxyribonucleotides, enzymes that take both ribonucleotide and 
deoxyribonucleotide substrates will, in situ, not favor the catalysis of 
deoxyribonucleotides. This is certainly true for enzymes that possess higher affinities for 
ribonucleotides, but also for those enzymes that have only slightly better kinetics for 
deoxyribonucleotides. In these cases ribonucleotide substrates will simply out-compete 
the deoxyribonucleotides substrates owing to the relative abundance of ribonucleotides.  
 
The contribution of cytoplasmic nucleotide metabolism in producing dNTP 
substrates for mtDNA replication: One plausible interpretation of this analysis is that 
import of cytoplasmic deoxyribonucleotides is the primary source that supplies the direct 
precursors for the replication of mitochondrial genome while the mitochondrial salvage 
pathway acts as a back-up metabolism with a minimal role to play in cycling cells. The 
occurrence of deoxyribonucleotide transport between the mitochondria and cytoplasm 
and the substantial contribution of cytoplasm deoxynucleotides toward intra-
mitochondrial dNTP pools have been demonstrated [17, 18]. Our results make it possible 
to comment on why this must be so, due to the kinetic properties of the enzymes of 
mitochondrial salvage.  Our results also enable us to conclude that import of 
deoxyribonucleotides is in fact essential to support an mtDNA replication time of ~2 
hours. Furthermore, simulations based on these enzyme kinetics indicate that this import 
occurs either at the dNDP or dNTP level. In cells where cytoplasmic deoxynucleotide 
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concentrations are low, mitochondrial salvage would assume a greater role and, in 
combination with some other supply such as RRM2B mediated reduction of 
ribonucleotides in the cytoplasm followed by deoxyribonucleotide transport into the 
mitochondrion, would produce the dNTPs for both the replication of mitochondrial DNA 
and perhaps repair of nuclear DNA. Possibly, the dNDPs produced by RRM2B activity 
might first undergo the terminal phosphorylation by NME4 in the intermembrane space 
(Figure 1B) and may then be imported into the mitochondrion matrix at the dNTP level to 
combine with the dNTP pool from intra-mitochondrial salvage. Indeed, this is consistent 
with defects in the mitochondrial salvage pathway having their most severe phenotype in 
postmitotic tissues. That mitochondrial salvage has only a back-up role in supporting 
mtDNA replication is one explanation why DGUOK and TK2 deficiency phenotypes are 
tissue-restricted and not systemic.  
   
 Similarities and differences between nucleotide metabolism in the cytoplasm and 
mitochondria: The kinetic characteristics of the cytoplasmic counterparts of 
mitochondrial salvage enzymes expose informative parallels and distinctions between the 
cytoplasmic and mitochondrial pathways of nucleotide metabolism. The good activity of 
the mitochondrial enzymes (except the nucleoside kinases TK2 and DGUOK) with 
ribonucleotide substrates implies that these enzymes might play as important a role in 
ribonucleotide production to support RNA synthesis as they do in supporting DNA 
synthesis. Based on our analysis, we would argue that future studies of the kinetics of the 
mitochondrial salvage enzymes would benefit from a broader characterization of the 
kinetics, particularly the activity of the enzymes with ribonucleotide substrates relative to 
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the activity with deoxyribonucleotide substrates. The majority of the cytoplasmic 
counterparts also show a preference for non-DNA precursors (such as dUMP) and 
ribonucleotide substrates [81, 100, 108]. However, the role of nucleoside salvage as a 
source of dNTPs for nuclear DNA replication is generally assumed to be minimal. In the 
S-phase of the cell cycle, ribonucleotide reductase irreversibly converts ribonucleoside 
diphosphates to deoxyribonucleoside diphosphates, and subsequently, 
deoxyribonucleotides originating from de novo sources proceed to become the 
predominant precursors to nDNA replication. Thus, ribonucleotide affinities of these 
cytoplasmic enzymes not only provide the ribonucleoside diphosphates for ribonucleotide 
reduction but also ensure an adequate supply of RNA substrates. The terminal kinase 
(NDPK) of the cytoplasmic salvage pathway accepts both ribonucleoside and 
deoxyribonucleoside diphosphates, and the products can then be appropriately diverted 
for either RNA or DNA synthesis. Salvage enzymes of deoxythymidine metabolism fit 
nicely into such a model - examples being the excellent kinetics of TK1 and TK2 with 
dT, and those of cytoplasmic deoxythymidylate kinase (essential for both salvage and de 
novo pathways of dTTP synthesis) with dTMP – since deoxythymidine is not an RNA 
substrate and because of the crucial allosteric control exerted by deoxythymidine 
nucleotides on ribonucleotide reductase [109] as well as feedback control on 
mitochondrial TK2 [90]. Such similarities in the enzyme kinetics of the parallel 
mitochondrial and cytoplasmic metabolisms lead to the question of a ribonucleotide 
reductase connection to mitochondrial nucleotide metabolism. Such a connection is 
hinted at by the data supporting a connection between the mitochondrial dNTP pool and 
the ribonucleotide reductase RRM2B [18, 25]. There has been at least one report of 
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ribonucleotide reductase activity within the mitochondrion [5], though this has never 
been confirmed as far as we are aware of. 
 
The identity of the imported substrate and the contribution of import in quiescent 
cells: Our simulations show that mitochondrial salvage is inadequate to account for the 
observed replication time of ~1-2 hours in cycling cells. It is likely that the deficit is 
supplied by import from the cytoplasm. We propose that deoxyribonucleotide import into 
the mitochondria not only does occur, but is in fact essential to replicate and maintain 
mtDNA in cycling cells. Furthermore, in our simulations, import at the monophosphate 
level was not able to support mtDNA replication under the constraint of a replication 
duration of 2 hours or less. Our observation that either dNDP or dNTP transport are able 
to nearly identically support mtDNA replication is due to the extremely fast kinetics of 
NME4, the nucleoside diphosphate kinase. The fact that the NME4 kinetics for the 
conversion of dNDP to dNTP are fast lends weight to the hypothesis that transport occurs 
mainly at the dNDP level, and not at the dNTP level which would bypass the NME4 
activity.  
 
Our results are not necessarily in disagreement with previous reports that observed that 
supplementation with external dA and dG or dAMP and dGMP rescued mtDNA 
depletion [27, 30]. In those cases, it was undetermined whether these externally supplied 
substrates changed their phosphorylation level prior to or after entering the mitochondria, 
or even the cell. In the study conducted by Saada [27], in patient fibroblasts harboring 
DGUOK defects while dGTP pools were reduced compared to controls, dATP pools 
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were only moderately affected. In this study when these patient fibroblasts were given 
external supplementation of both deoxyguanosine and deoxyadenosine, mitochondrial 
dGTP notably increased, while the increase in mitochondrial dATP was less pronounced.  
Our observation on the inefficient kinetics of DGUOK with dA is consistent with these 
findings. We are not aware of any studies on the effects of pyrimidine supplementation in 
TK2 deficiency.  
 
We have chosen a somewhat arbitrary target replication time of 10 hours for the mtDNA 
in quiescent cells. It has been reported that even in quiescent cells (rat hepatocytes), 
mitochondrial DNA is subject to rapid turnover [73]. Moreover, it is plausible to suspect 
that long replication durations might compromise the integrity of either or both the 
template and the synthesis strand by increasing the probability of damage to the exposed 
DNA or unfaithful replication (deletions, frameshifting, etc). Therefore, it is possible that 
the mtDNA replication time may be practically constrained to a shorter duration than 10 
hours. In that case deoxynucleotide import could be essential even in quiescent cells. 
There is a lack of data on mtDNA replication times in quiescent cells, a critically 
important gap in our knowledge since quiescent cells are the most severely affected cells 
in most forms of Mitochondrial DNA Depletion Syndromes. 
 
Could there be more than one deoxynucleotide transporter?: The fact that clinical 
conditions arising from altered intra-mitochondrial dNTP pools mostly manifest in 
postmitotic tissues is consistent with our results. The possibility of there being more than 
one deoxynucleotide transporter, say one for purine deoxynucleotides and one for 
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pyrimidine deoxynucleotides, might explain why mutations in TK2 and DGUOK which 
are both nucleoside kinases produce different phenotypes. It is plausible that there exists 
more than one mitochondrial deoxynucleotide transporter whose expression levels, 
possibly in conjunction with other factors, contribute to tissue specificity of mtDNA 
depletion syndromes. There have been reports [16, 52] asserting a role of PNC1 
(pyrimidine nucleotide carrier encoded by solute carrier family 25, member 33 or 
SLC25A33) in nucleotide import into mitochondria as well as mitochondrial maintenance. 
PNC1 was able to transport a variety of metabolites, including purine and pyrimidine 
ribonucleotides and deoxyribonucleotides, with a preference for UTP. Intra-
mitochondrial UTP accumulation decreased in response to siRNA-transfection against 
PNC1. Mitochondrial ADP, ATP, and GTP levels were not significantly altered but the 
effect on dNTPs was not investigated. Suppression of PNC1 was associated with reduced 
mtDNA while overexpressed PNC1 was associated with increased mtDNA relative to 
controls. Since UTP is a cofactor of the mitochondrial helicase (PEO1 or twinkle), 
mtDNA levels might have been altered through increased or decreased UTP [52]. It is 
also possible that these consequences resulted from a lack of RNA primers or lack of 
mtDNA precursors that might be substrates of PNC1.  However, PNC1 mRNA was 
undetectable in skeletal muscle [16], a tissue that is a target of TK2 defects. Interestingly, 
ribonucleotide reductase overexpression caused mtDNA depletion in skeletal muscle of 
mice [110]. Also, per mg protein, PNC1 appeared to transport roughly 1.5 times more 
UTP compared to dTTP, the next most transported substrate. At this time, the role of 
PNC1 in transporting deoxyribonucleotides for mtDNA synthesis is inconclusive. Import 
of radioactively labeled dTMP into mitochondria has been observed [15]. However, it 
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was also observed that a fraction of the labeled dTMP was degraded as well as 
phosphorylated in the growth medium, leading to the possibility that the transport of 
phosphorylated states other than the monophosphate may have occurred. A transport 
activity with preference for dCTP has also been observed [14].   
 
Tissue specificity of mtDNA depletion syndromes: It has been proposed that low basal 
TK2 expression in muscle renders the tissue vulnerable to TK2 defects, while 
overlapping substrate specificity of cytosolic dCK prevents mtDNA depletion from 
mutant DGUOK in tissues where dCK expression is high [111]. While mtDNA defects 
that have a basis in mutated salvage enzymes might conceivably be rescued by other 
factors such as overlapping substrate specificity of cytoplasmic enzymes, this hypothesis 
cannot account for phenotypes relating to POLG defects. Importantly, the fact that 
phenotypes from mutations in POLG are also tissue-specific and not systemic indicate 
that other factors, such as rates of mtDNA turnover or energetic demand of tissues might 
also be a factor in the basis of tissue selectivity. In a recent review, Liya Wang discussed 
deoxynucleoside salvage enzymes and their association with tissue specific phenotypes of 
mtDNA depletion [20]. It was hypothesized that since mtDNA turnover rates are 
different in different tissues and also because dNTP pools show organ-specific 
differences, it would be expected that the regulation of dNTP pools would also be 
different for different tissues. Because both muscle and liver have high amounts of 
mtDNA and also of mtDNA turnover, and since the dTTP pool is lowest in muscle and 
the dGTP pool is smallest in liver, it was proposed that these tissues would be especially 
vulnerable to mutations in TK2 and DGUOK respectively. Other contributing factors 
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could include limiting RRM2B, thymidylate synthase, or nucleotide transporter activity. 
In our opinion, it is probable that there is more than one underlying principle that 
explains tissue specificity – vulnerability of tissues to mutations might be from a 
combination of various factors such as transcriptional compensation, turnover rates, 
energetic demand, etc, and that different forms of mtDNA depletion syndromes may trace 
their etiology to different factors. 
 
The applicability of our results to different tissues and species: Based on their 
experiments with perfused rat heart, Morris et al concluded that in isolated perfused 
heart, there is no de novo synthesis of dNTPs [112], stressing the importance of TK2 in 
rat heart. This could indicate that our observations on the inadequacy of mitochondrial 
salvage enzymes may not hold across all tissue types. It is also possible that the 
deoxyribonucleotide pools in rat heart arose in part through salvage mediated by residual 
TK1 activity.  In a recent report of a TK2-/- H126N knockin mouse [113], the authors 
observed TK1 to be the main thymidine kinase component in heart, compared to TK2 in 
the brain. In this mouse, phenotypic manifestation of TK2 deficiency was related to TK1 
down-regulation and transcriptional compensation. Although by postnatal day 13 both 
brain and heart had suffered substantial mtDNA depletion, in contrast to brain, heart was 
spared as respiratory chain proteins were still at normal levels in this organ when assayed 
at postnatal day 13. This could indicate a difference in the importance of TK2 in the heart 
tissue of rats compared to mice. A recent report claimed that a cytosolic localization of 
TK2 is present in many rat tissues [12]. For the knockin mouse [113], a compensatory 
mechanism involving increased mtDNA transcription through suppression of MTERF3 
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(mitochondrial transcription termination factor 3) expression was implicated in 
alleviating some of the effects of mtDNA depletion. It was unclear why dTTP but not 
dCTP levels were affected and whether cytosolic ribonucleotide reduction had any 
influence in this observation. In humans, even in quiescent patient fibroblasts with only 
5-40% of residual TK2 activity, mitochondrial and cytosolic dTTP pools were unaltered 
[58]. This finding would be consistent with the possibility that the activities of 
mitochondrial salvage enzymes may not be strictly necessary even for quiescent cells. 
Alternatively, it is also possible for there to be practical important differences between 
species with regard to this metabolism. In their study of the rat heart, Morris et al [112] 
noted that although known as a substrate of TK2, dU was not converted to dUMP 
possibly due to ENT1 nucleoside transporter not being localized to mitochondria in 
rodents, unlike humans, suggesting that dU may not be transported into the mitochondria 
in rodents. It has been noted that genes involved in mtDNA depletion syndromes etiology 
are essential for life in mouse models [20]. However, the severe phenotype of knock-out 
mice is not identical to the phenotype in humans [114], although multi-organ phenotypes 
have come to light in humans also [115]. This divergence could perhaps be due to species 
differences or because of the complete absence of enzyme activity in knock-out models 
[114].  
 
 Limitations of our analysis: One limitation of modeling biochemical pathways is that 
kinetic parameters as reported in the literature and obtained from recombinant enzymes 
may not reflect the in situ reality, for instance, if the enzyme conformation is 
unknowingly affected in the in vitro analysis, or if the assay conditions do not represent 
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the cellular environment adequately. Similarly, we have relied on the literature and our 
judgment for selecting appropriate concentrations and enzyme copies within the 
mitochondrion. In our analysis we have assumed a nucleoside concentration of 0.5 µM 
[94].  There have been reports of nucleoside concentrations of approximately 50-fold 
lower [96].  Such lower concentrations would have two effects on this analysis.  First, the 
problems that we point out concerning the function of the nucleoside kinases TK2 and 
DGUOK would be even worse with significantly lower nucleoside concentrations.  
Second, there is a more subtle problem that the enzyme kinetics for TK2 were measured 
at much higher substrate concentrations (1 µM to more than 100 µM) [90].  If the true 
substrate concentrations were on the order of 10 nM, then the kinetics would have to be 
extrapolated to much lower concentrations, which could introduce additional uncertainty 
in the kinetic constants. Finally, our estimate of time taken to replicate mtDNA (2 hours) 
comes from a study of mouse cells [80]. It is worth mentioning that POLG kinetics 
suggest that polymerization itself is capable of proceeding at a rate much faster than 2 
hours [83]. A more comprehensive investigation into mtDNA replication durations in a 
variety of human cells and particularly in the cell types affected by mtDNA depletion 
syndromes would thus be very beneficial. 
 
For simplicity, we assumed that only one mtDNA molecule is replicating at any given 
time in a particular mitochondrion. If two or more mtDNA molecules were replicating 
simultaneously, then the deficit in the required dNTPs would be even larger than our 
analysis indicates. It should also be noted that mitochondria are very dynamic and 
undergo continuous fusion and fission. However, the effects of fusion and fission on the 
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mitochondrial dNTP content would most likely average out. While fusion of two 
mitochondria would result in a larger dNTP pool (measured as number of molecules per 
organelle), fission would result in a smaller dNTP pool. 
 
Summary: Since the known elements of the mitochondrial salvage pathway do not have 
sufficient enzyme kinetics to support mtDNA replication in the observed duration of ~1-2 
hours, an alternative source of mtDNA precursors must be essential. Despite the intensive 
focus of research on this pathway associated with mitochondrial depletion syndromes, it 
seems likely that our knowledge of mitochondrial nucleotide metabolism is still 
incomplete and that this pathway might need to be considerably expanded in the future to 
include new enzymes, mechanisms, nucleotide transporters and modes of regulation.   
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CHAPTER V 
 
CONCLUSION 
 
V.1. Summary and future directions 
Mitochondrial DNA depletion syndromes are a consequence of defective maintenance of 
mitochondrial DNA. Defective maintenance of mtDNA results from problems in the 
homeostasis of mitochondrial dNTP pools or with problems in the replication apparatus 
that maintains mitochondrial DNA. As noted in Chapter I, mitochondrial dNTP pools and 
mtDNA integrity are significant also in numerous other human pathologies. Thus, also 
from a clinical perspective, it is imperative that we increase our knowledge of the biology 
of mitochondrial dNTP pools. This dissertation has presented the results obtained from an 
extensive investigation into mitochondrial deoxyribonucleotide metabolism, the pathway 
that generates dNTPs within the mitochondria. Together with dNTPs generated in the 
cytoplasm, mitochondrial dNTPs become the substrates for mitochondrial DNA 
replication and repair.   
 
Through the research described in Chapter II, I discovered that cytoplasmic and 
mitochondrial dNTPs are strongly and highly statistically significantly correlated in 
normal cells but not in transformed cells. This discovery is significant due to several 
reasons. The mitochondrial matrix space is generally not considered to be in equilibrium 
with the cytoplasmic space, particularly to charged molecules such as 
deoxyribonucleoside phosphates owing to the double membrane that bounds the 
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mitochondrial matrix. The extent of the contribution of cytoplasmic deoxyribonucleotides 
to mitochondrial deoxyribonucleotides was also unclear. The cytoplasmic pathway that 
generates dNTPs is also much more complex than the pathway carrying out the same 
function in the mitochondria. Moreover, dNTP generation in the cytoplasm is tightly 
controlled, and coordinated with cell cycle progression, to ensure the integrity of genomic 
DNA. At the time I commenced my research, the prevailing notion was that 
mitochondrial dNTP levels are not stringently controlled. Although this notion is 
consistent with the fact that mitochondrial DNA replication is not strictly synchronized 
with nDNA replication, the results I described in Chapter II clearly show that 
mitochondrial dNTP levels are not independent of cytoplasmic dNTP levels (which are 
under stringent control) in normal cells. However, this correlation is broken in 
transformed cells. There are practical implications of this observation. Transformed cells 
are commonly used for experiments in this field. The advantage of transformed cell lines 
is that they are more readily available and more maneuverable compared to normal cell 
lines. Through my research, I alerted other researchers in this field of the disadvantages 
of transformed cell lines. My research served to caution that if something about 
mitochondrial dNTPs is fundamentally different in transformed cells compared to normal 
cells, then conclusions meant to apply to the normal functioning of intra-mitochondrial 
deoxyribonucleotide metabolism from studies on transformed cells may not be reliable. 
Another practical benefit of my work presented in Chapter II was the resource 
comprising estimated dNTP concentrations that I created by converting previously 
published data to a more meaningful form. This resource enables comparisons between 
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existing data as well as of future data to existing data, something which was not strictly 
possible prior to my work. 
 
The results described in Chapter II gave rise to several important hypotheses, one of 
which was tested in Chapter III. An alternative to that hypothesis is that the correlation in 
mitochondrial and cytoplasmic dNTP concentrations results from a strong cytoplasmic 
control on mitochondrial dNTP concentrations. 
 
One plausible mechanism for enforcing such control would be through the 
regulation of deoxyribonucleotide transport between the cytoplasm and 
mitochondria. In that case, the hypothetical transport protein could be a candidate 
gene for mitochondrial DNA depletion syndromes. Particularly, its tissue-expression 
patterns might reveal critical insights regarding the tissue-specificity of mtDNA 
depletion syndromes. Similarly, many of the genes coding for enzymes acting in 
cytoplasmic dNTP production would also be candidates for mtDNA depletion 
syndromes. 
 
Regarding the disruption of the correlation in transformed cells, we might hypothesize 
that the disruption is connected to the Warburg effect. Otto Warburg observed that 
cancerous cells derive most of their energy from cytoplasmic glycolysis even in the 
availability of oxygen [69].  One way to shut down oxidative phosphorylation in the 
mitochondria would be reduced transcription or translation of the mitochondrial genome 
thereby limiting the availability of mtDNA-encoded components of the oxidative 
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phosphorylation machinery. The results in chapter II suggest that unlike cytoplasmic 
dNTP concentrations, mitochondrial dNTP concentrations are not unusually elevated in 
transformed cells compared to normal cells.  
 
Might diminished import of cytoplasmic deoxyribonucleotides into the mitochondria 
be a mechanism through which transformed cells suppress oxidative 
phosphorylation?  
 
Although the correlations in dNTP concentrations described in Chapter II were highly 
statistically significant, the underlying data came from a small set of cell lines and only a 
handful of labs. It would be very beneficial for a research group to test my conclusions in 
a controlled environment with a variety of cycling, non-cycling, and transformed cell 
lines; and particularly the cell types affected in mtDNA depletion syndromes. It is also 
important to verify whether all four of the canonical deoxyribonucleotides have similar 
behavior with respect to the observed correlations, or whether there are differences 
between the four dNTPs. Are there qualitative or quantitative differences in the origins of 
the four dNTPs? 
 
To further understand the results obtained from the research presented in Chapter II, 
namely the strong association between cytoplasmic and mitochondrial dNTPs in normal 
cells and the disappearance of that association in transformed cells, I hypothesized that 
correlation patterns in the expression of genes of the cytoplasmic and mitochondrial 
deoxyribonucleotide metabolisms would be consistent with the correlation patterns in the 
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corresponding dNTP concentrations. I obtained tissue expression data for a selected set of 
nDNA-encoded genes that code for enzymes that participate in the cytoplasmic and 
mitochondrial metabolisms. The pattern of correlations in expression profiles suggested 
that in normal tissues, the cytoplasmic and mitochondrial deoxyribonucleotide 
metabolisms coordinately generate dNTPs. However, consistent with the disruption in 
dNTP concentrations seen in Chapter II, the correlation structure in gene expression 
profiles is also disrupted in transformed tissues. Specifically, the results suggested that in 
transformed tissues, when dNTP levels are high in the cytoplasm, dNTP production in the 
mitochondria would be suppressed. Three correlations involving mitochondrial DGUOK 
were statistically significantly different between normal and transformed tissues 
suggesting that control on DGUOK expression relative to the expression of other genes 
might be important for transformed tissues.  
 
Dissecting the correlation patterns in transformed tissues hinted that the distinction 
between the metabolism in the mitochondrial matrix space and the intermembrane space, 
which is generally considered to be a subtle point, may actually be crucial. This is 
because in transformed tissues the matrix space metabolism is negatively regulated 
relative to the cytoplasmic metabolism whereas the intermembrane space is in fact 
positively regulated relative to the cytoplasmic metabolism. This fits with the fact that the 
mitochondrial intermembrane space is generally considered to be in equilibrium with the 
cytoplasm. 
 
119 
 
I also observed that genes of cytoplasmic nucleotide metabolism have higher expression 
in transformed tissues. This observation adds information to the correlation in dNTP 
concentrations that I observed in Chapter II and supports the proposition that the 
correlation in dNTP concentrations is broken in transformed cells perhaps due to an 
increase in cytoplasmic dNTPs without a similar increase in the mitochondrial production 
of dNTPs. The higher expression of cytoplasmic protein genes in transformed tissues and 
the lack of such an increase in the expression of the mitochondrial protein genes can be 
interpreted in the context of the Warburg effect. The production of mt-DNA encoded 
components of oxidative phosphorylation is partially dependent on the mitochondrial 
dNTP levels that are available to maintain mtDNA.  
 
Might suppressed expression of nuclear genes of mitochondrial deoxyribonucleotide 
metabolism be a mechanism through which cancer tissues suppress oxidative 
phosphorylation?  
 
The research presented in Chapter III helped discover a large number of correlations. 
However, it is not necessary to verify each of those correlations. It would be valuable to 
test either the strongest, most statistically significant, or the most biologically interesting 
correlations. Additionally, since DGUOK expression appears to be so important for 
transformed tissues, the correlations it participates in deserve special attention. An 
important future study would involve manipulating DGUOK expression to determine the 
effects of the manipulation on the transformation state of the cells or tissues. A key 
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extension to the work presented in Chapter III would be to test corresponding normal and 
transformed samples from the same tissue.  
 
The dynamics of mitochondrial dNTP pools were studied in Chapter IV. The research 
presented in Chapter IV involved building a computational model of mitochondrial 
deoxyribonucleotide metabolism and mtDNA replication. To accomplish this, I surveyed 
the literature for the purposes of accurately defining the set of reactions to model and 
obtaining the experimental data necessary for the construction of a relevant model. By 
computationally simulating mitochondrial deoxyribonucleotide metabolism and 
mitochondrial DNA replication, I discovered three properties of the mitochondrial 
enzymes of this pathway: i) The majority of the enzymes of this pathway are not 
restricted or specific for metabolism of mtDNA precursors. ii) The majority of the 
characterized enzymes prefer non-DNA precursor substrates. iii) For the majority of 
substrate-enzyme pairs, the kinetic constants are physiologically unreasonable for 
achieving efficient catalysis with the expected substrate concentrations in situ. 
Significantly, my results showed that the output from mitochondrial salvage is inadequate 
to support the experimentally observed mtDNA replication duration of 1-2 hours in 
cycling cells. Additional sources of either dNDPs or dNTPs are required. Importantly, an 
additional source of nucleotides at the dNMP level does not suffice. 
 
Although other researchers had observed that deoxyribonucleotide import from the 
cytoplasm to the mitochondria occurs, my results suggest that import is in fact essential. 
Furthermore, despite intensive study from wet lab groups, we scarcely knew any details 
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about the transport mechanism. My results strongly suggest that transport at the dNMP 
level is not sufficient to explain previously published experimental results regarding the 
rate of mtDNA replication. Transport at the dNDP or dNTP level is also consistent with 
the results presented in Chapters II and III. The fact that the mitochondrial metabolism 
has minimal contribution towards mitochondrial dNTP pools in most conditions is also 
one explanation for the fact that the depletion of mitochondrial in cases of mtDNA 
depletion syndromes is observed in only a small subset of all tissues.  
 
My results on the kinetic characteristics of the mitochondrial enzymes of 
deoxyribonucleotide metabolism also point towards the need for exploring the role of 
these enzymes in generating ribonucleoside triphosphates.  
 
Do the enzymes of mitochondrial deoxyribonucleotide metabolism also influence 
mitochondrial ribonucleoside triphosphate and mitochondrial RNA levels? 
 
My results from Chapter IV also generate numerous ideas for future studies. It would be 
advisable for researchers in the field to estimate the mtDNA replication duration in a 
variety of human cell lines, but particularly cells in the tissues that are affected by 
mtDNA depletion syndromes. This information could then help calibrate the model I 
have developed more precisely to the affected tissues. Another important area for future 
investigation is the identity of the transported substrate. My results indicate that dNMP is 
not a viable import candidate and this hypothesis should be tested. Finally, the very slow 
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kinetics of DGUOK with deoxyadenosine appear to be one of the major bottlenecks of 
this pathway. These kinetics should be verified to ensure their accuracy. 
 
V.2. Concluding remarks 
At the time I commenced my research, there were several open questions regarding the 
biology of mitochondrial deoxyribonucleotide metabolism. I addressed many of these 
open questions through the research presented here in my dissertation. The process of 
inquiry is of course never-ending. I have attempted to contribute to broadening the 
horizons of this research field, and I hope my attempts at highlighting the importance of 
mitochondrial deoxyribonucleotide metabolism to the fields of cancer biology and 
maintenance of mitochondrial ribonucleoside triphosphates receive the attention they 
deserve.  
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Appendix 
 
Table 9: Gene expression in normal tissues. 
 
 
 
Tissue TK2 DGUOK NT5M AK2 NME4 RRM1 RRM2 RRM2B TK1 DCK AK1 AK5 GUK1 CMPK1 DTYMK NME1 NME3 ADK NT5E NT5C2 NT5C1B NT5C NT5C3 UCK1 UCK2 
Adipose tissue 76 0 0 152 152 76 0 76 0 76 76 76 76 76 76 0 0 0 0 76 0 0 0 0 0 
Adrenal gland 30 60 0 150 120 60 30 0 60 30 0 0 90 30 0 301 60 0 0 0 0 0 0 30 0 
Bladder 0 33 0 168 0 134 201 67 67 67 33 0 67 336 0 235 0 67 33 100 0 33 134 33 0 
Blood 8 113 16 194 16 275 356 24 129 24 16 0 72 72 48 315 16 56 16 186 0 64 64 48 16 
Bone 69 55 13 195 97 111 167 41 111 0 83 13 153 139 69 362 55 83 41 27 0 27 27 0 13 
Bone marrow 0 143 0 225 20 614 286 0 40 81 0 20 20 61 0 122 0 20 40 20 0 0 0 0 0 
Brain 52 26 8 88 34 219 128 38 23 43 42 46 127 65 28 125 29 31 53 261 0 20 19 54 47 
Cervix 124 41 20 435 20 394 332 0 290 0 103 0 186 41 103 166 0 62 62 20 0 0 124 145 83 
Connective tissue 33 80 6 120 13 388 80 20 0 0 46 100 53 80 20 234 6 683 428 147 0 0 33 26 6 
Ear 61 0 0 0 0 123 0 61 0 0 0 0 61 123 0 61 0 0 0 0 0 0 0 0 0 
Embryonic tissue 9 78 4 199 74 88 111 37 148 27 4 4 64 64 88 361 55 27 55 97 0 13 32 27 74 
Esophagus 0 49 0 98 49 1533 2276 0 49 0 0 0 148 0 0 197 0 0 49 98 0 0 0 49 49 
Eye 14 75 9 213 66 108 127 33 104 23 56 14 260 47 56 407 94 28 23 94 0 42 23 47 66 
Heart 44 189 11 234 78 167 100 0 22 33 189 0 278 11 44 245 44 33 33 55 0 22 44 22 66 
Intestine 8 68 0 179 63 132 243 4 179 29 89 8 200 98 76 260 42 29 51 76 0 46 29 63 76 
Kidney 33 51 14 226 28 283 283 47 70 56 18 9 132 99 80 207 18 33 151 94 0 23 18 61 47 
Larynx 41 0 0 0 41 621 0 0 0 0 0 0 0 0 0 165 0 0 0 82 0 0 0 0 41 
Liver 4 52 14 120 48 81 240 28 43 43 19 9 62 96 24 462 4 48 43 33 0 24 33 14 33 
Lung 35 74 5 183 62 121 83 14 56 20 124 2 234 106 35 302 35 29 130 62 0 26 32 35 47 
124 
 
Lymph 0 45 0 564 0 225 519 0 813 90 0 0 135 135 67 542 90 0 0 180 0 22 0 0 45 
Lymph node 10 87 0 185 21 141 76 130 174 98 0 0 240 87 141 130 0 21 87 76 0 0 120 10 54 
Mammary gland 6 91 6 182 182 228 110 32 365 32 58 13 150 45 52 411 19 228 39 91 0 26 6 39 26 
Mouth 14 29 0 74 59 313 492 29 29 0 14 0 29 208 0 74 0 14 104 611 0 0 29 14 44 
Muscle 37 46 27 157 27 37 278 55 18 0 445 0 120 120 111 139 46 102 18 83 0 18 139 46 9 
Nerve 190 0 0 126 63 63 63 63 63 0 63 0 63 126 0 190 63 0 0 126 0 0 0 126 0 
Ovary 0 107 9 225 107 48 88 0 274 19 88 0 274 68 88 284 19 9 9 48 0 97 39 29 9 
Pancreas 13 107 0 167 55 41 79 9 125 37 135 0 228 93 46 274 97 23 18 41 0 41 79 0 41 
Parathyroid 0 243 0 584 0 194 0 97 0 0 146 0 243 0 97 292 97 0 0 48 0 0 0 48 48 
Pharynx 24 290 0 24 72 96 0 0 24 0 0 0 72 0 0 435 0 96 0 72 0 0 24 0 0 
Pituitary gland 60 60 0 60 0 0 0 0 0 0 0 0 60 60 60 361 0 0 60 0 0 0 0 0 0 
Placenta 35 56 0 156 24 156 188 53 99 21 21 3 106 64 46 160 10 28 121 138 0 14 14 28 99 
Prostate 26 63 0 137 359 184 52 21 110 31 31 0 195 68 63 274 68 58 42 73 0 52 0 52 36 
Salivary gland 0 49 0 99 99 49 99 49 198 0 347 0 893 148 99 446 0 0 0 49 0 99 49 49 0 
Skin 14 61 0 280 99 175 289 23 194 33 33 0 322 113 90 579 33 37 204 80 0 47 18 85 61 
Spleen 0 0 0 166 37 166 129 0 0 18 55 0 92 74 0 0 0 0 18 166 0 0 55 55 0 
Stomach 10 10 0 144 62 124 538 10 155 20 20 10 113 165 72 269 51 31 41 41 0 20 31 20 20 
Testis 57 42 12 114 9 311 257 6 3 57 57 15 63 18 18 96 21 9 63 517 311 12 27 60 27 
Thymus 24 24 0 172 0 788 1898 0 0 98 0 0 12 24 24 12 0 0 24 850 0 12 73 123 12 
Thyroid 42 21 0 252 21 63 147 84 42 0 42 0 84 105 0 84 0 0 231 358 0 0 21 84 0 
Tonsil 0 176 0 0 0 58 235 0 705 0 0 0 352 0 0 117 0 58 0 0 0 117 58 235 0 
Trachea 0 57 0 171 0 209 19 95 0 0 38 0 0 76 0 0 0 0 209 1774 0 0 38 38 0 
Umbilical cord 0 0 0 73 73 219 146 0 0 0 146 0 0 0 0 511 0 0 0 0 0 0 0 0 219 
Uterus 12 72 8 214 72 120 94 38 98 30 51 12 257 128 77 218 51 47 184 128 0 21 17 30 30 
Vascular 0 38 0 135 19 347 289 38 0 19 38 0 38 173 19 173 0 0 347 173 0 38 38 19 0 
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Table 10: Gene expression in transformed tissues. 
 
 
 
Tissue TK2 DGUOK NT5M AK2 NME4 RRM1 RRM2 RRM2B TK1 DCK AK1 AK5 GUK1 CMPK1 DTYMK NME1 NME3 ADK NT5E NT5C2 NT5C1B NT5C NT5C3 UCK1 UCK2 
Adrenal tumor 78 156 0 156 78 0 78 0 156 0 0 0 0 0 0 547 0 0 0 0 0 0 0 0 0 
Bladder carcinoma 0 57 0 57 0 114 57 0 0 57 0 0 171 114 0 114 0 0 0 0 0 57 57 0 57 
Breast (mammary gland) 
tumor 
0 74 0 212 233 318 159 31 584 31 31 10 180 31 63 530 31 318 31 106 0 42 0 31 21 
Cervical tumor 58 58 29 436 0 436 378 0 261 0 145 0 116 58 87 145 0 87 29 29 0 0 174 174 58 
Chondrosarcoma 84 60 24 169 72 156 181 36 60 0 108 12 108 169 60 169 36 24 169 36 0 12 12 12 36 
Colorectal tumor 17 35 0 192 35 157 315 0 280 26 105 0 201 70 26 297 61 52 52 70 0 0 43 17 52 
Esophageal tumor 0 57 0 115 57 1792 2660 0 57 0 0 0 173 0 0 231 0 0 0 115 0 0 0 57 57 
Gastrointestinal tumor 8 25 8 309 83 276 695 8 217 33 83 41 192 117 75 309 58 41 16 117 0 67 16 67 100 
Germ cell tumor 18 41 0 204 34 458 363 45 128 75 34 72 117 49 34 208 3 30 53 250 3 41 15 56 60 
Glioma 0 65 56 112 84 140 205 0 84 18 37 18 187 46 140 93 84 37 65 9 0 74 18 74 74 
Head and neck tumor 29 29 0 132 80 183 300 36 58 0 58 0 176 124 14 176 0 0 124 425 0 14 22 22 14 
Kidney tumor 29 29 0 72 72 43 58 14 188 87 43 14 188 87 87 261 0 29 0 87 0 14 29 58 43 
Leukemia 0 104 20 239 20 417 219 0 114 73 0 0 104 52 52 313 10 62 83 177 0 31 41 20 31 
Liver tumor 10 41 0 124 62 124 415 31 83 20 10 10 51 83 20 373 10 51 72 51 0 20 51 31 31 
Lung tumor 19 67 19 203 126 106 135 19 174 9 58 0 416 58 38 533 19 67 87 9 0 19 29 38 77 
Lymphoma 0 27 0 404 0 181 487 0 668 83 0 0 153 167 55 445 55 0 0 125 0 13 55 55 27 
Ovarian tumor 0 117 0 247 39 52 78 13 234 26 91 0 286 91 117 286 26 13 0 52 0 78 52 13 13 
Pancreatic tumor 19 9 0 152 76 66 114 19 258 0 191 0 296 76 95 353 114 0 38 57 0 47 19 0 38 
Primitive 
neuroectodermal tumor 
7 7 31 198 135 310 1034 0 302 7 55 15 198 15 127 286 95 71 87 23 0 23 31 87 127 
Prostate cancer 9 87 0 107 253 214 97 29 194 48 0 0 233 68 68 477 68 87 19 77 0 9 0 68 58 
Retinoblastoma 43 21 21 172 107 302 496 43 302 0 21 0 517 21 86 992 107 0 0 43 0 21 0 21 172 
Skin tumor 16 72 0 256 112 112 360 24 312 32 0 0 464 88 120 824 16 48 56 32 0 40 24 136 64 
Soft tissue/ 
muscle tissue tumor 
31 103 0 215 79 343 311 23 159 39 23 119 159 103 111 367 47 910 343 31 0 7 23 23 15 
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Uterine tumor 11 55 0 166 66 44 88 33 55 22 44 22 243 121 33 188 11 77 77 110 0 44 44 44 22 
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Table 11: List of correlations. 
 
 
 
Gene 1 Gene 2 Normal tissues Transformed tissues 
  Spearman Rho p-value Spearman Rho p-value 
DGUOK TK2 -0.27 0.08 -0.07 0.73 
NT5M TK2 0.28 0.07 0.10 0.65 
NT5M DGUOK 0.22 0.16 -0.10 0.63 
AK2 TK2 -0.10 0.50 -0.01 0.95 
AK2 DGUOK 0.34 0.02 0.11 0.60 
AK2 NT5M 0.31 0.04 0.20 0.35 
NME4 TK2 0.10 0.54 0.11 0.61 
NME4 DGUOK 0.11 0.48 0.04 0.84 
NME4 NT5M 0.11 0.50 0.18 0.40 
NME4 AK2 0.05 0.74 -0.13 0.56 
RRM1 TK2 -0.13 0.42 -0.15 0.48 
RRM1 DGUOK -0.15 0.34 -0.07 0.73 
RRM1 NT5M 0.02 0.91 0.27 0.20 
RRM1 AK2 0.07 0.65 0.33 0.12 
RRM1 NME4 -0.30 0.05 -0.07 0.76 
RRM2 TK2 -0.25 0.10 -0.07 0.74 
RRM2 DGUOK -0.18 0.24 -0.45 0.03 
RRM2 NT5M 0.20 0.20 0.31 0.14 
RRM2 AK2 0.22 0.16 0.40 0.05 
RRM2 NME4 -0.20 0.18 0.00 1.00 
RRM2 RRM1 0.43 0.00 0.68 0.00 
RRM2B TK2 0.13 0.41 0.40 0.05 
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RRM2B DGUOK -0.14 0.37 -0.09 0.68 
RRM2B NT5M 0.02 0.88 -0.20 0.36 
RRM2B AK2 0.14 0.35 -0.08 0.72 
RRM2B NME4 -0.08 0.62 0.34 0.11 
RRM2B RRM1 -0.20 0.19 0.00 0.99 
RRM2B RRM2 -0.22 0.15 -0.05 0.82 
TK1 TK2 -0.21 0.17 -0.01 0.95 
TK1 DGUOK 0.35 0.02 -0.18 0.40 
TK1 NT5M 0.16 0.29 0.08 0.73 
TK1 AK2 0.38 0.01 0.58 0.00 
TK1 NME4 0.31 0.04 0.27 0.20 
TK1 RRM1 -0.22 0.16 0.10 0.63 
TK1 RRM2 0.30 0.05 0.28 0.18 
TK1 RRM2B -0.06 0.71 -0.10 0.64 
DCK TK2 -0.08 0.62 -0.42 0.04 
DCK DGUOK 0.12 0.44 0.11 0.61 
DCK NT5M 0.09 0.56 -0.34 0.10 
DCK AK2 0.36 0.02 0.15 0.49 
DCK NME4 0.06 0.72 -0.21 0.32 
DCK RRM1 0.16 0.31 0.04 0.86 
DCK RRM2 0.22 0.16 -0.17 0.42 
DCK RRM2B -0.01 0.94 -0.06 0.77 
DCK TK1 0.21 0.17 0.11 0.59 
AK1 TK2 0.09 0.55 0.36 0.08 
AK1 DGUOK 0.02 0.91 -0.32 0.13 
AK1 NT5M 0.36 0.02 0.31 0.15 
AK1 AK2 0.27 0.08 0.18 0.40 
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AK1 NME4 0.34 0.03 0.00 0.99 
AK1 RRM1 -0.23 0.13 -0.12 0.57 
AK1 RRM2 -0.12 0.45 -0.04 0.84 
AK1 RRM2B 0.22 0.15 0.12 0.58 
AK1 TK1 0.02 0.87 0.11 0.60 
AK1 DCK -0.16 0.30 -0.39 0.06 
AK5 TK2 0.21 0.18 0.04 0.86 
AK5 DGUOK 0.07 0.64 -0.15 0.50 
AK5 NT5M 0.41 0.01 0.14 0.51 
AK5 AK2 0.08 0.61 0.02 0.93 
AK5 NME4 0.18 0.23 0.17 0.44 
AK5 RRM1 0.09 0.55 0.14 0.52 
AK5 RRM2 0.06 0.69 0.12 0.58 
AK5 RRM2B 0.15 0.34 0.28 0.18 
AK5 TK1 0.02 0.88 -0.19 0.37 
AK5 DCK 0.34 0.02 0.26 0.23 
AK5 AK1 0.13 0.41 0.18 0.40 
GUK1 TK2 -0.09 0.56 -0.06 0.78 
GUK1 DGUOK 0.47 0.00 -0.24 0.27 
GUK1 NT5M 0.21 0.18 -0.01 0.98 
GUK1 AK2 0.43 0.00 0.00 1.00 
GUK1 NME4 0.37 0.01 0.51 0.01 
GUK1 RRM1 -0.34 0.02 -0.29 0.18 
GUK1 RRM2 -0.01 0.93 -0.08 0.70 
GUK1 RRM2B 0.03 0.83 0.20 0.35 
GUK1 TK1 0.65 0.00 0.39 0.06 
GUK1 DCK 0.11 0.48 -0.07 0.75 
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GUK1 AK1 0.38 0.01 0.25 0.24 
GUK1 AK5 -0.01 0.94 -0.15 0.48 
CMPK1 TK2 0.00 1.00 0.08 0.72 
CMPK1 DGUOK -0.31 0.04 -0.14 0.53 
CMPK1 NT5M -0.02 0.89 -0.25 0.23 
CMPK1 AK2 0.12 0.43 0.11 0.61 
CMPK1 NME4 0.01 0.95 -0.25 0.23 
CMPK1 RRM1 -0.22 0.16 -0.32 0.13 
CMPK1 RRM2 0.20 0.19 -0.20 0.34 
CMPK1 RRM2B 0.50 0.00 0.24 0.25 
CMPK1 TK1 0.20 0.20 -0.17 0.43 
CMPK1 DCK 0.06 0.68 0.28 0.19 
CMPK1 AK1 0.14 0.38 0.24 0.26 
CMPK1 AK5 0.05 0.74 0.12 0.57 
CMPK1 GUK1 0.04 0.82 0.00 0.98 
DTYMK TK2 0.06 0.68 -0.01 0.95 
DTYMK DGUOK 0.27 0.08 -0.03 0.90 
DTYMK NT5M 0.38 0.01 0.41 0.05 
DTYMK AK2 0.52 0.00 0.33 0.12 
DTYMK NME4 0.24 0.12 0.39 0.06 
DTYMK RRM1 -0.21 0.18 0.01 0.97 
DTYMK RRM2 0.05 0.77 0.08 0.70 
DTYMK RRM2B 0.24 0.12 -0.02 0.91 
DTYMK TK1 0.47 0.00 0.55 0.01 
DTYMK DCK 0.21 0.16 0.07 0.76 
DTYMK AK1 0.36 0.02 0.30 0.16 
DTYMK AK5 0.16 0.30 0.26 0.21 
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DTYMK GUK1 0.59 0.00 0.43 0.04 
DTYMK CMPK1 0.19 0.21 -0.02 0.92 
NME1 TK2 -0.22 0.15 0.10 0.65 
NME1 DGUOK 0.39 0.01 0.15 0.48 
NME1 NT5M 0.17 0.27 -0.22 0.31 
NME1 AK2 0.17 0.26 0.27 0.21 
NME1 NME4 0.42 0.00 0.46 0.02 
NME1 RRM1 -0.23 0.13 -0.10 0.64 
NME1 RRM2 -0.03 0.82 0.10 0.64 
NME1 RRM2B -0.20 0.20 0.17 0.43 
NME1 TK1 0.43 0.00 0.56 0.00 
NME1 DCK 0.01 0.92 0.07 0.76 
NME1 AK1 0.14 0.36 -0.38 0.07 
NME1 AK5 0.00 1.00 -0.29 0.17 
NME1 GUK1 0.32 0.03 0.28 0.19 
NME1 CMPK1 0.00 0.99 -0.25 0.25 
NME1 DTYMK 0.33 0.03 0.07 0.76 
NME3 TK2 0.13 0.41 -0.11 0.62 
NME3 DGUOK 0.31 0.04 -0.29 0.17 
NME3 NT5M 0.30 0.05 0.31 0.14 
NME3 AK2 0.40 0.01 0.14 0.52 
NME3 NME4 0.34 0.02 0.46 0.02 
NME3 RRM1 -0.26 0.09 0.04 0.84 
NME3 RRM2 -0.07 0.64 0.21 0.32 
NME3 RRM2B 0.08 0.62 0.07 0.75 
NME3 TK1 0.35 0.02 0.51 0.01 
NME3 DCK 0.22 0.16 -0.06 0.78 
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NME3 AK1 0.33 0.03 0.24 0.25 
NME3 AK5 0.23 0.13 0.14 0.51 
NME3 GUK1 0.45 0.00 0.51 0.01 
NME3 CMPK1 0.11 0.48 -0.04 0.87 
NME3 DTYMK 0.41 0.01 0.57 0.00 
NME3 NME1 0.45 0.00 0.30 0.15 
ADK TK2 0.12 0.44 -0.03 0.88 
ADK DGUOK 0.44 0.00 0.32 0.13 
ADK NT5M 0.57 0.00 0.18 0.40 
ADK AK2 0.14 0.36 0.31 0.14 
ADK NME4 0.16 0.28 0.30 0.16 
ADK RRM1 -0.02 0.88 0.28 0.19 
ADK RRM2 0.18 0.25 0.04 0.86 
ADK RRM2B 0.01 0.93 0.07 0.74 
ADK TK1 0.40 0.01 0.19 0.38 
ADK DCK 0.11 0.48 0.23 0.28 
ADK AK1 0.14 0.37 0.11 0.61 
ADK AK5 0.34 0.02 0.38 0.07 
ADK GUK1 0.31 0.04 0.05 0.83 
ADK CMPK1 0.08 0.61 -0.09 0.67 
ADK DTYMK 0.27 0.07 0.30 0.15 
ADK NME1 0.26 0.09 0.10 0.64 
ADK NME3 0.23 0.13 0.15 0.47 
NT5E TK2 0.12 0.45 0.23 0.28 
NT5E DGUOK 0.05 0.74 0.07 0.74 
NT5E NT5M 0.21 0.18 0.29 0.17 
NT5E AK2 0.22 0.14 0.10 0.65 
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NT5E NME4 -0.14 0.37 0.25 0.23 
NT5E RRM1 0.28 0.06 0.14 0.51 
NT5E RRM2 0.27 0.08 0.11 0.62 
NT5E RRM2B 0.23 0.14 0.33 0.12 
NT5E TK1 -0.02 0.92 -0.25 0.25 
NT5E DCK 0.10 0.53 -0.16 0.47 
NT5E AK1 -0.02 0.89 0.29 0.17 
NT5E AK5 0.30 0.05 0.39 0.06 
NT5E GUK1 -0.06 0.70 -0.09 0.69 
NT5E CMPK1 0.28 0.07 0.19 0.36 
NT5E DTYMK 0.12 0.43 0.12 0.59 
NT5E NME1 -0.18 0.25 -0.14 0.51 
NT5E NME3 -0.08 0.59 0.14 0.52 
NT5E ADK 0.23 0.13 0.49 0.02 
NT5C2 TK2 -0.03 0.83 -0.24 0.26 
NT5C2 DGUOK -0.25 0.11 -0.27 0.20 
NT5C2 NT5M 0.04 0.78 -0.34 0.10 
NT5C2 AK2 0.11 0.49 0.15 0.49 
NT5C2 NME4 -0.25 0.10 -0.21 0.33 
NT5C2 RRM1 0.41 0.01 0.34 0.10 
NT5C2 RRM2 0.30 0.05 0.24 0.27 
NT5C2 RRM2B 0.28 0.06 0.29 0.17 
NT5C2 TK1 -0.17 0.26 -0.02 0.92 
NT5C2 DCK 0.17 0.27 0.33 0.12 
NT5C2 AK1 -0.07 0.63 -0.02 0.92 
NT5C2 AK5 0.08 0.61 0.08 0.71 
NT5C2 GUK1 -0.27 0.08 -0.06 0.78 
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NT5C2 CMPK1 0.20 0.19 0.22 0.29 
NT5C2 DTYMK -0.16 0.31 -0.24 0.25 
NT5C2 NME1 -0.37 0.01 -0.05 0.80 
NT5C2 NME3 -0.05 0.74 -0.10 0.65 
NT5C2 ADK -0.09 0.54 -0.08 0.70 
NT5C2 NT5E 0.41 0.01 -0.04 0.86 
NT5C1B TK2 0.19 0.22 0.08 0.72 
NT5C1B DGUOK -0.09 0.56 -0.09 0.67 
NT5C1B NT5M 0.22 0.16 -0.14 0.50 
NT5C1B AK2 -0.14 0.37 0.11 0.62 
NT5C1B NME4 -0.16 0.29 -0.23 0.29 
NT5C1B RRM1 0.16 0.29 0.32 0.13 
NT5C1B RRM2 0.11 0.46 0.14 0.53 
NT5C1B RRM2B -0.08 0.61 0.36 0.09 
NT5C1B TK1 -0.13 0.41 -0.11 0.62 
NT5C1B DCK 0.19 0.21 0.29 0.17 
NT5C1B AK1 0.09 0.56 -0.02 0.94 
NT5C1B AK5 0.24 0.11 0.35 0.09 
NT5C1B GUK1 -0.12 0.44 -0.20 0.36 
NT5C1B CMPK1 -0.17 0.26 -0.17 0.44 
NT5C1B DTYMK -0.09 0.55 -0.14 0.53 
NT5C1B NME1 -0.17 0.26 -0.17 0.44 
NT5C1B NME3 0.06 0.72 -0.17 0.44 
NT5C1B ADK -0.06 0.69 -0.05 0.83 
NT5C1B NT5E 0.13 0.41 0.05 0.83 
NT5C1B NT5C2 0.22 0.15 0.32 0.13 
NT5C TK2 -0.28 0.07 -0.49 0.01 
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NT5C DGUOK 0.34 0.02 -0.10 0.64 
NT5C NT5M 0.29 0.06 0.08 0.70 
NT5C AK2 0.20 0.19 0.04 0.85 
NT5C NME4 0.25 0.10 0.11 0.62 
NT5C RRM1 -0.23 0.14 -0.23 0.27 
NT5C RRM2 0.27 0.08 -0.21 0.32 
NT5C RRM2B 0.00 0.98 0.14 0.53 
NT5C TK1 0.61 0.00 -0.02 0.91 
NT5C DCK 0.27 0.07 0.23 0.28 
NT5C AK1 0.24 0.11 0.12 0.56 
NT5C AK5 0.07 0.63 0.27 0.20 
NT5C GUK1 0.57 0.00 0.36 0.08 
NT5C CMPK1 0.27 0.07 0.14 0.50 
NT5C DTYMK 0.37 0.01 0.33 0.11 
NT5C NME1 0.43 0.00 -0.15 0.49 
NT5C NME3 0.37 0.01 0.25 0.24 
NT5C ADK 0.43 0.00 -0.08 0.73 
NT5C NT5E 0.00 0.99 -0.02 0.92 
NT5C NT5C2 -0.05 0.73 0.05 0.82 
NT5C NT5C1B -0.04 0.81 0.14 0.53 
NT5C3 TK2 -0.18 0.25 -0.21 0.33 
NT5C3 DGUOK 0.16 0.29 -0.10 0.64 
NT5C3 NT5M 0.32 0.03 -0.01 0.96 
NT5C3 AK2 0.14 0.35 0.25 0.24 
NT5C3 NME4 -0.20 0.18 -0.60 0.00 
NT5C3 RRM1 -0.12 0.46 -0.21 0.31 
NT5C3 RRM2 0.28 0.06 -0.08 0.73 
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NT5C3 RRM2B 0.04 0.79 -0.37 0.08 
NT5C3 TK1 0.20 0.19 0.01 0.95 
NT5C3 DCK 0.06 0.71 0.27 0.21 
NT5C3 AK1 0.24 0.11 0.17 0.43 
NT5C3 AK5 -0.18 0.24 -0.13 0.55 
NT5C3 GUK1 0.18 0.24 -0.08 0.72 
NT5C3 CMPK1 0.21 0.17 0.42 0.04 
NT5C3 DTYMK 0.20 0.20 0.02 0.91 
NT5C3 NME1 -0.14 0.36 -0.30 0.15 
NT5C3 NME3 -0.15 0.33 -0.21 0.33 
NT5C3 ADK 0.37 0.01 0.13 0.54 
NT5C3 NT5E 0.17 0.26 0.05 0.80 
NT5C3 NT5C2 0.15 0.34 -0.11 0.59 
NT5C3 NT5C1B 0.00 1.00 -0.17 0.44 
NT5C3 NT5C 0.35 0.02 0.12 0.57 
UCK1 TK2 0.01 0.93 -0.16 0.44 
UCK1 DGUOK -0.04 0.78 -0.14 0.52 
UCK1 NT5M 0.16 0.30 0.28 0.19 
UCK1 AK2 0.21 0.17 0.20 0.35 
UCK1 NME4 -0.07 0.65 0.27 0.21 
UCK1 RRM1 0.10 0.53 0.32 0.12 
UCK1 RRM2 0.31 0.04 0.45 0.03 
UCK1 RRM2B 0.07 0.66 -0.09 0.69 
UCK1 TK1 0.24 0.11 0.26 0.23 
UCK1 DCK -0.03 0.87 0.18 0.41 
UCK1 AK1 0.20 0.20 -0.07 0.75 
UCK1 AK5 -0.09 0.57 0.30 0.16 
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UCK1 GUK1 0.33 0.03 0.15 0.47 
UCK1 CMPK1 -0.09 0.57 -0.16 0.45 
UCK1 DTYMK 0.10 0.53 0.42 0.04 
UCK1 NME1 -0.20 0.20 -0.08 0.70 
UCK1 NME3 0.09 0.58 0.03 0.89 
UCK1 ADK 0.11 0.47 0.43 0.03 
UCK1 NT5E 0.18 0.24 0.05 0.83 
UCK1 NT5C2 0.32 0.03 0.08 0.72 
UCK1 NT5C1B 0.16 0.29 0.11 0.62 
UCK1 NT5C 0.24 0.11 -0.03 0.87 
UCK1 NT5C3 0.23 0.13 0.02 0.93 
UCK2 TK2 0.03 0.85 -0.03 0.88 
UCK2 DGUOK 0.15 0.32 -0.40 0.05 
UCK2 NT5M 0.26 0.08 0.56 0.00 
UCK2 AK2 0.32 0.03 0.01 0.97 
UCK2 NME4 0.19 0.21 0.30 0.16 
UCK2 RRM1 0.31 0.04 0.27 0.21 
UCK2 RRM2 0.25 0.10 0.44 0.03 
UCK2 RRM2B -0.10 0.52 -0.06 0.79 
UCK2 TK1 0.28 0.06 0.22 0.30 
UCK2 DCK 0.19 0.22 -0.03 0.88 
UCK2 AK1 0.19 0.21 0.06 0.78 
UCK2 AK5 0.14 0.37 0.09 0.69 
UCK2 GUK1 0.32 0.03 0.42 0.04 
UCK2 CMPK1 -0.23 0.14 -0.32 0.13 
UCK2 DTYMK 0.40 0.01 0.32 0.13 
UCK2 NME1 0.29 0.05 0.00 0.99 
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UCK2 NME3 0.35 0.02 0.35 0.09 
UCK2 ADK 0.18 0.24 0.09 0.68 
UCK2 NT5E 0.23 0.13 -0.03 0.87 
UCK2 NT5C2 0.00 0.98 -0.22 0.31 
UCK2 NT5C1B 0.01 0.97 0.17 0.44 
UCK2 NT5C 0.13 0.42 0.15 0.48 
UCK2 NT5C3 -0.05 0.77 -0.13 0.53 
UCK2 UCK1 0.08 0.61 0.54 0.01 
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Table 12: kcat/Km. Molecular weights taken for multimer forms of the proteins. 
 
 
 
 Molecular 
weight (kd) 
References 
(for molecular 
weight) 
Vmax  
(µmol per min 
per mg) 
References 
(for Vmax) 
Km 
(µM) 
Vmax/Km (µmol per min 
per mg per µM) 
kcat/Km (per 
M per s) 
Notes 
DGUOK 58 [91]       
dG   0.04 [89] 4.00 0.01 10391.67  
dA   0.43 [89] 467.0
0 
0.00 888.01  
dI   0.39 [89] 12.00 0.03 31416.67  
TK2 87 [91]      TK2 exists both as dimer and tetramer: 
mean molecular weight assumed 
dT   1.29 [90] 3.61 0.36 517979.04 Hill kinetics: 'Km' = 13^0.5 
dC   0.79 [90] 11.00 0.07 104004.55  
dU    [6]   31078.74 dU activity is about 6% of dT activity  
NT5M 46 [92]       
dUMP   110.00 [85] 100.0
0 
1.10 843333.33  
dTMP   74.00 [85] 200.0
0 
0.37 283666.67  
dCMP   0.00 [88] 150.0
0 
0.00 0.00  
dGMP   4.40 [88] 150.0
0 
0.03 22488.89  
dAMP   2.20 [88] 150.0
0 
0.01 11244.44  
dIMP   6.60 [88] 150.0
0 
0.04 33733.33  
UMP   81.40 [88] 150.0
0 
0.54 416044.44  
CMP   0.00 [88] 150.0
0 
0.00 0.00  
GMP   0.00 [88] 150.0
0 
0.00 0.00  
AMP   2.20 [88] 150.0
0 
0.01 11244.44  
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IMP   2.20 [88] 150.0
0 
0.01 11244.44  
3’-dTMP   226.60 [88] 150.0
0 
1.51 1158177.78  
3’-UMP   74.80 [88] 150.0
0 
0.50 382311.11  
3’-CMP   0.00 [88] 150.0
0 
0.00 0.00  
2’-UMP   33.00 [88] 150.0
0 
0.22 168666.67  
2’-GMP   0.00 [88] 150.0
0 
0.00 0.00  
dTDP   2.20 [88] 150.0
0 
0.01 11244.44  
dTTP   0.00 [88] 150.0
0 
0.00 0.00  
AK2 26 [91]       
AMP   198.40 [81] 80.00 2.48 1074666.67  
dAMP   272.80 [81] 210.0
0 
1.30 562920.63  
CMP   161.20 [81] 6000.
00 
0.03 11642.22  
UMP   3.96 [81] 9000.
00 
0.00 190.67  
CMPK2 44.5 [8]       
dUMP   0.48 [8] 100.0
0 
0.00 3560.00  
dCMP   1.77 [8] 1310.
00 
0.00 1002.10  
CMP   1.64 [8] 3090.
00 
0.00 393.64  
UMP   0.19 [8] 6300.
00 
0.00 22.37  
POLG        POLG Vmaxs are Kcat (per s), and reduced 
by 1/2 
dTTP   12.50 [83] 0.63  19841269.84  
dCTP   21.50 [83] 0.90  23888888.89  
dATP   22.50 [83] 0.80  28125000.00  
dGTP   18.50 [83] 0.80  23125000.00  
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CTP   0.01 [87] 67.00  143.28  
ATP   0.01 [87] 100.0
0 
 56.00  
DNC (Lam 
et al 2005) 
32 [84]      Presence of cholesterol and iADP 
assumed 
dCTP   0.04 [84] 3000.
00 
0.00 7.89  
dATP   0.01 [84] 2700.
00 
0.00 2.39  
dTTP   0.00 [84] 600.0
0 
0.00 4.00  
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Table 13: Concentration/Km values. Concentration assumptions can be thought of as approximating the substrate concentrations in 
mitochondria of 'quiescent' (Low) or 'cycling' (High) cells. dNXP = dNMP or dNDP or dNTP. 
 
 
 
   High 
concentrations 
 Low 
concentrations 
  
 Km 
(µM) 
Reference
s 
(for Km) 
Concentration 
(µM) 
Concentration / 
Km 
Concentration 
(µM) 
Concentration / 
Km 
Notes 
DGUOK        
dG 4.0 [89] 0.5 0.13 0.50 0.13  
dA 467.0 [89] 0.5 0.00 0.50 0.00  
dI 12.0 [89] 0.5 0.04 0.50 0.04  
TK2        
dT  3.6 [90] 0.71 0.20 0.71 0.20 Hill kinetics: 'Km' = 13^0.5, 'Concentration' = 0.5^0.5 
dC 11.0 [90] 0.5 0.05 0.50 0.05  
dU 6.0 [6] 0.5 0.08 0.50 0.08  
NT5M        
dUMP 100.0 [85] 1 0.01 0.10 0.00 dUMP and dTMP Kms were available, rest assumed to be 150 
µM 
dTMP 200.0 [85] 10 0.05 1.00 0.01  
dCMP 150.0 [88] 10 0.07 1.00 0.01 No reaction (Vmax = 0) 
dGMP 150.0 [88] 10 0.07 1.00 0.01  
dAMP 150.0 [88] 10 0.07 1.00 0.01  
dIMP 150.0 [88] 0.1 0.00 0.01 0.00  
UMP 150.0 [88] 100 0.67 100.00 0.67  
CMP 150.0 [88] 100 0.67 100.00 0.67 No reaction (Vmax = 0) 
GMP 150.0 [88] 100 0.67 100.00 0.67 No reaction (Vmax = 0) 
AMP 150.0 [88] 100 0.67 100.00 0.67  
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IMP 150.0 [88] 1 0.01 1.00 0.01  
3’-dTMP 150.0 [88] 0.1 0.00 0.01 0.00  
3’-UMP 150.0 [88] 0.1 0.00 0.01 0.00  
3’-CMP 150.0 [88] 0.1 0.00 0.01 0.00 No reaction (Vmax = 0) 
2’-UMP 150.0 [88] 0.1 0.00 0.01 0.00  
2’-GMP 150.0 [88] 0.1 0.00 0.01 0.00  
dTDP 150.0 [88] 10 0.07 1.00 0.01  
dTTP 150.0 [88] 10 0.07 1.00 0.01 No reaction (Vmax = 0) 
AK2        
AMP 80.0 [81] 100 1.25 100.00 1.25  
dAMP 210.0 [81] 10 0.05 1.00 0.00  
CMP 6000.0 [81] 100 0.02 100.00 0.02  
UMP 9000.0 [81] 100 0.01 100.00 0.01  
CMPK2        
dUMP 100.0 [8] 1 0.01 0.10 0.00  
dCMP 1310.0 [8] 10 0.01 1.00 0.00  
CMP 3090.0 [8] 100 0.03 100.00 0.03  
UMP 6300.0 [8] 100 0.02 100.00 0.02  
POLG        
dTTP 0.6 [83] 10 15.87 1.00 1.59  
dCTP 0.9 [83] 10 11.11 1.00 1.11  
dATP 0.8 [83] 10 12.50 1.00 1.25  
dGTP 0.8 [83] 10 12.50 1.00 1.25  
CTP 67.0 [87] 100 1.49 100.00 1.49  
ATP 100.0 [87] 100 1.00 100.00 1.00  
NME4        
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dTDP 1000.0 [86] 10 0.01 1.00 0.00  
DNC 
(Dolce et al 
2001) 
       
ATP 42.6 [82] 100 2.35 100.00 2.35 ATP and ADP Kms available, rest assumed to be same as Ki 
ADP 106.0 [82] 100 0.94 100.00 0.94  
GDP 197.0 [82] 100 0.51 100.00 0.51  
CDP 284.0 [82] 100 0.35 100.00 0.35  
UDP 380.0 [82] 100 0.26 100.00 0.26  
dADP 14.0 [82] 10 0.71 1.00 0.07  
dGDP 55.0 [82] 10 0.18 1.00 0.02  
dCDP 99.0 [82] 10 0.10 1.00 0.01  
dTDP 117.0 [82] 10 0.09 1.00 0.01  
dUDP 179.0 [82] 1 0.01 0.10 0.00  
dGTP 230.0 [82] 10 0.04 1.00 0.00  
dCTP 423.0 [82] 10 0.02 1.00 0.00  
dTTP 595.0 [82] 10 0.02 1.00 0.00  
dUTP 963.0 [82] 1 0.00 0.10 0.00  
DNC 
(Lam et al 
2005) 
      Presence of cholesterol and iADP assumed 
dCTP 3000.0 [84] 10 0.00 1.00 0.00  
dATP 2700.0 [84] 10 0.00 1.00 0.00  
dTTP 600.0 [84] 10 0.02 1.00 0.00  
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Table 14: Enzyme inhibitions. Ki taken to be Km when Ki not available. ‘high’ = High concentrations, ‘low’ = Low concentrations. 
 
 
 
 Concentration (µM) 
(‘high’) 
Ki 
(µM) 
References 
(for Ki) 
[i]/Ki Sum([i]/Ki) Concentration 
(µM) 
[i]/Ki Sum([i]/Ki) Notes 
    (‘high’) (‘high’) (‘low’) (‘low’) (‘low’)  
DGUOK     28.27   2.98  
dG 0.50 4.00 [89] 0.13  0.50 0.13   
dA 0.50 467.00 [89] 0.00  0.50 0.00   
dI 0.50 12.00 [89] 0.04  0.50 0.04   
dGMP 10.00 4.00 [97] 2.50  1.00 0.25   
dAMP 10.00 28.00 [97] 0.36  1.00 0.04   
dIMP 0.10 78.00 [97] 0.00  0.01 0.00   
dGTP 10.00 0.40 [97] 25.00  1.00 2.50   
dATP 10.00 41.00 [97] 0.24  1.00 0.02   
dITP 0.10 41.00 [97] 0.00  0.01 0.00  Ki of dITP set equal to dATP Ki 
TK2     17.24   1.83  
dT  0.50 4.90 [90] 0.10  0.50 0.10   
dC 0.50 40.00 [90] 0.01  0.50 0.01   
dU 0.50 227.00 [6] 0.00  0.50 0.00  Ki of dU set as geometric mean 
dTTP 10.00 2.30 [90] 4.35  1.00 0.43   
dCTP 10.00 0.83 [90] 12.05  1.00 1.20   
dUTP 1.00 1.38 [90] 0.72  0.10 0.07  Ki of dUTP on TK2 geometric mean of dCTP and 
dTTP values 
NT5M     3.07   2.71  
dUMP 1.00 100.00 [85] 0.01  0.10 0.00   
dTMP 10.00 200.00 [85] 0.05  1.00 0.01   
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dCMP 10.00 150.00 [88] 0.07  1.00 0.01   
dGMP 10.00 150.00 [88] 0.07  1.00 0.01   
dAMP 10.00 150.00 [88] 0.07  1.00 0.01   
dIMP 0.10 150.00 [88] 0.00  0.01 0.00   
UMP 100.00 150.00 [88] 0.67  100.00 0.67   
CMP 100.00 150.00 [88] 0.67  100.00 0.67   
GMP 100.00 150.00 [88] 0.67  100.00 0.67   
AMP 100.00 150.00 [88] 0.67  100.00 0.67   
IMP 1.00 150.00 [88] 0.01  1.00 0.01   
3’-dTMP 0.10 150.00 [88] 0.00  0.01 0.00   
3’-UMP 0.10 150.00 [88] 0.00  0.01 0.00   
3’-CMP 0.10 150.00 [88] 0.00  0.01 0.00   
2’-UMP 0.10 150.00 [88] 0.00  0.01 0.00   
2’-GMP 0.10 150.00 [88] 0.00  0.01 0.00   
dTDP 10.00 150.00 [88] 0.07  1.00 0.01   
dTTP 10.00 150.00 [88] 0.07  1.00 0.01   
AK2     1.33   1.28  
AMP 100.00 80.00 [81] 1.25  100.00 1.25   
dAMP 10.00 210.00 [81] 0.05  1.00 0.00   
CMP 100.00 6000.00 [81] 0.02  100.00 0.02   
UMP 100.00 9000.00 [81] 0.01  100.00 0.01   
CMPK2     0.07   0.05  
dUMP 1.00 100.00 [8] 0.01  0.10 0.00   
dCMP 10.00 1310.00 [8] 0.01  1.00 0.00   
CMP 100.00 3090.00 [8] 0.03  100.00 0.03   
UMP 100.00 6300.00 [8] 0.02  100.00 0.02   
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S1: Simulation parameters (not Mathematica-readable). 
 
 
 
Start of L strand replication 
Lstrandstart=10969; 
 
The fractions of A, C, G, T on the heavy and light strands of mtDNA 
fdTH=0.309; 
fdTL=0.247; 
fdCH=0.131; 
fdCL=0.313; 
fdAH=0.247; 
fdAL=0.309; 
fdGH=0.313; 
fdGL=0.131; 
 
Hill coefficient of TK2-deoxythymidine reaction 
Reference [6] 
tk2hill=0.5; 
 
The length of both strands of mtDNA 
DNAlength=33136; 
The length of one strand of mtDNA 
strandDNA=DNAlength / 2; 
 
Volume of a mitochondrion 
Reference [93] 
volmito=2 x 10-16; 
 
Conversion factor used to convert Kms and concentrations from micromolar to molecules per mitochondrion 
(conversion = 120.4;) 
conversion=1 x 10-6 x 6.022 x 1023 x volmito; 
secondsperminute=60; 
 
Factor used to decrease the Vmax of the polymerase on double stranded templates with lower primer density 
Reference [93] 
dsfact=1 / 2; 
 
Polymerase kinetic constants 
Reference [83] 
VmaxPoldT=25.0 x dsfact x secondsperminute; 
VmaxPoldC=43.0 x dsfact x secondsperminute; 
VmaxPoldA=45.0 x dsfact x secondsperminute; 
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VmaxPoldG=37.0 x dsfact x secondsperminute; 
KmPoldT=0.63 x conversion; 
KmPoldC=0.9 x conversion; 
KmPoldA=0.8 x conversion; 
KmPoldG=0.8 x conversion; 
 
Ki of dTTP on TK2 
Reference [90] 
kidttptk2=2.3 x conversion; 
 
Ki of dUTP on TK2: geometric mean of dCTP and dTTP values 
kidutptk2=1.38 x conversion; 
 
Ki of dCTP on TK2 
Reference [90] 
kidctptk2=0.83 x conversion; 
 
Ki of dU on TK2: geometric mean 
Reference [6] 
kidutk2=227 x conversion; 
 
Ki of dC on TK2 
Reference [90] 
kidctk2=40 x conversion; 
 
Ki of dT on TK2 
Reference [90] 
kidttk2=4.9 x conversion; 
 
(Substrate Kis on DGUOK set equal to substrate Kms) 
 
Ki of dI on DGUOK set equal to Km 
Reference [89] 
kididgk=12 x conversion; 
 
Ki of dIMP on DGUOK 
Reference [97] 
kidimpdgk=78 x conversion; 
 
Ki of dITP on DGUOK set equal to dATP Ki 
kiditpdgk=kidatpdgk; 
 
Ki of dGMP on DGUOK 
Reference [97] 
kidgmpdgk=4 x conversion; 
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Ki of dAMP on DGUOK 
Reference [97] 
kidampdgk=28 x conversion; 
 
Ki of dATP on DGUOK 
Reference [97] 
kidatpdgk=41 x conversion; 
 
Ki of dGTP on DGUOK 
Reference [97] 
kidgtpdgk=0.4 x conversion; 
 
Estimated nucleoside transporter (ENT) molecular weight in kilodalton 
Reference [93] 
transporterMW=50; 
 
TK2 and DGUOK molecular weights in kilodalton 
(DGUOK is a dimer, TK2 exists both as dimer and tetramer (mean taken)) 
Reference [76, 101] 
dgkMW=58; 
tk2MW=87; 
 
Molecular weight of NT5M in kilodalton (dimer) 
Reference [88, 92] 
dnt2MW=46; 
 
Ectonucleotidase molecular weight in kilodalton (tetramer) 
Reference [91] 
enMW=210; 
 
TMPK2 molecular weight in kilodalton 
Reference [9] 
tmpk2MW=44; 
 
GMPK2 assumed molecular weight in kilodalton 
Reference [91] 
gmpk2MW=22; 
 
CMPK2 molecular weight in kilodalton 
Reference [8] 
cmpk2MW=44.5; 
 
AK2 molecular weight in kilodalton 
Reference [UniProt accession P54819] 
akMW=26; 
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NME4 molecular weight in kilodalton (homohexamer) 
Reference [86] 
ndpkMW=120; 
 
Nucleoside kinase molecules in each mitochondrion 
Reference [93] 
tk2moleculespermito=100; 
dgkmoleculespermito=200; 
 
NT5M molecules in each mitochondrion 
Reference [93] 
dnt2moleculespermito=50; 
 
Ectonucleotidase molecules in each mitochondrion 
enmoleculespermito=50; 
 
TMPK2 molecules in each mitochondrion 
Reference [93] 
tmpk2moleculespermito=50; 
 
GMPK2 molecules in each mitochondrion 
Reference [93] 
gmpk2moleculespermito=50; 
 
CMPK2 molecules in each mitochondrion 
Reference [93] 
cmpk2moleculespermito=50; 
 
NME4 molecules in each mitochondrion 
Reference [93] 
ndpkmoleculespermito=300; 
 
The factor that the reverse reaction is faster than the forward reaction for NMPK 
factorMD=0.1; (AMP/ADP) 
 
The factor that the reverse reaction is faster than the forward reaction for NDPK 
factorDT=0.1; (ADP/ATP) 
 
ENT molecules per mitochondrion 
Reference [93] 
transportermoleculespermito=38; 
 
Adenylate kinase molecules per mitochondrion 
Reference [93] 
akmoleculespermito=450; 
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ENT Vmax converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [98, 102] 
transportervmax=0.000086/0.0000021 x transportermoleculespermito; 
 
Vmax of the first phosphorylation of dT in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [90] 
Vmax1PfdT=1.288 x tk2MW x tk2moleculespermito; 
 
Vmax of the first phosphorylation of dC in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [90] 
Vmax1PfdC=0.789 x tk2MW x tk2moleculespermito; 
 
Vmax of dC with DGUOK converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [89] 
Vmax1PfdCdgk=0.059 x dgkMW x dgkmoleculespermito; 
 
Vmax of the first phosphorylation of dA in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [89] 
Vmax1PfdA=0.429 x dgkMW x dgkmoleculespermito; 
 
Vmax of the first phosphorylation of dG in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [89] 
Vmax1PfdG=0.043 x dgkMW x dgkmoleculespermito; 
 
Vmax of the first phosphorylation of dT in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [85] 
Vmax1PrdT=74 x dnt2MW x dnt2moleculespermito; 
 
Ectonucleotidase Vmax of the first phosphorylation of dT in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Vmax1PrdTen=4.5 x enMW x enmoleculespermito; 
 
Vmax of the first phosphorylation of dC in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Vmax1PrdC=4.5 x enMW x enmoleculespermito; 
 
Vmax of the first phosphorylation of dA in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Vmax1PrdA=4.5 x enMW x enmoleculespermito; 
 
Vmax of the first phosphorylation of dG in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Vmax1PrdG=4.5 x enMW x enmoleculespermito; 
 
Vmax of the second phosphorylation of dT in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [91] 
Vmax2PfdT=0.821 x tmpk2MW x tmpk2moleculespermito; 
 
Vmax of the second phosphorylation of dC in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [8] 
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Vmax2PfdC=1.77 x cmpk2MW x cmpk2moleculespermito; 
 
Vmax of the second phosphorylation of dA in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [81] 
Vmax2PfdA=272.8 x akMW x akmoleculespermito; 
 
Vmax of the second phosphorylation of dG in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [81] 
Vmax2PfdG=1.54 x gmpk2MW x gmpk2moleculespermito; 
 
Vmax of the second phosphorylation of dT in the reverse direction 
Vmax2PrdT=Vmax2PfdT x factorMD; 
 
Vmax of the second phosphorylation of dC in the reverse direction 
Vmax2PrdC=Vmax2PfdC x factorMD; 
 
Vmax of the second phosphorylation of dA in the reverse direction 
Vmax2PrdA=Vmax2PfdA x factorMD; 
 
Vmax of the second phosphorylation of dG in the reverse direction 
Vmax2PrdG=Vmax2PfdG x factorMD; 
 
Vmax of the third phosphorylation of dT in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [99] 
Vmax3PfdT=140 x ndpkMW x ndpkmoleculespermito; 
 
Vmax of the third phosphorylation of dC in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [99] 
Vmax3PfdC=50 x ndpkMW x ndpkmoleculespermito; 
  
Vmax of the third phosphorylation of dA in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [86] 
Vmax3PfdA=225 x ndpkMW x ndpkmoleculespermito; (set equal to dGDP Vmax) 
 
Vmax of the third phosphorylation of dG in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute 
Reference [99] 
Vmax3PfdG=225 x ndpkMW x ndpkmoleculespermito; 
 
Vmax of the third phosphorylation of dT in the reverse direction 
Vmax3PrdT=Vmax3PfdT x factorDT; 
 
Vmax of the third phosphorylation of dC in the reverse direction 
Vmax3PrdC=Vmax3PfdC x factorDT; 
 
Vmax of the third phosphorylation of dA in the reverse direction 
Vmax3PrdA=Vmax3PfdA x factorDT; 
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Vmax of the third phosphorylation of dG in the reverse direction 
Vmax3PrdG=Vmax3PfdG x factorDT; 
 
ENT Km 
Reference [98] 
transporterkm=2 x conversion; 
 
Km of the first phosphorylation of dT in the forward direction 
Reference [90] 
km1PfdT=13 x conversion; 
 
Km of the first phosphorylation of dC in the forward direction 
Reference [90] 
km1PfdC=11 x conversion; 
 
Km of dC with DGUOK 
Reference [89] 
km1PfdCdgk=336 x conversion; 
 
Km of the first phosphorylation of dA in the forward direction 
Reference [89] 
km1PfdA=467 x conversion; 
 
Km of the first phosphorylation of dG in the forward direction 
Reference [89] 
km1PfdG=4 x conversion; 
 
Km of the first phosphorylation of dT, dU in the reverse direction 
Reference [88] 
km1PrdT=200 x conversion; 
km1PrdU=100 x conversion; 
km1PrrU=1.5 x km1PrdT; 
 
Ectonucleotidase data: geometric means for substrate Kms, higher Kms plugged for inhibitions to be conservative 
Reference [91, 92] 
Ectonucleotidase Km of the first phosphorylation of dT, dU, rU in the reverse direction 
km1PrdTen=22.5 x conversion; 
km1PrdUen=110 x conversion; (set equal to UMP Km) 
km1PrrUen=110 x conversion; (set equal to Km) 
 
Ectonucleotidase Km of the first phosphorylation of dC, rC in the reverse direction 
km1PrdC=290 x conversion; 
km1PrrC=360 x conversion; 
 
Ectonucleotidase Km of the first phosphorylation of da, rA in the reverse direction 
154 
 
km1PrdA=62 x conversion; 
km1PrrA=19 x conversion; (set equal to Km) 
 
kiadpen=17 x conversion; 
kiatpen=15 x conversion; 
 
Ectonucleotidase Km of the first phosphorylation of dG, rG in the reverse direction 
km1PrdG=48 x conversion; 
km1PrrG=59 x conversion; (set equal to Km) 
 
Ectonucleotidase Km of the first phosphorylation of dI, rI in the reverse direction 
km1PrdI=100 x conversion; (set equal to Km of IMP) 
km1PrrI=100 x conversion; (set equal to Km) 
 
Km of the second phosphorylation of dT in the forward direction 
Reference [81] 
km2PfdT=20 x conversion; 
km2PfdUtmpk2=2600 x conversion; (Km is 170, but Ki is 2600) 
 
Miscellaneous inhibitions 
Reference [91] 
kidttptmpk2=700 x conversion; 
kidttmpk2=180 x conversion; 
 
Km of the second phosphorylation of dC in the forward direction 
Reference [8] 
km2PfdC=1310 x conversion; 
km2PfrC=3090 x conversion; 
km2PfrU=6300 x conversion; 
km2PfdUcmpk2=100 x conversion; 
 
CMPK1 can phosphorylate AMP and dAMP 
Reference [100] 
km2PfrAcmpk2=km2PrrAcmpk2=km2PfdAcmpk2=km2PrdAcmpk2=100 x 500 x conversion; (Km of CMP is 500 micromolar) 
 
Km of the second phosphorylation of dA in the forward direction 
Reference [81] 
km2PfdA=210 x conversion; 
km2PfrA=80 x conversion; 
 
CMP and UMP have some reactivity with AK2 - included as inhibitions 
Reference [81] 
km2PfrCak2=6000 x conversion; 
km2PfrUak2=9000 x conversion; 
 
Km of the second phosphorylation of dG in the forward direction 
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Reference [91] 
km2PfdG=112 x conversion; 
km2PfrG=18 x conversion; 
 
Km of the second phosphorylation of dT in the reverse direction 
km2PrdT=km2PfdT; 
km2PrdUtmpk2=km2PfdUtmpk2; 
 
Km of the second phosphorylation of dC in the reverse direction 
km2PrdC=km2PfdC; 
km2PrrC=km2PfrC; 
km2PrrU=km2PfrU; 
km2PrdUcmpk2=km2PfdUcmpk2; 
 
Km of the second phosphorylation of dA in the reverse direction 
km2PrdA=km2PfdA; 
km2PrrA=km2PfrA; 
 
km2PrrCak2=km2PfrCak2; 
km2PrrUak2=km2PfrUak2; 
 
Km of the second phosphorylation of dG in the reverse direction 
km2PrdG=km2PfdG; 
km2PrrG=km2PfrG; 
 
 
(Reaction is linear for dTDP and UDP until at least 1000 uM) 
Km of the third phosphorylation of dT in the forward direction 
Reference [99] 
km3PfdT=1000 x conversion; 
km3PfdU=km3PfdT; 
km3PfrU=km3PfdT; 
 
Km of the third phosphorylation of dC in the forward direction 
Reference [99] 
km3PfdC=1000 x conversion; (dNDPs are weaker substrates than rNDPs: author statement but data n/a so same value used) 
km3PfrC=1000 x conversion; (Reaction linear until at least 1000 uM) 
 
Km of the third phosphorylation of dA in the forward direction 
Reference [99] 
km3PfdA=70 x conversion; (Km of ADP is about 70 micromolar, Km of dADP set equal to that of dGDP) 
km3PfrA=300 x conversion; (substrate inhibition, Ki) 
 
Km of the third phosphorylation of dG in the forward direction 
Reference [99] 
km3PfdG=75 x conversion; 
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km3PfrG=100 x conversion; (substrate inhibition, Ki) 
 
Inosine inhibitions 
km3PfrI=km3PrrI=km3PfdI=km3PrdI=1000 x conversion; 
 
Km of the third phosphorylation of dT in the reverse direction 
km3PrdT=km3PfdT; 
km3PrdU=km3PrdT; 
km3PrrU=km3PrdT; 
 
Km of the third phosphorylation of dC in the reverse direction 
km3PrdC=km3PfdC; 
km3PrrC=km3PrdC; 
 
Km of the third phosphorylation of dA in the reverse direction 
km3PrdA=km3PfdA; 
km3PrrA=km3PrdA; 
 
Km of the third phosphorylation of dG in the reverse direction 
km3PrdG=km3PfdG; 
km3PrrG=km3PrdG; 
 
(Initial concentrations selected randomly) 
 
Initial dN concentrations 
dTcyto=RandomReal[{0.05 x conversion, 5 x conversion}]; 
dCcyto=RandomReal[{0.05 x conversion, 5 x conversion}]; 
dAcyto=RandomReal[{0.05 x conversion, 5 x conversion}]; 
dGcyto=RandomReal[{0.05 x conversion, 5 x conversion}]; 
 
dT0=dTcyto; 
dC0=dCcyto; 
dA0=dAcyto; 
dG0=dGcyto; 
 
Initial dNXP and rNXP levels 
If[celltype==1,dTTPcyto=RandomReal[{0.1 x conversion, 10 x conversion}]]; 
If[celltype==1,dCTPcyto=RandomReal[{0.1 x conversion, 10 x conversion}]]; 
If[celltype==1,dATPcyto=RandomReal[{0.1 x conversion, 10 x conversion}]]; 
If[celltype==1,dGTPcyto=RandomReal[{0.1 x conversion, 10 x conversion}]]; 
 
dTMP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dTDP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dTTP0=dTTPcyto; 
 
dCMP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
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dCDP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dCTP0=dCTPcyto; 
 
dAMP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dADP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dATP0=dATPcyto; 
 
dGMP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dGDP0=RandomReal[{0.01 x conversion, 10 x conversion}]; 
dGTP0=dGTPcyto; 
 
dU=dUcyto=dTcyto; 
rU=rUcyto=dTcyto; 
dI=dIcyto=0.1 x dAcyto; 
rI=rIcyto=0.1 x dAcyto; 
rC=rCcyto=dCcyto; 
rA=rAcyto=dAcyto; 
rG=rGcyto=dGcyto; 
 
dUMP=1 x conversion; (0.1 x dTMP0;) 
rUMP=10 x conversion; (10 x dTMP0;) 
dIMP=1 x conversion; (0.1 x dAMP0;) 
rIMP=1 x conversion; (0.1 x dAMP0;) 
rCMP=10 x conversion; (10 x dCMP0;) 
rAMP=10 x conversion; (10 x dAMP0;) 
rGMP=10 x conversion; (10 x dGMP0;) 
 
dUDP=1 x conversion; (0.1 x dTDP0;) 
rUDP=10 x conversion; (10 x dTDP0;) 
dIDP=1 x conversion; (0.1 x dADP0;) 
rIDP=1 x conversion; (0.1 x dADP0;) 
rCDP=10 x conversion; (10 x dCDP0;) 
rADP=10 x conversion; (10 x dADP0;) 
rGDP=10 x conversion; (10 x dGDP0;) 
 
dUTP=1 x conversion; (0.1 x dTTP0;) 
rUTP=10 x conversion; (10 x dTTP0;) 
dITP=1 x conversion; (0.1 x dATP0;) 
rITP=1 x conversion; (0.1 x dATP0;) 
rCTP=10 x conversion; (10 x dCTP0;) 
rATP=10 x conversion; (10 x dATP0;) 
rGTP=10 x conversion; (10 x dGTP0;) 
 
DNA0=0; 
LDNA0=0; 
HDNA0=0; 
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S2: Mathematica simulation code. 
 
 
 
(*Mitochondrial deoxynucleotide metabolism and DNA replication*) 
(*Vishal V Gandhi and David C Samuels*) 
(*The model simulates transport of deoxynucleosides and dexoynucleotides into and out of a mitochondrion,*)(*their subsequent phosphorylation and 
dephosphorylation and uptake into mtDNA*) 
 
ClearAll["Global`*"]; (*clear any previous variables in memory*) 
Off[General::spell1]; (*Turn off spelling checker*) 
            Off[General::spell]; 
 
(* directory where this file and constants file is located *) 
SetDirectory["C:\\Documents and Settings\\gandhiv\\My Documents\\pro\\data\\mathematicaexpbase\\transport_experiments"];  
 
 celltype=1; 
 
(*Choose the number of separate mitochondrial DNA replication events*) 
(*Partially overlapping mtDNA replication events are not supported in this version of the code*) 
numDNAmols=1; 
replication=1; (*0 = Off, 1 = On, starts immediately with the simulation*) 
                                        
(*Set the length of the total simulation in minutes*) 
(*Replication time is determined by initial and spot dNTP levels*) 
 
simtime=120;(*Total simulation time (min)*) 
 
replengths = {}; 
repdurations = {}; 
parameters = {}; 
 
Do[ 
<<modelconstants.txt;(*Load constants file*) 
 
parameters = Append[parameters,{dT0,dC0,dA0,dG0,dTMP0,dTDP0,dTTP0,dCMP0,dCDP0,dCTP0,dAMP0,dADP0,dATP0,dGMP0,dGDP0,dGTP0}]; 
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count = 0; 
Do[ 
count++; 
 
(*Michaelis Menten equations of deoxythymidine metabolism*) 
 
dTnucleosidetransport= 
mm10[transportervmax,transporterkm,dTcyto,dCcyto,transporterkm,dAcyto,transporterkm,dGcyto,transporterkm,dUcyto,transporterkm,rUcyto,transporterkm,rC
cyto,transporterkm,rAcyto,transporterkm,rGcyto,transporterkm,dIcyto,transporterkm,rIcyto,transporterkm]-
mm10[transportervmax,transporterkm,dT[t],dC[t],transporterkm,dA[t],transporterkm,dG[t],transporterkm,dU,transporterkm,rU,transporterkm,rC,transporterkm,r
A,transporterkm,rG,transporterkm,dI,transporterkm,rI,transporterkm];  
(*nucleoside transport in and out*) 
dTnucleosidekinase= hill5[Vmax1PfdT,km1PfdT,dT[t],dTTP[t],kidttptk2,dC[t],kidctk2,dCTP[t],kidctptk2,dU,kidutk2,dUTP,kidutptk2,tk2hill];(*nucleoside 
kinase*) 
dTnucleotidase=mm2[Vmax1PrdT,km1PrdT,dTMP[t],dUMP,km1PrdU,rUMP,km1PrrU]+mm12[Vmax1PrdTen,km1PrdTen,dTMP[t],dCMP[t],km1PrdC,dAMP
[t],km1PrdA,dGMP[t],km1PrdG,dUMP,km1PrdUen,rUMP,km1PrrUen,rCMP,km1PrrC,rAMP,km1PrrA,rGMP,km1PrrG,dIMP,km1PrdI,rIMP,km1PrrI,rADP,ki
adpen,rATP,kiatpen];(*nucleotidase modeled through both dnt2 and ectonucleotidase*) 
dTmpkforward= mm5[Vmax2PfdT,km2PfdT,dTMP[t],dTDP[t],km2PrdT,dUMP,km2PfdUtmpk2,dUDP,km2PrdUtmpk2,dTTP[t],kidttptmpk2,dT[t],kidttmpk2]; 
(*nucleoside monophosphate kinase forward*) 
dTmpkreverse=mm5[Vmax2PrdT,km2PrdT,dTDP[t], dTMP[t], km2PfdT, dUMP, 
km2PfdUtmpk2,dUDP,km2PrdUtmpk2,dTTP[t],kidttptmpk2,dT[t],kidttmpk2];(*nucleoside monophosphate kinase reverse*) 
dTdpkforward= mm21[Vmax3PfdT,km3PfdT,dTDP[t],dCDP[t],km3PfdC,dADP[t],km3PfdA,dGDP[t],km3PfdG,dTTP[t], km3PrdT, dCTP[t],km3PrdC, 
dATP[t],km3PrdA,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3PfrA,rATP,k
m3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI];(*nucleoside diphosphate kinase forward*) 
dTdpkreverse=mm21[Vmax3PrdT,km3PrdT,dTTP[t],dTDP[t],km3PfdT,dCDP[t],km3PfdC,dADP[t],km3PfdA,dGDP[t],km3PfdG,dCTP[t],km3PrdC, 
dATP[t],km3PrdA,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3PfrA,rATP,k
m3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI];(*nucleoside diphosphate kinase reverse*) 
  
 (*Michaelis Menten equations of deoxycytidine metabolism*) 
 
dCnucleosidetransport 
=mm10[transportervmax,transporterkm,dCcyto,dTcyto,transporterkm,dAcyto,transporterkm,dGcyto,transporterkm,dUcyto,transporterkm,rUcyto,transporterkm,r
Ccyto,transporterkm,rAcyto,transporterkm,rGcyto,transporterkm,dIcyto,transporterkm,rIcyto,transporterkm]-
mm10[transportervmax,transporterkm,dC[t],dT[t],transporterkm,dA[t],transporterkm,dG[t],transporterkm,dU,transporterkm,rU,transporterkm,rC,transporterkm,r
A,transporterkm,rG,transporterkm,dI,transporterkm,rI,transporterkm]; 
(*nucleoside transport in and out*) 
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dCnucleosidekinase = 
mm5[Vmax1PfdC,km1PfdC,dC[t],dTTP[t],kidttptk2,dT[t],kidttk2,dCTP[t],kidctptk2,dU,kidutk2,dUTP,kidutptk2]+mm9[Vmax1PfdCdgk,km1PfdCdgk,dC[t],d
ATP[t],kidatpdgk,dGTP[t],kidgtpdgk,dGMP[t],kidgmpdgk,dAMP[t],kidampdgk,dG[t],km1PfdG,dA[t],km1PfdA,dI,kididgk,dIMP,kidimpdgk,dITP,kiditpdgk]; 
(*nucleoside kinase, dC transformation modeled through both tk2 and dgk routes*) 
dCnucleotidase=mm12[Vmax1PrdC,km1PrdC,dCMP[t],dTMP[t],km1PrdTen,dAMP[t],km1PrdA,dGMP[t],km1PrdG,dUMP,km1PrdUen,rUMP,km1PrrUen,rC
MP,km1PrrC,rAMP,km1PrrA,rGMP,km1PrrG,dIMP,km1PrdI,rIMP,km1PrrI,rADP,kiadpen,rATP,kiatpen]; 
dCmpkforward 
=mm11[Vmax2PfdC,km2PfdC,dCMP[t],dCDP[t],km2PrdC,rCMP,km2PfrC,rCDP,km2PrrC,dUMP,km2PfdUcmpk2,dUDP,km2PrdUcmpk2,rUMP,km2PfrU,rU
DP,km2PrrU,rAMP,km2PfrAcmpk2,rADP,km2PrrAcmpk2,dAMP[t],km2PfdAcmpk2,dADP[t],km2PrdAcmpk2];(*nucleoside monophosphate kinase forward*) 
dCmpkreverse 
=mm11[Vmax2PrdC,km2PrdC,dCDP[t],dCMP[t],km2PfdC,rCMP,km2PfrC,rCDP,km2PrrC,dUMP,km2PfdUcmpk2,dUDP,km2PrdUcmpk2,rUMP,km2PfrU,rU
DP,km2PrrU ,rAMP,km2PfrAcmpk2,rADP,km2PrrAcmpk2,dAMP[t],km2PfdAcmpk2,dADP[t],km2PrdAcmpk2]; (*nucleoside monophosphate kinase 
reverse*) 
dCdpkforward = mm21[Vmax3PfdC,km3PfdC,dCDP[t],dTDP[t],km3PfdT,dADP[t],km3PfdA,dGDP[t],km3PfdG,dTTP[t], km3PrdT, dCTP[t],km3PrdC, 
dATP[t],km3PrdA,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3PfrA,rATP,k
m3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI];(*nucleoside diphosphate kinase forward*) 
dCdpkreverse = mm21[Vmax3PrdC,km3PrdC,dCTP[t],dCDP[t],km3PfdC,dTDP[t],km3PfdT,dADP[t],km3PfdA,dGDP[t],km3PfdG,dTTP[t], 
km3PrdT,dATP[t],km3PrdA,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3Pfr
A,rATP,km3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI];(*nucleoside diphosphate kinase reverse*) 
  
(*Michaelis Menten equations of deoxyadenosine metabolism*) 
 
dAnucleosidetransport=mm10[transportervmax,transporterkm,dAcyto,dCcyto,transporterkm,dTcyto,transporterkm,dGcyto,transporterkm,dUcyto,transporterkm,r
Ucyto,transporterkm,rCcyto,transporterkm,rAcyto,transporterkm,rGcyto,transporterkm,dIcyto,transporterkm,rIcyto,transporterkm]-
mm10[transportervmax,transporterkm,dA[t],dC[t],transporterkm,dT[t],transporterkm,dG[t],transporterkm,dU,transporterkm,rU,transporterkm,rC,transporterkm,r
A,transporterkm,rG,transporterkm,dI,transporterkm,rI,transporterkm]; 
(*nucleoside transport in and out*) 
dAnucleosidekinase= 
mm8[Vmax1PfdA,km1PfdA,dA[t],dG[t],km1PfdG,dATP[t],kidatpdgk,dGTP[t],kidgtpdgk,dGMP[t],kidgmpdgk,dAMP[t],kidampdgk,dI,kididgk,dIMP,kidimpdg
k,dITP,kiditpdgk]; 
(*nucleoside kinase*) 
dAnucleotidase=mm12[Vmax1PrdA,km1PrdA,dAMP[t],dTMP[t],km1PrdTen,dCMP[t],km1PrdC,dGMP[t],km1PrdG,dUMP,km1PrdUen,rUMP,km1PrrUen,rC
MP,km1PrrC,rAMP,km1PrrA,rGMP,km1PrrG,dIMP,km1PrdI,rIMP,km1PrrI,rADP,kiadpen,rATP,kiatpen]; 
dAmpkforward= 
mm7[Vmax2PfdA,km2PfdA,dAMP[t],dADP[t],km2PrdA,rAMP,km2PfrA,rADP,km2PrrA,rCMP,km2PfrCak2,rUMP,km2PfrUak2,rCDP,km2PrrCak2,rUDP,km
2PrrUak2];(*nucleoside monophosphate kinase forward*) 
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dAmpkreverse 
=mm7[Vmax2PrdA,km2PrdA,dADP[t],dAMP[t],km2PfdA,rADP,km2PrrA,rAMP,km2PfrA,rCMP,km2PfrCak2,rUMP,km2PfrUak2,rCDP,km2PrrCak2,rUDP,k
m2PrrUak2];(*nucleoside monophosphate kinase reverse*)  
dAdpkforward= mm21[Vmax3PfdA,km3PfdA,dADP[t],dCDP[t],km3PfdC,dTDP[t],km3PfdT,dATP[t],km3PrdA,dGDP[t],km3PfdG,dTTP[t], km3PrdT, 
dCTP[t],km3PrdC,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3PfrA,rATP,k
m3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI ];(*nucleoside diphosphate kinase forward*) 
dAdpkreverse =mm21[Vmax3PrdA,km3PrdA,dATP[t],dCDP[t],km3PfdC,dTDP[t],km3PfdT,dADP[t],km3PfdA,dGDP[t],km3PfdG,dTTP[t], km3PrdT, 
dCTP[t],km3PrdC,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3PfrA,rATP,k
m3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI ];(*nucleoside diphosphate kinase reverse*) 
 
(*Michaelis Menten equations of deoxyguanosine metabolism*) 
 
dGnucleosidetransport= 
mm10[transportervmax,transporterkm,dGcyto,dCcyto,transporterkm,dTcyto,transporterkm,dAcyto,transporterkm,dUcyto,transporterkm,rUcyto,transporterkm,rC
cyto,transporterkm,rAcyto,transporterkm,rGcyto,transporterkm,dIcyto,transporterkm,rIcyto,transporterkm]-
mm10[transportervmax,transporterkm,dG[t],dC[t],transporterkm,dT[t],transporterkm,dA[t],transporterkm,dU,transporterkm,rU,transporterkm,rC,transporterkm,r
A,transporterkm,rG,transporterkm,dI,transporterkm,rI,transporterkm]; 
(*nucleoside transport in and out*) 
dGnucleosidekinase= 
mm8[Vmax1PfdG,km1PfdG,dG[t],dA[t],km1PfdA,dATP[t],kidatpdgk,dGTP[t],kidgtpdgk,dGMP[t],kidgmpdgk,dAMP[t],kidampdgk,dI,kididgk,dIMP,kidimpdg
k,dITP,kiditpdgk]; 
(*nucleoside kinase*) 
dGnucleotidase=mm12[Vmax1PrdG,km1PrdG,dGMP[t],dTMP[t],km1PrdTen,dAMP[t],km1PrdA,dCMP[t],km1PrdC,dUMP,km1PrdUen,rUMP,km1PrrUen,rC
MP,km1PrrC,rAMP,km1PrrA,rGMP,km1PrrG,dIMP,km1PrdI,rIMP,km1PrrI,rADP,kiadpen,rATP,kiatpen]; 
dGmpkforward=mm3[Vmax2PfdG,km2PfdG,dGMP[t],dGDP[t],km2PrdG,rGMP,km2PfrG,rGDP,km2PrrG];(*nucleoside monophosphare kinase forward*) 
dGmpkreverse=mm3[Vmax2PrdG,km2PrdG,dGDP[t],dGMP[t],km2PfdG,rGMP,km2PfrG,rGDP,km2PrrG];(*nucleoside monophosphate kinase reverse*)  
dGdpkforward=mm21[Vmax3PfdG,km3PfdG,dGDP[t],dCDP[t],km3PfdC,dTDP[t],km3PfdT,dADP[t],km3PfdA,dATP[t],km3PrdA,dTTP[t], km3PrdT, 
dCTP[t],km3PrdC,dGTP[t],km3PrdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3PfrA,rATP,k
m3PrrA,rGDP,km3PfrG,rGTP,km3PrrG ,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI];(*nucleoside diphosphate kinase forward*) 
dGdpkreverse =mm21[Vmax3PrdG,km3PrdG,dGTP[t],dCDP[t],km3PfdC,dTDP[t],km3PfdT,dADP[t],km3PfdA,dATP[t],km3PrdA,dTTP[t], 
km3PrdT,dCTP[t],km3PrdC,dGDP[t],km3PfdG,dUDP,km3PfdU,dUTP,km3PrdU,rUDP,km3PfrU,rUTP,km3PrrU,rCDP,km3PfrC,rCTP,km3PrrC,rADP,km3Pfr
A,rATP,km3PrrA,rGDP,km3PfrG,rGTP,km3PrrG,rIDP,km3PfrI,rITP,km3PrrI,dIDP,km3PfdI,dITP,km3PrdI ];(*nucleoside diphosphate kinase reverse*) 
 
(*Rates of polymerization for individual dNTP species alone*) 
rdT:=If[replication>0,1,0]*mm[VmaxPoldT,KmPoldT,dTTP[t]]; 
rdC:=If[replication>0,1,0]*mm[VmaxPoldC,KmPoldC,dCTP[t]]; 
rdA:=If[replication>0,1,0]*mm[VmaxPoldA,KmPoldA,dATP[t]]; 
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rdG:=If[replication>0,1,0]*mm[VmaxPoldG,KmPoldG,dGTP[t]]; 
 
(*Heavy Strand Polymerization Start and Stop Directions*) 
 PolrateH:=If[ (startPol> t)  || ((HDNA[t])>strandDNA)  ,0,1]*HPolrate[t]; 
(*Light Strand Polymerization Start and Stop Directions*) 
 PolrateL:= If[ ((startPol> t)  || ((LDNA[t])>strandDNA)|| ((HDNA[t])< Lstrandstart)),0,1]*LPolrate[t]; 
 
(*                                                                                                          *) 
(*Definition of michaelis menten and hill functions*) 
 
(*Michaelis Menten function with no inhibitors*) 
mm[vmax_,km_,s_]:= If[s>0,1,0]*vmax*s/(km+s); 
                
(*Michaelis Menten function with 1 inhibitor*) 
mm1[vmax_,km_,s_,i_,ki_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i>0,1,0]*(i/ki))); 
 
   (*Michaelis Menten function with 2 inhibitors*) 
mm2[vmax_,km_,s_,i1_,ki1_,i2_,ki2_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)));                     
                             
(*Michaelis Menten function with 3 inhibitors*) 
mm3[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3))); 
 
(*Michaelis Menten function with 4 inhibitors*) 
mm4[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i
4>0,1,0]*(i4/ki4))); 
                                              
(*Michaelis Menten function with 5 inhibitors*) 
mm5[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/
ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5))); 
 
(*Michaelis Menten function with 6 inhibitors*) 
mm6[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_]:=If[s>0,1,0]* 
  vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6))); 
 
(*Michaelis Menten function with 7 inhibitors*) 
mm7[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_]:=If[s>0,1,0]* 
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vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1
,0]*(i7/ki7)));                         
                      
(*Michaelis menten function with 8 inhibitors*) 
mm8[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_,i8_,ki8_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]
*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1,0]*(i7/ki7)+If[i8>0,1,0]*(i8/ki8))); 
 
(*Michaelis menten function with 9 inhibitors*) 
mm9[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_,i8_,ki8_,i9_,ki9_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[
i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1,0]*(i7/ki7)+If[i8>0,1,0]*(i8/ki8)+If[i9>0,1,0
]*(i9/ki9))); 
 
(*Michaelis menten function with 10 inhibitors*) 
mm10[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_,i8_,ki8_,i9_,ki9_,i10_,ki10_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]
*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1,0]*(i7/ki7)+If[i8>0,1,0]*(i8/ki8)
+If[i9>0,1,0]*(i9/ki9)+If[i10>0,1,0]*(i10/ki10))); 
 
(*Michaelis menten function with 11 inhibitors*) 
mm11[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_,i8_,ki8_,i9_,ki9_,i10_,ki10_,i11_,ki11_]:=If[s>0,1,0]*vmax*s/(s+km+km*(
If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1,0]*(i7/ki7)+If[i8>0,1
,0]*(i8/ki8)+If[i9>0,1,0]*(i9/ki9)+If[i10>0,1,0]*(i10/ki10)+If[i11>0,1,0]*(i11/ki11))); 
 
(*Michaelis menten function with 12 inhibitors*) 
mm12[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_,i8_,ki8_,i9_,ki9_,i10_,ki10_,i11_,ki11_,i12_,ki12_]:=If[s>0,1,0]*vmax*s/(s
+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1,0]*(i7/ki7
)+If[i8>0,1,0]*(i8/ki8)+If[i9>0,1,0]*(i9/ki9)+If[i10>0,1,0]*(i10/ki10)+If[i11>0,1,0]*(i11/ki11)+If[i12>0,1,0]*(i12/ki12))); 
 
(*Michaelis Menten function with 17 inhibitors*) 
mm21[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,i6_,ki6_,i7_,ki7_,i8_,ki8_,i9_,ki9_,i10_,ki10_,i11_,ki11_,i12_,ki12_,i13_,ki13_,i14_,ki14_,i1
5_,ki15_,i16_,ki16_,i17_,ki17_,i18_,ki18_,i19_,ki19_,i20_,ki20_,i21_,ki21_]:=If[s>0,1,0]*vmax*s/(s+km+km*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/ki2)+If[i3
>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)+If[i6>0,1,0]*(i6/ki6)+If[i7>0,1,0]*(i7/ki7)+If[i8>0,1,0]*(i8/ki8)+ 
+If[i9>0,1,0]*(i9/ki9)+If[i10>0,1,0]*(i10/ki10)+If[i11>0,1,0]*(i11/ki11)+If[i12>0,1,0]*(i12/ki12)+If[i13>0,1,0]*(i13/ki13)+If[i14>0,1,0]*(i14/ki14)+If[i15>0,1
,0]*(i15/ki15)+If[i16>0,1,0]*(i16/ki16)+If[i17>0,1,0]*(i17/ki17)+If[i18>0,1,0]*(i18/ki18)+If[i19>0,1,0]*(i19/ki19)+If[i20>0,1,0]*(i20/ki20)+If[i21>0,1,0]*(i21
/ki21)));  
 
(*Hill equation function with 5 inhibitors*) 
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hill5[vmax_,km_,s_,i1_,ki1_,i2_,ki2_,i3_,ki3_,i4_,ki4_,i5_,ki5_,hc_]:=If[s>0,1,0]*vmax*(s^hc)/((s^hc)+(km^hc+km^hc*(If[i1>0,1,0]*(i1/ki1)+If[i2>0,1,0]*(i2/
ki2)+If[i3>0,1,0]*(i3/ki3)+If[i4>0,1,0]*(i4/ki4)+If[i5>0,1,0]*(i5/ki5)))); 
 
(*                                                                                                                 *) 
 
(*The total simulation time is broken up so that one mtDNA molecule is copied each time through a loop*) 
(*the amount of time of each separate differential equation*) 
 
DNAmolreptime=simtime/numDNAmols; 
 
(*A Do loop that replicates one molecule of mtDNA each time through, the loop counter i counts from 1 to numDNAmols*) 
 
Timing[Do[      
(*Hold all simulation results in an array called solution, first mtDNA molecule synthesized in solution[1],   
second mtDNA molecule replicated in solution[2], so on*) 
If[i!=1, Table[solution[i-1]]]; 
 
(*Variable k holds a data Table of time (min) and dNTP molecules/mitochondrion*) 
If[i!=1,k=Flatten[Table[{t,dTTP[t],dCTP[t],dATP[t],dGTP[t]} /.solution[i-1],{t,start,end,1}],1]]; 
 
(*Get rid of blank lines in between each data line*) 
 If[i!=1,data=ToString[TableForm[k],OutputForm]]; 
If[i!=1,data2=StringReplace[data,{"\n\n"-> "\n"}]]; 
If[i!=1,data3=ToExpression["data2"]]; 
(*output 5 columns, the time (min), dTTP, dCTP, dATP, dGTP (molecules) to a file called dNTPs.txt*) 
If[i!=1, OutputForm[data3] >>>"dNTPs.txt"]; 
 
 
(*loop counter used outside of loop for last iteration*) 
lin=i; 
(*Start polymerization at beginning*) 
startPol=DNAmolreptime*(i)-DNAmolreptime;(*start time of each differential equation loop where polymerase starts*) 
start=If[i==1,0,end];(*beginning time of each differential equation loop*) 
end=If[i==1,DNAmolreptime,start+DNAmolreptime];(*ending time of each differential equation loop*) 
 
(*Set the nucleotide levels initially or this time through loop to the concentrations at the end of the last loop*) 
dT0=If[i==1,dT0,First[dT[start]/.solution[i-1]]]; 
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dTMP0=If[i==1,dTMP0,First[dTMP[start]/.solution[i-1]]]; 
dTDP0=If[i==1,dTDP0,First[dTDP[start]/.solution[i-1]]]; 
dTTP0=If[i==1,dTTP0,First[dTTP[start]/.solution[i-1]]]; 
dC0=If[i==1,dC0,First[dC[start]/.solution[i-1]]]; 
dCMP0=If[i==1,dCMP0,First[dCMP[start]/.solution[i-1]]]; 
dCDP0=If[i==1,dCDP0,First[dCDP[start]/.solution[i-1]]]; 
dCTP0=If[i==1,dCTP0,First[dCTP[start]/.solution[i-1]]]; 
dA0=If[i==1,dA0,First[dA[start]/.solution[i-1]]]; 
dAMP0=If[i==1,dAMP0,First[dAMP[start]/.solution[i-1]]]; 
dADP0=If[i==1,dADP0,First[dADP[start]/.solution[i-1]]]; 
dATP0=If[i==1,dATP0,First[dATP[start]/.solution[i-1]]]; 
dG0=If[i==1,dG0,First[dG[start]/.solution[i-1]]]; 
dGMP0=If[i==1,dGMP0,First[dGMP[start]/.solution[i-1]]]; 
dGDP0=If[i==1,dGDP0,First[dGDP[start]/.solution[i-1]]]; 
dGTP0=If[i==1,dGTP0,First[dGTP[start]/.solution[i-1]]]; 
 
(*                                                                                                                *) 
(*differential equations*) 
(*Determine individual pool levels over time by adding and subtracting kinetic equations*) 
 
(*transport*) 
ri = Range[0,1200,100];  
(*OutputForm[ri] >>>"ri.txt";*) 
  
solution[i]=NDSolve [{ 
dT'[t]==dTnucleosidetransport-dTnucleosidekinase+dTnucleotidase, 
dTMP'[t]==dTnucleosidekinase-dTnucleotidase-dTmpkforward+dTmpkreverse, 
dTDP'[t]==dTmpkforward-dTmpkreverse-dTdpkforward+dTdpkreverse, 
dTTP'[t]==dTdpkforward-dTdpkreverse- PolrateL*fdTL- PolrateH*fdTH+ri[[count]], 
dC'[t]==dCnucleosidetransport-dCnucleosidekinase+dCnucleotidase, 
dCMP'[t]==dCnucleosidekinase-dCmpkforward+dCmpkreverse-dCnucleotidase, 
dCDP'[t]==dCmpkforward-dCmpkreverse-dCdpkforward+dCdpkreverse, 
dCTP'[t]==dCdpkforward-dCdpkreverse- PolrateL*fdCL-PolrateH*fdCH+ri[[count]], 
dA'[t]==dAnucleosidetransport-dAnucleosidekinase+dAnucleotidase, 
dAMP'[t]==dAnucleosidekinase-dAmpkforward+dAmpkreverse-dAnucleotidase, 
dADP'[t]==dAmpkforward-dAmpkreverse-dAdpkforward+dAdpkreverse, 
dATP'[t]==dAdpkforward-dAdpkreverse- PolrateL*fdAL-PolrateH*fdAH+ri[[count]], 
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dG'[t]==dGnucleosidetransport-dGnucleosidekinase+dGnucleotidase, 
dGMP'[t]==dGnucleosidekinase-dGmpkforward+dGmpkreverse-dGnucleotidase, 
dGDP'[t]==dGmpkforward-dGmpkreverse-dGdpkforward+dGdpkreverse, 
dGTP'[t]==dGdpkforward-dGdpkreverse-  PolrateL*fdGL-  PolrateH*fdGH+ri[[count]], 
LDNA'[t]==PolrateL , 
HDNA'[t]==PolrateH , 
LPolrate[t]==rdT*rdC*rdA *rdG/((fdTL*rdC*rdA*rdG)+(fdCL*rdT*rdA*rdG)+(fdAL*rdT*rdC*rdG)+ (fdGL*rdT*rdC*rdA)+0.1), 
HPolrate[t]==rdT*rdC*rdA *rdG/((fdTH*rdC*rdA*rdG)+(fdCH*rdT*rdA*rdG)+(fdAH*rdT*rdC*rdG)+(fdGH*rdT*rdC*rdA)+0.1), 
dT[start]==dT0, 
dTMP[start]==dTMP0, 
dTDP[start]==dTDP0, 
dTTP[start]==dTTP0, 
dC[start]==dC0, 
dCMP[start]==dCMP0, 
dCDP[start]==dCDP0, 
dCTP[start]==dCTP0, 
dA[start]==dA0, 
dAMP[start]==dAMP0, 
dADP[start]==dADP0, 
dATP[start]==dATP0, 
dG[start]==dG0, 
dGMP[start]==dGMP0, 
dGDP[start]==dGDP0, 
dGTP[start]==dGTP0, 
LDNA[start]==LDNA0, 
HDNA[start]==HDNA0, 
LPolrate'[start]==0, 
HPolrate'[start]==0}, 
{dT,dTMP,dTDP,dTTP,dC,dCMP,dCDP,dCTP,dA,dAMP,dADP,dATP,dG,dGMP,dGDP,dGTP,LDNA,HDNA,LPolrate,HPolrate}, 
{t,start,end},MaxSteps->10000000,PrecisionGoal->4,Method->Automatic ],{i,1,numDNAmols}]]; 
      (*end loop*) 
 
(*Analysis*) 
 
k=Flatten[Table[{PolrateL+PolrateH} /.solution[lin],{t,start,end,0.1}],2]; 
          reptime=(10*end-Count[k,0])*0.1;(*calculate the replication time of the last mtDNA molecule replicated*) 
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hd=HDNA[end]/.solution[1]; 
ld=LDNA[end]/.solution[1]; 
replengths = Append[replengths,hd[[1]]+ld[[1]]]; 
repdurations = Append[repdurations,reptime]; 
reprates = replengths/repdurations; 
 
(*OutputForm[reprates] >>>"reprates.txt"; *) 
 
,{13}]; 
 
,{100}]; 
(*Analysis*) 
 
replengths 
repdurations 
reprates 
Max[replengths] 
Min[repdurations] 
TableForm[Partition[reprates,13]] 
TableForm[parameters] 
 
(*Data & Plots*) 
 
(*write last iteration to end of file*) 
(*Variable k* holds a data Table of time (min) and dN and dNXP molecules per mitochondrion*) 
kn=Flatten[Table[{t, dT[t],dC[t],dA[t],dG[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
datan=ToString[TableForm[kn],OutputForm]; 
data2n=StringReplace[datan,{"\n\n"-> "\n"}]; 
data3n=ToExpression["data2n"]; 
(*output 5 columns, the time (min), dT, dC, dA, dG (molecules) to a file called dNs.txt*) 
OutputForm[data3n] >>>"dNs.txt";  
 
kmono=Flatten[Table[{t, dTMP[t],dCMP[t],dAMP[t],dGMP[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
datamono=ToString[TableForm[kmono],OutputForm]; 
data2mono=StringReplace[datamono,{"\n\n"-> "\n"}]; 
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data3mono=ToExpression["data2mono"]; 
(*output 5 columns, the time (min), dTMP, dCMP, dAMP, dGMP (molecules) to a file called dNMPs.txt*) 
OutputForm[data3mono] >>>"dNMPs.txt"; 
 
kdi=Flatten[Table[{t, dTDP[t],dCDP[t],dADP[t],dGDP[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
datadi=ToString[TableForm[kdi],OutputForm]; 
data2di=StringReplace[datadi,{"\n\n"-> "\n"}]; 
data3di=ToExpression["data2di"]; 
(*output 5 columns, the time (min), dTDP, dCDP, dADP, dGdP (molecules) to a file called dNDPs.txt*) 
OutputForm[data3di] >>>"dNDPs.txt";  
 
ktri=Flatten[Table[{t, dTTP[t],dCTP[t],dATP[t],dGTP[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
datatri=ToString[TableForm[ktri],OutputForm]; 
data2tri=StringReplace[datatri,{"\n\n"-> "\n"}]; 
data3tri=ToExpression["data2tri"]; 
(*output 5 columns, the time (min), dTTP, dCTP, dATP, dGTP (molecules) to a file called dNTPs.txt*) 
OutputForm[data3tri] >>>"dNTPs.txt";   
 
kT=Flatten[Table[{t, dT[t],dTMP[t],dTDP[t],dTTP[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
dataT=ToString[TableForm[kT],OutputForm]; 
data2T=StringReplace[dataT,{"\n\n"-> "\n"}]; 
data3T=ToExpression["data2T"]; 
(*output 5 columns, the time (min), dT, dTMP, dTDP, dTTP (molecules) to a file called t.txt*) 
OutputForm[data3T] >>>"T.txt";  
 
kC=Flatten[Table[{t, dC[t],dCMP[t],dCDP[t],dCTP[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
dataC=ToString[TableForm[kC],OutputForm]; 
data2C=StringReplace[dataC,{"\n\n"-> "\n"}]; 
data3C=ToExpression["data2C"]; 
(*output 5 columns, the time (min), dC, dCMP, dCDP, dCTP (molecules) to a file called C.txt*) 
OutputForm[data3C] >>>"C.txt";  
 
kA=Flatten[Table[{t, dA[t],dAMP[t],dADP[t],dATP[t]} /.solution[lin],{t,start,end,1}],1]; 
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(*Get rid of blank lines in between each data line*) 
dataA=ToString[TableForm[kA],OutputForm]; 
data2A=StringReplace[dataA,{"\n\n"-> "\n"}]; 
data3A=ToExpression["data2A"]; 
(*output 5 columns, the time (min), dA, dAMP, dADP, dATP (molecules) to a file called A.txt*) 
OutputForm[data3A] >>>"A.txt";  
 
kG=Flatten[Table[{t, dG[t],dGMP[t],dGDP[t],dGTP[t]} /.solution[lin],{t,start,end,1}],1]; 
(*Get rid of blank lines in between each data line*) 
dataG=ToString[TableForm[kG],OutputForm]; 
data2G=StringReplace[dataG,{"\n\n"-> "\n"}]; 
data3G=ToExpression["data2G"]; 
(*output 5 columns, the time (min), dG, dGMP, dGDP, dGTP (molecules) to a file called G.txt*) 
OutputForm[data3G] >>>"G.txt";  
(*                                                                                                                    *) 
(*Plots of simulation results*) 
(*Change simulation array solution[lin] to observe other mtDNA molecules besides the last*)  
(*                                                                                                                    *) 
 
(*In the graphs of different dNTPs, T=Red, C=Green, A=Blue, G=Black*) 
(*In the graphs of different phosphorylated states, dN=Red, dNMP=Green, dNDP=Blue, dNTP=Black*)  
 
(*Plot the levels of dNTPs for all mtDNA replications separately*) 
For[i=1,i<(lin+1),i++,dNTP[i]=Plot[Evaluate[{dTTP[t]/conversion,dCTP[t]/conversion,dATP[t]/conversion,dGTP[t]/conversion} /. solution[i]], 
{t,DNAmolreptime*(i-1),DNAmolreptime*i}, AxesLabel -> {"Time (min)", "concentration dNTPs (micromoles/L)"}, PlotRange-> {0,dTTPcyto}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
If[i==lin && i>1,Show[dNTP[i],dNTP[i-1]]]]; (*Plot dNTP levels for last two mtDNA replications together*) 
 
(*dTXP concentration plots for the last mtDNA replication*) 
Plot[Evaluate[{dT[t]/conversion,dTMP[t]/conversion,dTDP[t]/conversion,dTTP[t]/conversion} /. solution[lin]], 
{t,start,end}, AxesLabel -> {"Time (min)", "Concentration T (uM)"}, PlotRange-> {0,dTTPcyto/conversion}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*dCXP concentration plots for the last mtDNA replication*) 
Plot[Evaluate[{dC[t]/conversion,dCMP[t]/conversion,dCDP[t]/conversion,dCTP[t]/conversion} /. solution[lin]], 
{t,start,end}, AxesLabel -> {"Time (min)", "Concentration C (uM)"}, PlotRange-> {0,dTTPcyto/conversion}, 
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PlotStyle->{Red,Green,Blue,Black}] 
 
(*dAXP concentration plots for the last mtDNA replication*) 
Plot[Evaluate[{dA[t]/conversion,dAMP[t]/conversion,dADP[t]/conversion,dATP[t]/conversion} /. solution[lin]], 
{t,start,end}, AxesLabel -> {"Time (min)", "Concentration A (uM)"}, PlotRange-> {0,dTTPcyto/conversion}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*dGXP concentration plots for the last mtDNA replication*) 
Plot[Evaluate[{dG[t]/conversion,dGMP[t]/conversion,dGDP[t]/conversion,dGTP[t]/conversion} /. solution[lin]], 
{t,start,end}, AxesLabel -> {"Time (min)", "Concentration G (uM)"}, PlotRange-> {0,dTTPcyto/conversion}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNs*) 
Plot[Evaluate[{dT[t],dC[t],dA[t],dG[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNs (molecules/mitochondrion)"}, PlotRange-> {0,100}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNMPs*) 
Plot[Evaluate[{dTMP[t],dCMP[t],dAMP[t],dGMP[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNMPs (molecules/mitochondrion)"}, PlotRange-> {0,dTTPcyto}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNDPs*) 
Plot[Evaluate[{dTDP[t],dCDP[t],dADP[t],dGDP[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNDPs (molecules/mitochondrion)"}, PlotRange-> {0,dTTPcyto}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNTPs*) 
Plot[Evaluate[{dTTP[t],dCTP[t],dATP[t],dGTP[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNTPs (molecules/mitochondrion)"}, PlotRange-> {0,dTTPcyto}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNs'*) 
Plot[Evaluate[{dT'[t],dC'[t],dA'[t],dG'[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNs' (molecules per minute)"}, PlotRange-> {0,100}, 
PlotStyle->{Red,Green,Blue,Black}] 
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(*Plot dNMPs'*) 
Plot[Evaluate[{dTMP'[t],dCMP'[t],dAMP'[t],dGMP'[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNMPs' (molecules per minute)"}, PlotRange-> {0,100}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNDPs'*) 
Plot[Evaluate[{dTDP'[t],dCDP'[t],dADP'[t],dGDP'[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNDPs' (molecules per minute)"}, PlotRange-> {0,100}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
(*Plot dNTPs'*) 
Plot[Evaluate[{dTTP'[t],dCTP'[t],dATP'[t],dGTP'[t]} /. solution[1]], 
{t,start,end}, AxesLabel -> {"Time (min)", "dNTPs' (molecules per minute)"}, PlotRange-> {0,100}, 
PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{HDNA[t], LDNA[t], (HDNA[t]+LDNA[t])}/.solution[1]],{t,DNAmolreptime/2,end}, AxesLabel -> 
{"Time(min)","DNA(nucleotides)"},PlotRange -> {0,17000}, PlotStyle -> {Red,Blue, Black}]   
 
Plot[Evaluate[{HDNA'[t], LDNA'[t], (HDNA'[t]+LDNA'[t])}/.solution[1]],{t,DNAmolreptime/2,end}, AxesLabel -> {"Time(min)","DNA'(nucleotides per 
minute)"},PlotRange -> {0,500}, PlotStyle -> {Red,Blue, Black}]   
 
Plot[Evaluate[{dTnucleosidekinase,dCnucleosidekinase,dAnucleosidekinase,dGnucleosidekinase}/.solution[1]],{t,start,end},AxesLabel->{"Time 
(min)","nucleoside kinase output (molecules per minute)"},PlotRange->{0,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{dTnucleotidase,dCnucleotidase,dAnucleotidase,dGnucleotidase}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","nucleotidase output 
(molecules per minute)"},PlotRange->{0,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{dTmpkforward,dCmpkforward,dAmpkforward,dGmpkforward}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","monophosphate kinase 
forward output (molecules per minute)"},PlotRange->{0,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{dTmpkreverse,dCmpkreverse,dAmpkreverse,dGmpkreverse}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","monophosphate kinase 
reverse output (molecules per minute)"},PlotRange->{0,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{dTdpkforward,dCdpkforward,dAdpkforward,dGdpkforward}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","diphosphate kinase forward 
output (molecules per minute)"},PlotRange->{0,1000},PlotStyle->{Red,Green,Blue,Black}] 
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Plot[Evaluate[{dTdpkreverse,dCdpkreverse,dAdpkreverse,dGdpkreverse}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","diphosphate kinase reverse 
output (molecules per minute)"},PlotRange->{0,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{dTnucleosidetransport,dCnucleosidetransport,dAnucleosidetransport,dGnucleosidetransport}/.solution[1]],{t,start,end},AxesLabel->{"Time 
(min)","nucleoside transport reaction output (molecules per minute)"},PlotRange->{-1000,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{(dTnucleosidekinase-dTnucleotidase),(dCnucleosidekinase-dCnucleotidase),(dAnucleosidekinase-dAnucleotidase),(dGnucleosidekinase-
dGnucleotidase)}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","net monophosphate production (molecules per minute)"},PlotRange->{-
1000,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{(dTmpkforward-dTmpkreverse),(dCmpkforward-dCmpkreverse),(dAmpkforward-dAmpkreverse),(dGmpkforward-
dGmpkreverse)}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","net diphosphate production (molecules per minute)"},PlotRange->{0,1000},PlotStyle-
>{Red,Green,Blue,Black}] 
 
Plot[Evaluate[{(dTdpkforward-dTdpkreverse),(dCdpkforward-dCdpkreverse),(dAdpkforward-dAdpkreverse),(dGdpkforward-
dGdpkreverse)}/.solution[1]],{t,start,end},AxesLabel->{"Time (min)","net triphosphate production (molecules per minute)"},PlotRange->{-
1000,1000},PlotStyle->{Red,Green,Blue,Black}] 
 
t 
 
{dT[t],dC[t],dA[t],dG[t]}/.solution[1] 
 
{dTMP[t],dCMP[t],dAMP[t],dGMP[t]}/.solution[1] 
 
{dTDP[t],dCDP[t],dADP[t],dGDP[t]}/.solution[1] 
 
{dTTP[t],dCTP[t],dATP[t],dGTP[t]}/.solution[1] 
 
{dT'[t],dC'[t],dA'[t],dG'[t]}/.solution[1] 
 
{dTMP'[t],dCMP'[t],dAMP'[t],dGMP'[t]}/.solution[1] 
 
{dTDP'[t],dCDP'[t],dADP'[t],dGDP'[t]}/.solution[1] 
 
{dTTP'[t],dCTP'[t],dATP'[t],dGTP'[t]}/.solution[1] 
 
{HDNA[t], LDNA[t], HDNA[t] + LDNA[t]}/.solution[1] 
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{HDNA'[t], LDNA'[t], HDNA'[t] + LDNA'[t]}/.solution[1] 
 
{dTnucleosidetransport,dCnucleosidetransport,dAnucleosidetransport,dGnucleosidetransport}/.solution[1] 
 
{dTnucleosidekinase,dCnucleosidekinase,dAnucleosidekinase,dGnucleosidekinase}/.solution[1] 
 
{dTnucleotidase,dCnucleotidase,dAnucleotidase,dGnucleotidase}/.solution[1] 
 
{dTmpkforward,dCmpkforward,dAmpkforward,dGmpkforward}/.solution[1] 
 
{dTmpkreverse,dCmpkreverse,dAmpkreverse,dGmpkreverse}/.solution[1] 
 
{dTdpkforward,dCdpkforward,dAdpkforward,dGdpkforward}/.solution[1] 
 
{dTdpkreverse,dCdpkreverse,dAdpkreverse,dGdpkreverse}/.solution[1] 
 
{(dTnucleosidekinase-dTnucleotidase),(dCnucleosidekinase-dCnucleotidase),(dAnucleosidekinase-dAnucleotidase),(dGnucleosidekinase-
dGnucleotidase)}/.solution[1] 
 
{(dTmpkforward-dTmpkreverse),(dCmpkforward-dCmpkreverse),(dAmpkforward-dAmpkreverse),(dGmpkforward-dGmpkreverse)}/.solution[1] 
 
{(dTdpkforward-dTdpkreverse),(dCdpkforward-dCdpkreverse),(dAdpkforward-dAdpkreverse),(dGdpkforward-dGdpkreverse)}/.solution[1] 
 
 
 
 
 
 
174 
 
S3: Simulation parameters (Mathematica-readable). 
 
 
 
(*Mitochondrial Deoxyribonucleoside Salvage Pathway*) 
(*Vishal V Gandhi and David C Samuels*) 
 
(*DeoxynucleotideModelConstants.txt*) 
(*This file is the constants file for the Mathematica*) 
(*mitochondrial deoxynucleotide metabolism and mtDNA*) 
(*synthesis model*) 
 
Lstrandstart=10969; 
 
(*the fractions of A,C,T, and G on the heavy and light strands of mtDNA*) 
fdTH=0.309; 
fdTL=0.247; 
fdCH=0.131; 
fdCL=0.313; 
fdAH=0.247; 
fdAL=0.309; 
fdGH=0.313; 
fdGL=0.131; 
 
(*the Hill coefficient of TK2 for deoxythymidine*) 
tk2hill=0.5; 
 
(*The length of both strands of mtDNA*) 
DNAlength=33136; 
(*the length of one strand of mtDNA*) 
strandDNA=DNAlength/2; 
 
(*volume of a mitochondrion*) 
volmito=2*^-16; 
 
(*conversion factor used to convert kms and concentrations from microMolar to molecules/mitochondrion*) 
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(*conversion = 120.4;*) 
conversion=1*^-6*6.022*^23*volmito; 
secondsperminute=60; 
 
(*factor used to decrease the vmax of the polymerase on double stranded templates with lower primer density*) 
dsfact=1/2; 
 
(*Polymerase kinetic constants Johnson 01 JBC*) 
VmaxPoldT=25.0*dsfact*secondsperminute; 
VmaxPoldC=43.0*dsfact*secondsperminute; 
VmaxPoldA=45.0*dsfact*secondsperminute; 
VmaxPoldG=37.0*dsfact*secondsperminute; 
KmPoldT=0.63*conversion; 
KmPoldC=0.9*conversion; 
KmPoldA=0.8*conversion; 
KmPoldG=0.8*conversion; 
 
(*Ki of dTTP on tk2 Wang 03 DOI 10.1074/jbc.M206143200*) 
kidttptk2=2.3*conversion; 
 
(*Ki of dUTP on tk2 Geometric mean of dCTP and dTTP values*) 
kidutptk2=1.38*conversion; 
 
(*Ki of dCTP on tk2 Wang 03 DOI 10.1074/jbc.M206143200*) 
kidctptk2=0.83*conversion; 
 
(*Ki of dU on tk2 Geometric mean Munch-Petersen 91 JBC*) 
kidutk2=227*conversion; 
 
(*Ki of dC on tk2 Wang 03 DOI 10.1074/jbc.M206143200*) 
kidctk2=40*conversion; 
 
(*Ki of dT on tk2 Wang 03 DOI 10.1074/jbc.M206143200*) 
kidttk2=4.9*conversion; 
 
(*Substrate Kis on dgk set equal to substrate kms*) 
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(*Ki of dI on dgk set equal to km Sjoberg 98 Molecular Pharmacology*) 
kididgk=12*conversion; 
 
(*Sjoberg 01 DOI: 10.1128/AAC.45.3.739–742.2001, Ki of dITP on dgk set equal to dATP Ki*) 
kidimpdgk=78*conversion; 
kiditpdgk=kidatpdgk; 
 
(*Ki of dGMP on dgk Sjoberg 01 DOI: 10.1128/AAC.45.3.739–742.2001*) 
kidgmpdgk=4*conversion; 
 
(*Ki of dAMP on dgk Sjoberg 01 DOI: 10.1128/AAC.45.3.739–742.2001*) 
kidampdgk=28*conversion; 
 
(*Ki of dATP on dgk Sjoberg 01 DOI: 10.1128/AAC.45.3.739–742.2001*) 
kidatpdgk=41*conversion; 
 
(*Ki of dGTP on dgk Sjoberg 01 DOI: 10.1128/AAC.45.3.739–742.2001*) 
kidgtpdgk=0.4*conversion; 
 
(*estimated nucleoside transporter molecular weight in kD Griffiths 97 Nature Medicine assumed monomer?*) 
transporterMW=50; 
 
(*tk2 and dgk molecular weight in kD=29 Wang 99 Febs Letters, Mandel 01 doi:10.1038/ng746*) 
(*dgk is a dimer, tk2 exists both as dimer and tetramer: tetramer is more active but less abundant, transition between the 2 states is possible and ATP-mediated 
(mean taken)*) 
dgkMW=58; 
tk2MW=87; 
 
(*molecular weight of dnt2 in kD Rampazzo 00 PNAS Hunsucker 05 dimer = 2*23*) 
dnt2MW=46; 
 
(*Ectonucleotidase molecular weight Tetramer Brenda*) 
enMW=210; 
 
(*tmpk2 molecular weight in kD Chen 08 Genes to Cells*) 
tmpk2MW=44; 
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(*gmpk2 molecular weight in kD Brenda*) 
gmpk2MW=22; 
 
(*cmpk2 molecular weight in kD Xu08 JBC*) 
cmpk2MW=44.5; 
 
(*ak2 molecular weight in kD Uniprot/other literature*) 
akMW=26; 
 
(*human nme4 molecular weight in kD=20 Uniprot/Milon 00, homohexamer*) 
ndpkMW=120; 
 
(*nucleoside kinase molecules in each mitochondrion from Saada 01 and 03 Nature Genetics and Mol Gen Metabolism*) 
(*as much as 20-fold variation may exist between tissues*) 
tk2moleculespermito=100; 
dgkmoleculespermito=200; 
 
(*dnt2 molecules in each mitochondrion*) 
dnt2moleculespermito=50; 
 
(*Ectonucleotidase molecules in each mitochondrion*) 
enmoleculespermito=50; 
 
(*tmpk2 molecules in each mitochondrion*) 
tmpk2moleculespermito=50; 
 
(*gmpk2 molecules in each mitochondrion*) 
gmpk2moleculespermito=50; 
 
(*cmpk2 molecules in each mitochondrion*) 
cmpk2moleculespermito=50; 
 
(*ndpk molecules in each mitochondrion*) 
ndpkmoleculespermito=300; 
 
(*the factor that the reverse reaction is faster than the forward reaction for NMPK*) 
factorMD=0.1;(*AMP/ADP*) 
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(*the factor that the reverse reaction is faster than the forward reaction for NDPK*) 
factorDT=0.1;(*ADP/ATP*) 
 
(*ent molecules per mitochondrion Life Sciences Camins 96, Escubedo 00*) 
transportermoleculespermito=38; 
 
(*adenylate kinase molecules per mitochondrion Eur. J. Biochem. 93, 263 1979 Tomaselli*) 
akmoleculespermito=450; 
 
(*number of total proteins in a mitochondrion assuming average MW of 30 kD and 5x10^10 mito/mg mito protein*) 
(*proteinspermito=400000;*) 
 
(*transporter Vmax converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute refer base model constants, camins 
95, jimenez 00*) 
transportervmax=0.000086/0.0000021*transportermoleculespermito; 
 
(*agreement between kcat from gerth 07 for tk2 at least and the Vmax values - so ok*) 
 
(*Vmax of the first phosphorylation of dT in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Wang 03 DOI 10.1074/jbc.M206143200*) 
Vmax1PfdT=1.288*tk2MW*tk2moleculespermito; 
 
(*Vmax of the first phosphorylation of dC in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Wang 03 DOI 10.1074/jbc.M206143200*) 
Vmax1PfdC=0.789*tk2MW*tk2moleculespermito; 
 
(*Vmax of dC with dgk converting from micromoles substrate/mg enzyme/minute to molecules substrate/mitochondrion/minute Sjoberg 98 Molecular 
Pharmacology*) 
Vmax1PfdCdgk=0.059*dgkMW*dgkmoleculespermito; 
 
(*Vmax of the first phosphorylation of dA in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Sjoberg 98 Molecular Pharmacology*) 
Vmax1PfdA=0.429*dgkMW*dgkmoleculespermito; 
 
(*Vmax of the first phosphorylation of dG in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Sjoberg 98 Molecular Pharmacology*) 
Vmax1PfdG=0.043*dgkMW*dgkmoleculespermito; 
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(*turnover numbers for cytosolic nucleotidases from Brenda seem to match Vmax below*) 
 
(*Vmax of the first phosphorylation of dT in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Mazzon 03 Biochemical Pharmacology*) 
Vmax1PrdT=74*dnt2MW*dnt2moleculespermito; 
 
(*Various sources, Spychala 89 for Vmax 45 for AMP so setting lower here, also refer Hunsucker 05*) 
 
(*Ectonucleotidase Vmax of the first phosphorylation of dT in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute*) 
Vmax1PrdTen=4.5*enMW*enmoleculespermito; 
 
(*Vmax of the first phosphorylation of dC in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute*) 
Vmax1PrdC=4.5*enMW*enmoleculespermito; 
 
(*Vmax of the first phosphorylation of dA in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute*) 
Vmax1PrdA=4.5*enMW*enmoleculespermito; 
 
(*Vmax of the first phosphorylation of dG in the reverse direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute*) 
Vmax1PrdG=4.5*enMW*enmoleculespermito; 
 
(*Vmax of the second phosphorylation of dT in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Brenda, also refer Pasti 03 Kcat value for cytoplasmic enzyme is 1 per second*) 
Vmax2PfdT=0.821*tmpk2MW*tmpk2moleculespermito; 
 
(*Vmax of the second phosphorylation of dC in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Xu 08 JBC*) 
Vmax2PfdC=1.77*cmpk2MW*cmpk2moleculespermito; 
 
(*Vmax of the second phosphorylation of dA in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Alexandre 07 Nucleic Acids Research*) 
Vmax2PfdA=272.8*akMW*akmoleculespermito; 
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(*Vmax of the second phosphorylation of dG in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute from Brenda mouse and rat unreliable values* Hall 86 Eur J Biochem unreliable value*) 
Vmax2PfdG=1.54*gmpk2MW*gmpk2moleculespermito; 
 
(*Vmax of the second phosphorylation of dT in the reverse direction*) 
Vmax2PrdT=Vmax2PfdT*factorMD; 
 
(*Vmax of the second phosphorylation of dC in the reverse direction*) 
Vmax2PrdC=Vmax2PfdC*factorMD; 
 
(*Vmax of the second phosphorylation of dA in the reverse direction*) 
Vmax2PrdA=Vmax2PfdA*factorMD; 
 
(*Vmax of the second phosphorylation of dG in the reverse direction*) 
Vmax2PrdG=Vmax2PfdG*factorMD; 
 
(*Milon 00 human and Lambeth 97 pigeon both have data but Lambeth 97 has more, and there is overlap between dTDP values - so using Lambeth 97 for all 
nme4 data*) 
 
(*Vmax of the third phosphorylation of dT in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Lambeth 97 JBC*) 
Vmax3PfdT=140*ndpkMW*ndpkmoleculespermito; 
 
(*Vmax of the third phosphorylation of dC in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Lambeth 97 JBC*) 
Vmax3PfdC=50*ndpkMW*ndpkmoleculespermito;(*author statement: dNDPs are slower than rNDPs, so taking dCDP Vmax=CDP*) 
 
(*Vmax of the third phosphorylation of dA in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Milon 00 JBC*) 
Vmax3PfdA=225*ndpkMW*ndpkmoleculespermito;(*set equal to dGDP Vmax*) 
 
(*Vmax of the third phosphorylation of dG in the forward direction converting from micromoles substrate/mg enzyme/minute to molecules 
substrate/mitochondrion/minute Lambeth 97 JBC*) 
Vmax3PfdG=225*ndpkMW*ndpkmoleculespermito; 
 
(*Vmax of the third phosphorylation of dT in the reverse direction*) 
Vmax3PrdT=Vmax3PfdT*factorDT; 
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(*Vmax of the third phosphorylation of dC in the reverse direction*) 
Vmax3PrdC=Vmax3PfdC*factorDT; 
 
(*Vmax of the third phosphorylation of dA in the reverse direction*) 
Vmax3PrdA=Vmax3PfdA*factorDT; 
 
(*Vmax of the third phosphorylation of dG in the reverse direction*) 
Vmax3PrdG=Vmax3PfdG*factorDT; 
 
(*transporter Km Escubedo 00*) 
transporterkm=2*conversion; 
 
(*Km of the first phosphorylation of dT in the forward direction Wang 03 DOI 10.1074/jbc.M206143200*) 
km1PfdT=13*conversion; 
 
(*Km of the first phosphorylation of dC in the forward direction Wang 03 DOI 10.1074/jbc.M206143200*) 
km1PfdC=11*conversion; 
 
(*Km of dC with dgk Sjoberg 98 Molecular Pharmacology*) 
km1PfdCdgk=336*conversion; 
 
(*Km of the first phosphorylation of dA in the forward direction Sjoberg 98 Molecular Pharmacology*) 
km1PfdA=467*conversion; 
 
(*Km of the first phosphorylation of dG in the forward direction Sjoberg 98 Molecular Pharmacology*) 
km1PfdG=4*conversion; 
 
(*Km of the first phosphorylation of dT, dU in the reverse direction Rampazzo 00 PNAS*) 
km1PrdT=200*conversion; 
km1PrdU=100*conversion; 
km1PrrU=1.5*km1PrdT; 
 
(*Ectonucleotidase data from Hunsucker 05 or Brenda*) 
(*Geometric means for substrate Kms, higher Kms plugged for inhibitions to be conservative*) 
 
(*Ectonucleotidase Km of the first phosphorylation of dT, dU, rU in the reverse direction*) 
km1PrdTen=22.5*conversion; 
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km1PrdUen=110*conversion;(*set equal to UMP Km*) 
km1PrrUen=110*conversion;(*set equal to Km*) 
 
(*Ectonucleotidase Km of the first phosphorylation of dC, rC in the reverse direction*) 
km1PrdC=290*conversion; 
km1PrrC=360*conversion; 
 
(*Ectonucleotidase Km of the first phosphorylation of da, rA in the reverse direction*) 
km1PrdA=62*conversion; 
km1PrrA=19*conversion;(*set equal to Km*) 
 
kiadpen=17*conversion; 
kiatpen=15*conversion; 
 
(*Ectonucleotidase Km of the first phosphorylation of dG, rG in the reverse direction*) 
km1PrdG=48*conversion; 
km1PrrG=59*conversion;(*set equal to Km*) 
 
(*Ectonucleotidase Km of the first phosphorylation of dI, rI in the reverse direction*) 
km1PrdI=100*conversion;(*set equal to Km of IMP*) 
km1PrrI=100*conversion;(*set equal to Km*) 
 
(*Km of the second phosphorylation of dT in the forward direction Alexandre 07,misc*) 
km2PfdT=20*conversion; 
km2PfdUtmpk2=2600*conversion;(*Km is 170, but Ki is 2600*) 
 
(*miscellaneous inhibitions Brenda*) 
(*deoxythymidine inhibition excluded because even at 770 uM only 27% inhibition observed*) 
kidttptmpk2=700*conversion; 
kidttmpk2=180*conversion; 
 
(*Km of the second phosphorylation of dC in the forward direction Xu 08*) 
km2PfdC=1310*conversion; 
km2PfrC=3090*conversion; 
km2PfrU=6300*conversion; 
km2PfdUcmpk2=100*conversion; 
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(*Refer VanRompay 99 Molecular Pharmacology cmpk1 can phosphorylate AMP and dAMP*) 
km2PfrAcmpk2=km2PrrAcmpk2=km2PfdAcmpk2=km2PrdAcmpk2=100*500*conversion; (*km of CMP is 500 uM*) 
 
(*Km of the second phosphorylation of dA in the forward direction Alexandre 07 Nucleic Acids Research*) 
km2PfdA=210*conversion; 
km2PfrA=80*conversion;(*Km is 80, Ki is 500 - but this gives the incorrect impression that dAMP is a better substrate*) 
 
(*Refer Alexandre 07 Nucleic Acids Research 07 - CMP and UMP have some reactivity with ak2 - included as inhibitions*) 
km2PfrCak2=6000*conversion; 
km2PfrUak2=9000*conversion; 
 
(*Km of the second phosphorylation of dG in the forward direction, Brenda*) 
km2PfdG=112*conversion; 
km2PfrG=18*conversion; 
 
(*Km of the second phosphorylation of dT in the reverse direction*) 
km2PrdT=km2PfdT; 
km2PrdUtmpk2=km2PfdUtmpk2; 
 
(*Km of the second phosphorylation of dC in the reverse direction*) 
km2PrdC=km2PfdC; 
km2PrrC=km2PfrC; 
km2PrrU=km2PfrU; 
km2PrdUcmpk2=km2PfdUcmpk2; 
 
(*Km of the second phosphorylation of dA in the reverse direction*) 
km2PrdA=km2PfdA; 
km2PrrA=km2PfrA; 
 
km2PrrCak2=km2PfrCak2; 
km2PrrUak2=km2PfrUak2; 
 
(*Km of the second phosphorylation of dG in the reverse direction*) 
km2PrdG=km2PfdG; 
km2PrrG=km2PfrG; 
 
(*Reaction is linear for dTDP and UDP until at least 1000 uM Lambeth 97 JBC*) 
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(*Km of the third phosphorylation of dT in the forward direction Lambeth 97 JBC*) 
km3PfdT=1000*conversion; 
km3PfdU=km3PfdT; 
km3PfrU=km3PfdT; 
 
(*Km of the third phosphorylation of dC in the forward direction Lambeth 97 JBC*) 
km3PfdC=1000*conversion;(*dNDPs are weaker substrates than rNDPs: author statement but data n/a so same value used*) 
km3PfrC=1000*conversion;(*Reaction linear until at least 1000 uM*) 
 
(*Km of the third phosphorylation of dA in the forward direction Lambeth 97 JBC*) 
km3PfdA=70*conversion;(*Km of ADP is about 70 uM OR Km of dADP set equal to that of dGDP*) 
km3PfrA=300*conversion;(*substrate inhibition, Ki*) 
 
(*Km of the third phosphorylation of dG in the forward direction Lambeth 97 JBC*) 
km3PfdG=75*conversion; 
km3PfrG=100*conversion;(*substrate inhibition,Ki*) 
 
(*inosine inhibitions*) 
km3PfrI=km3PrrI=km3PfdI=km3PrdI=1000*conversion; 
 
(*Km of the third phosphorylation of dT in the reverse direction*) 
km3PrdT=km3PfdT; 
km3PrdU=km3PrdT; 
km3PrrU=km3PrdT; 
 
(*Km of the third phosphorylation of dC in the reverse direction*) 
km3PrdC=km3PfdC; 
km3PrrC=km3PrdC; 
 
(*Km of the third phosphorylation of dA in the reverse direction*) 
km3PrdA=km3PfdA; 
km3PrrA=km3PrdA; 
 
(*Km of the third phosphorylation of dG in the reverse direction*) 
km3PrdG=km3PfdG; 
km3PrrG=km3PrdG; 
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(*initial concentrations*) 
 
dTcyto=RandomReal[{0.05*conversion, 5*conversion}]; 
dCcyto=RandomReal[{0.05*conversion, 5*conversion}]; 
dAcyto=RandomReal[{0.05*conversion, 5*conversion}]; 
dGcyto=RandomReal[{0.05*conversion, 5*conversion}]; 
 
dT0=dTcyto; 
dC0=dCcyto; 
dA0=dAcyto; 
dG0=dGcyto; 
 
(*initial dNTP levels*) 
 
(*for transport model, have set these to be chosen randomly*) 
 
If[celltype==1,dTTPcyto=RandomReal[{0.1*conversion, 10*conversion}]]; 
If[celltype==1,dCTPcyto=RandomReal[{0.1*conversion, 10*conversion}]]; 
If[celltype==1,dATPcyto=RandomReal[{0.1*conversion, 10*conversion}]]; 
If[celltype==1,dGTPcyto=RandomReal[{0.1*conversion, 10*conversion}]]; 
 
dTMP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dTDP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dTTP0=dTTPcyto; 
 
dCMP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dCDP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dCTP0=dCTPcyto; 
 
dAMP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dADP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dATP0=dATPcyto; 
 
dGMP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dGDP0=RandomReal[{0.1*conversion, 10*conversion}]; 
dGTP0=dGTPcyto; 
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dU=dUcyto=dTcyto; 
rU=rUcyto=dTcyto; 
dI=dIcyto=0.1*dAcyto; 
rI=rIcyto=0.1*dAcyto; 
rC=rCcyto=dCcyto; 
rA=rAcyto=dAcyto; 
rG=rGcyto=dGcyto; 
 
dUMP=0.1*dTMP0; 
rUMP=10*dTMP0; 
dIMP=0.1*dAMP0; 
rIMP=0.1*dAMP0; 
rCMP=10*dCMP0; 
rAMP=10*dAMP0; 
rGMP=10*dGMP0; 
 
dUDP=0.1*dTDP0; 
rUDP=10*dTDP0; 
dIDP=0.1*dADP0; 
rIDP=0.1*dADP0; 
rCDP=10*dCDP0; 
rADP=10*dADP0; 
rGDP=10*dGDP0; 
 
dUTP=0.1*dTTP0; 
rUTP=10*dTTP0; 
dITP=0.1*dATP0; 
rITP=0.1*dATP0; 
rCTP=10*dCTP0; 
rATP=10*dATP0; 
rGTP=10*dGTP0; 
 
DNA0=0; 
LDNA0=0; 
HDNA0=0; 
 
(*end file*) 
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